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ABSTRACT
The incidence of cancer worldwide is continuously on the rise, and the death toll
associated with cancer, is constantly increasing. Available cancer therapy is
unable to combat this ever-changing disease, and the severe side effects
associated with various forms of therapy, indicate a serious need for the
development of more effective and safer alternatives to currently available
treatment.
The use of natural health products in disease treatment has contributed to the
development of over 75% of available chemotherapy. In this thesis, we study the
potential anti-cancer effect of two natural health products, dandelion root and
long pepper extracts.
The major objectives of this work were to;
-

Evaluate the efficacy and mechanism of these extracts in various cancer
models,

-

Assess any potential safety and toxicity issues associated with the use of
these extracts and,

-

De-convolute and identify the pharmacologically active components that
contribute to the anti-cancer activity of these extract

Using standard biochemical and morphological assays, the induction of various
programmed cell death processes was assessed, following treatment in cancer
and non-cancer cell models, as well as in animal models.
The results obtained indicate that dandelion root and long pepper extracts were
efficacious in selectively inducing apoptosis and pro-death autophagy in various

vi

cancer cell models. Dandelion root extract rapidly activated the extrinsic pathway
of apoptosis, a situation that was crucial to apoptosis induction in leukemia cells,
but not required for colorectal cancer cells. Gene expression analysis showed
that dandelion root extract efficiently targets multiple pathways to promote its
anti-cancer activity.
The generation of reactive oxygen species by long pepper extract treatment,
appeared to be partially responsible for the induction of apoptosis in cancer cells.
Furthermore, the lack of toxicity observed in animal models, on oral
administration regimens of dandelion root and long pepper extracts, further
confirm the safety of these extracts. Interestingly, the same regimen of oral
administration of these extracts was successful in halting the growth of colon
tumors in xenograft models.
These findings provide scientific validation concerning the safe and effective use
of natural health products as non-toxic and potentially more efficacious forms of
therapy.
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CHAPTER 1
GENERAL INTRODUCTION

1

CANCER
Cancer is mainly characterized a disease characterized by uncontrolled
cell growth and proliferation, however, it is a term that describes over a hundred
forms the disease, as almost every body tissue is capable of developing tumors
(Weinberg, 1996). Cancer arises from one cell, usually initiated by a program of
inappropriate cell division, with cells that have accumulated multiple mutations,
specifically in classes of genes (proto-oncogenes and tumor suppressors),
usually meant to control the cell growth and division processes; for instance
mutations in proto-oncogenes encourage their conversion to overly active
oncogenes, which drive excessive growth and multiplication, while mutations in
tumor suppressors are inactivating mutations, preventing their ability to halt
excessive growth and multiplication of cells with mutations. These mutations
result in uncontrolled cell proliferation, the very definition of cancer, and as these
cells continually divide, they accumulate more mutations that confer further
proliferative advantages, as well as safeguards against growth suppression
(Weinberg, 1996; Hanahan & Weinberg, 2000). This thesis will focus on targeting
some of the major ―hallmarks‖ of cancer cells that enhance their proliferative
signaling, especially in leukemia, pancreatic cancers and colorectal cancers.
According to the World Health Organization, in 2012, cancer led the
charge as the second leading cause of death worldwide, with 8.2 million cancerrelated deaths in that year alone, a rise from 2008, which saw 7.6 million deaths
(Jemal et al., 2011; Siegel et al., 2014). Canada alone saw a 3700 increase in the
incidence of cancer from 2013 to 2014; in 2013, there were 187,600 new cases
versus 191,300 in 2014. Along with this increase in the incidence of cancer, a
2

corresponding increase in cancer related deaths were observed, with 76,600
deaths estimated in 2014, compared to 75,500 deaths in 2013 (Statistics
Canada, 2013; Statistics Canada, 2014).
Not only is cancer a personal burden (on patients and loved ones), it also
has major economic consequences. The costs associated with cancer care,
including healthcare costs (physicians and hospital expenses) as well as costs
associated with lost productivity and premature death, have steadily increased
over the years and due to the rising increase in cancer incidence and related
death, these costs are predicted to continue to rise (Statistics Canada, 2014).
This begs the dire need to develop non-toxic, preventative and therapeutic
regimens for cancer.
HALLMARKS OF CANCER
The hurdles associated with finding an effective mode of chemotherapy
are generally caused by the acquired capabilities that define a cancer cell. These
hallmarks are essential to cancer cell growth and survival and enable cancer cells
evade routine safeguard mechanisms and therapeutic agents. The multistep
theory governing the process of tumorigenesis reflects the genetic alterations that
promote progressive transformation of normal human cells into their malignant
counterparts and the hallmarks of cancer can be associated with each step
(Hanahan & Weinberg, 2000). In 2000, Hanahan and Weinberg outlined the basic
hallmarks that are associated with cancer cell survival and this list was modified
in later years (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011). The
hallmarks are outlined below and in figure 1. They include;

3

i.

The ability to sustain growth signals by generating many oncogenes, which
act as growth signals and remove dependence on normal cell signaling, as
observed in the up-regulation of growth factors and growth factor receptors
(Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011).

ii.

The ability to evade growth suppressive signals, for instance, in the
disruption of the retinoblastoma (Rb) signaling pathway, which allows the
liberation of E2F to promote cell proliferation and render cancer cells
insensitive to anti-growth stimuli (Hanahan & Weinberg, 2000; Hanahan &
Weinberg, 2011).

iii.

The ability to metastasize and invade surrounding tissues, allowing tumor
cells escape primary site to a secondary site, where they can take up
residence. This is usually due to altered protein functions of proteins like
the cell - cell adhesion molecules (CAMs), which are involved in securing
cells to their surroundings (Hanahan & Weinberg, 2000; Hanahan &
Weinberg, 2011). Processes like anoikis, a form of cell death caused by
loss of contact with the extracellular matrix and/or neighboring cells, are
usually down-regulated in cancer cells, due to up-regulation of proteins,
such as TrkB (Liotta & Kohn, 2004). Such alterations provide cancer cells
with the ability to metastasize from their primary location to a distant site,
without the accompanying cell death.

iv.

The ability of cancer cells to maintain replicative signaling, usually as a
result of up-regulating the expression of the telomerase enzyme, so as to
inhibit telomere shortening and maintain telomere length (Hanahan &
Weinberg, 2000; Hanahan & Weinberg, 2011).
4

v.

The ability to develop new blood vessels (angiogenesis), which allows for
the continuous supply of oxygen and nutrients, required for the survival of
tumor cells. Angiogenesis signals include the up-regulation of proteins like
the vascular endothelial growth factor (VEGF) (Hanahan & Weinberg,
2000; Hanahan & Weinberg, 2011).

vi.

The ability to bypass cell death signal, such as apoptosis, anoikis and
autophagic cell death. This is usually observed in collaboration with the
overexpression of pro-survival proteins, such as the pro-survival members
of the Bcl-2 family (Frankin & McCubrey, 2000; Ghobrial et al., 2005).
Further research into the hallmarks of cancer cells that provide growth

advantage led to the introduction of new enabling characteristics and additional
hallmarks (Figure 1). These emerging hallmarks have been shown to be involved
in the development and progression of some, perhaps all cancers. The first newly
emerging hallmark is one that involves the ability of cancer cells to reprogram
their cellular metabolism, by deregulating cellular energetics, in order to
continuously promote cell proliferation and the other allows cancer cells evade
immune destruction, where the T and B lymphocytes, as well as macrophages
and natural killer cells would normally identify cancer cells and target them for
destruction. These hallmarks are still under investigation but however, are
supported by the emerging characteristics of genomic instability (which allows
multiple genetic alterations drive tumor progression) and inflammatory response
by innate immune cells, normally designed to fight infections and heal wounds.
These emerging characteristics and hallmarks therefore supports the previously

5

described hallmarks of cancer cells and have proven to promote tumor
progression (Hanahan and Weinberg, 2011).

6

Figure 1: The Hallmarks of Cancer that encourage the process of
carcinogenesis, the promotion of proliferation and the enhanced ability to escape
safeguard mechanisms of cell death programs and growth suppression. The
early onset mutations in proto-oncogenes and tumor suppressor genes are
enabling characteristics that promote cell proliferative signaling, evade growth
suppressors and enable replictive immortality. These mutations and further
replicative ability promote more mutations and metabolic changes in these cells,
promoting invasion, metastasis, the induction of angiogenesis and the evasion of
cell death programs. These hallmarks provide targets for the development of
future cancer therapies. (Adapted from Hanahan & Weinberg, 2000; Hanahan &
Weinberg, 2011).
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CANCER METABOLISM
Originally thought to be the root cause of carcinogenesis, the ―Warburg
effect‖ has gained a lot of notoriety, as a key metabolic hallmark of cancer cells
(Warburg, 1956; Hsu & Sabatini, 2008). The Warburg effect focuses on the ability
of cancer cells to bypass regular mitochondrial oxidative phosphorylation
(OXPHOS) for less favorable energy production by aerobic glycolysis (Warburg,
1956). Several studies have further explored the various aspects of cancer cell
metabolism and how it affects cancer cell proliferation and survival. Generally,
proliferating cancer cells have two main metabolic challenges to overcome; the
―challenge of meeting the bioenergetics and biosynthetic demands of increased
cell proliferation‖ and the ―challenge of surviving environmental fluctuations in
nutrients and oxygen availability‖ when tumor growth exceeds the delivery
capacities of existing structures. Evidence has shown that many mutated genes,
through oncogenic activation, loss of tumor suppression function, as well as
altered cellular metabolism, lead to the induction of the Warburg effect and all of
these mutations combined, are intricately involved in carcinogenesis and
metabolic regulation (Jones & Thompson, 2009; Chandel, 2014).
In agreement with the Warburg hypothesis, one of the primary metabolic
changes associated with rapidly proliferating cancer cells is the induction of
aerobic glycolysis, instead of OXPHOS for the generation of ATP (Figure 2),
while providing essential carbon sources for the biosynthesis of other essential
macromolecules. Over 90% of the pyruvate produced from aerobic glycolysis in
cancer cells is converted to lactate by lactate dehydrogenase (LDHA), to recover
NAD+ required for continuous glycolytic process, a step that has been shown to
8

be necessary for the continuous proliferation of tumor cells (Cairns et al., 2011).
Although the glycolytic process is less favorable for the generation of ATP
molecules, it does have the ability to produce ATP at a faster rate, while
generating metabolic intermediates that promote cell growth and proliferation,
such as 3-phosphoglycerate (3-PG), which serves as a carbon source for amino
acid and lipid synthesis. The remaining 10% of produced pyruvate (which does
not get converted to lactate) can be transported into the mitochondria but forced
out of the tricarboxylic acid cycle (TCA), which leads to a partial loss of
mitochondrial integrity, making the mitochondria a viable target for mitochondria
targeting drugs, MITOCANS (Kroemer, 2006; D’Souza et al., 2011).
It has been established that this deregulated cellular metabolism is
associated with drug resistance to some of the available cancer therapies (Zhao
et al., 2013). A common regulator of cell metabolism, both transformed and nontransformed cells, is the lipid kinase, phosphatidylinositol-3-kinase (PI3K), which
regulates levels of phosphorylated phosphatidylinositol (PIP3) at the plasma
membrane and downstream signaling cascade involved in metabolic processes
that promote cell proliferation. Non-transformed cells have a tight control on this
signaling pathway by dephosphorylation and thereby, inactivation of PIP3, by the
tumor suppressor, phosphate tensin homolog 10, PTEN. In transformed cancer
cells, however, mutations in PTEN support over-activation of the PI3K pathway
and the promotion of cell proliferation (Jones & Thompson, 2009). These findings
suggest that the mitochondria and the differential metabolic activity of cancer
cells, present potential viable and selective targets in cancer therapy (Zhao et al.,
2013).
9

Figure 2: The metabolism of a Cancer vs. Non-Cancer cell show the
differences between cancer cell and a normal cells that could contribute to the
strengths and vulnerabilities of cancer cells, compared to that of their normal cell
counterparts. Cancer cells up-regulate the expression of hexokinase II to promote
glycolysis and even under normal aerobic conditions, cancer cells convert most
of the product formed from glycolysis, pyruvate, into the lactate. Lactate promotes
cancer environment acidification, evasion of growth suppressors, invasion and
metastasis and the evasion of cell death programs. Furthermore, the dependence
of cancer cells on glycolysis leads to a reduction in the rate of mitochondrial ATP
production through the electron transport chain (OXPHOS), leading to the
hyperpolarization of the mitochondria in cancer cells, a vulnerability that could be
targeted for cancer therapy. (Adapted from Kroemer, 2006; D’Souza et al., 2011).
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PROGRAMMED CELL DEATH (PCD)
Cell death programs occur naturally in multicellular organisms as a way to
maintain tissue homeostasis (Ziegler, 2004). Therefore, it can be inferred that a
disruption in cell death processes can play a role in the development of various
diseases. One of the main hallmarks of cancer cells is their ability to evade
programmed cell death programs, even in the face of severe cellular damage
(Hanahan & Weinberg, 2011). These damaged cells are still able to replicate and
proliferate, leading to an increase in the amount of damaged cells. As these cells
continuously replicate, they accumulate more mutations allowing survival of
cancer cells, their translocation to a different location in the body (metastasis),
and the development of other characteristics found in cancer cells (Weinberg,
1996; Hanahan & Weinberg, 2011). These findings indicate that PCD play a
significant role in preventing carcinogenesis, and that defects in such processes
contribute significantly to the development of cancers, as well as other diseases.
Initially, necrosis and apoptosis were the major forms of cell death studied,
with apoptosis being distinguished from necrosis, as apoptosis was considered
physiological, programmed and inconspicuous, while necrosis was considered
pathological, and a response to traumatic situations and external injury (Ziegler,
2004; Ghobrial et al., 2005). More recently, other forms of PCD have been
discovered, including autophagy, necroptosis and oncosis, to name a few (Fadeel
& Orrenius, 2005; Coates et al., 2010). The introduction of new forms of PCD
have enabled further understanding of the role of cell death in the development of
diseases, especially cancer. This thesis focuses on the two main forms of PCD,
apoptosis and autophagy, and their roles in carcinogenesis.
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APOPTOSIS (PROGRAMMED CELL DEATH TYPE I) - 
The significance of PCD to cancer initiation and progression has being a
major hot button in cancer research. Kerr and colleagues studied a distinct mode
of cell death, separate from necrosis, and have shown that this process plays a
significant role in cancer. As with the hallmarks of cancers, they observed a
distinct lack of apoptosis, also known as ―cellular suicide‖ or PCD in cancer cells,
which was reversed when these cells were exposed to cytotoxic agents and/or
irradiation (Kerr et al., 1994). The morphological characteristics of this mode of
cell death were characterized and by the end of the 20th century, much was
known about the process of apoptosis (Ziegler, 2004).
Apoptosis, a term derived from the Greek word that describes the ―falling
off of petals from a flower or leaves from a tree‖, was coined in order to describe
a physiological, energy-dependent and highly regulated process of controlled
cellular self-destruction. This is distinct from necrosis, which is a passive,
degradative and energy-independent mode of cell death (Gewis, 2003; Fadeel &
Orrenius, 2005; Elmore, 2007). It is a process that occurs normally during
development and aging, and as a defense mechanism against immune reactions
and damage to the cell, induced by noxious agents, such as ionizing radiation
and some of the available forms of chemotherapy (Elmore, 2007).
Although both apoptosis and necrosis can occur independently,
sequentially

or

simultaneously,

the

identification

of

the

morphological

characteristics of both forms of cell death can be used to distinguish apoptosis
from necrosis and other forms of PCD (Elmore, 2007). Apoptosis occurs in a
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highly established sequence of events, often seen with the condensation of the
nuclear and cytoplasmic material, the activation of cysteine-dependent aspartic
proteases (caspases) and the reorganization and blebbing of the cell membrane
to externalize phopshatidylserine. This externalized phosphatidylserine (PS) is
essential in the apoptotic process, as it aids in the recognition of compact
membrane-enclosed structures, called apoptotic bodies, by phagocytes or
neighboring cells (Fadeel & Orrenius, 2005; Coates et al., 2010). The taking up of
the apoptotic bodies prevents the triggering of an inflammatory response, which
is also a distinguishing characteristic from necrosis. During necrosis, the swelling
of the plasma membrane and its eventual disruption, allows the release of the
cytoplasmic content into the surrounding tissue, eventually leading to the
recruitment of pro-inflammatory signals and inflammatory cells (Gewis, 2003;
Elmore, 2007).
There have been conflicting reports on the reversibility of apoptosis,
following apoptotic stimuli receipt and induction. Studies have shown that,
although thought to be a reversible process, blocking the engulfment of apoptotic
bodies by phagocytic cells in C. elegans, can enhance cell survival (Elmore,
2007). This is in direct contrast to other findings that show that once apoptotic
stimuli are received, the downstream cascade of events inevitably leads to the
permeabilization of the mitochondrial membrane, which leads to the release of
pro-apoptotic factors and the activation of caspases. The activated caspases
cleave downstream molecules, including the caspase activating DNase (CAD),
which cleaves DNA into fragments, and poly (ADP-ribose) polymerase (PARP),
which is involved in DNA repair, caused by cleavage. The cleavage of PARP
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prevents its repair mechanism and the process of apoptosis remains ongoing
(Wyllie, 2010). Once these events occur, the cell is usually committed to
apoptosis, hence no reversal in the process of apoptosis is possible (Coates et
al., 2010). The focus of cancer therapy is therefore aimed at providing enough of
an apoptotic stimulus that would cause the permeabilization of the mitochondrial
membrane, the release of apoptogenic factors and the downstream caspase
cascade in cancer cells.
For any of the aforementioned morphological characteristics to be
observed, the downstream signaling cascade of apoptosis has to commence,
following the receipt of apoptotic stimulus. There are two major pathways of
apoptosis; the first being the extrinsic (cytoplasmic) pathway, which is triggered
through receptors belonging to the Tumor Necrosis Factor (TNF) superfamily of
receptors and the second is the intrinsic (mitochondrial) pathways, which is
triggered by internal stress, such as irradiation or noxious agents (Figure 3). Both
pathways are linked by several factors and, as such, inhibitors of apoptosis tend
to inhibit both pathways (Ghobrial et al., 2005). These pathways involved in
apoptosis are discussed below;
THE EXTRINSIC PATHWAY OF APOPTOSIS
The extrinsic pathway, also known as the death receptor mediated
pathway of apoptosis, involves proteins in the TNF receptor superfamily (Figure
3). These proteins share a cysteine-rich extracellular domain, as well as a
cytoplasmic domain of about 80 amino acids, called the death domain (Elmore,
2007). These death domains play a significant role in transmitting the death
signal from the cell surface to intracellular signaling pathways (Ghobrial et al.,
14

2005). This process commences with the binding of a specific death ligand to its
corresponding death receptors (e.g. Fatty acid synthetase [FasL/FasR]; Tumor
Necrosis Factor [TNF-/TNFR1] and TNF-related Apoptosis Inducing Ligand
[TRAIL/TRAIL-R1, R2]) (Fulda & Debatin, 2006). Once the ligand is bound to its
receptor, cytoplasmic adapter domains with corresponding death domains that
bind the receptors, such as the Fas-associated death domain (FADD) and the
TNF receptor type-1 associated death domain (TRADD), are recruited to the
cytoplasmic side. This interaction recruits pro-caspase-8, an initiator caspase, by
its death effector domain (DED) to the death inducing signaling complex (DISC),
which is a complex of the membrane receptor, death domains and pro-caspase8. Once bound, several pro-caspase-8 molecules are in close proximity to one
another, resulting in the auto-catalytic cleavage and activation of caspase-8. The
activated caspase-8 then triggers the execution phase of apoptosis, by the
cleavage of downstream effector caspases, such as caspase-3 (Ghobrial et al.,
2005; Fulda & Debatin, 2006; Coates et al., 2010). If the activating signal in
extrinsic apoptosis is strong enough, the activated caspase-8 will can directly
activate the effector caspase-3, however if this signal is not strong enough for the
execution of apoptosis, the signal is usually amplified by linking the extrinsic
pathway to the intrinsic pathway. This occurs when the activated caspase-8
cleaves a member of the Bcl-2 family of proteins, Bid (BH3 interacting domain
death agonist), to its truncated form, tBID. tBID translocates to the mitochondria
and activates intrinsic apoptosis (Gewis, 2003).
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THE INTRINSIC PATHWAY OF APOPTOSIS
In apoptosis regulation, the mitochondria are not only effective in the
induction of apoptosis following Bid cleavage, but also plays an integral role in
the transmission of positive or negative death signals, following apoptotic stimuli.
The positive signals for mitochondrial apoptosis include radiation, toxins, some
chemotherapeutic agents, hypoxia, hyperthermia, viral infections, and free
radicals, while the negative signals include loss of growth factors and starvation
(Gewis, 2003; Elmore, 2007). These non-receptor mediated stimuli produce
intracellular signals that act on the Bcl-2 family of proteins, which then directly on
the mitochondria, to disrupt the mitochondrial inner transmembrane potential
(Δψm) and the mitochondrial permeability transition pore (Fadeel & Orrenius,
2005). The Bcl-2 family of proteins includes pro-survival members, such as BclXL, Bcl-w, A1, and Mcl-1, which all possess the domains BH1, BH2, BH3, and
BH4, and pro-apoptotic members, including Bax, Bak, and Bok, all with the BH1,
BH2 and BH3 domains, whereas Bid, Bim, Bik, Bad, Bmf, Hrk, Noxa, Puma, Blk
only possess the BH3 domains, which is sufficient for its apoptotic inducing
activity (Gewis, 2003; Fulda & Debatin, 2006; Plötz et al., 2013).
Upon activation of the pro-apoptotic Bcl-2 members and the disruption of
the mitochondrial membrane potential, a series of biochemical events occur,
which include the halting of ATP synthesis, the oxidation of NADH, NADPH and
glutathione, the generation of reactive oxygen species (ROS) and the release of
pro-apoptotic factors from the inner mitochondrial membrane into the cytosol
(Ghobrial et al., 2005). These factors include cytochrome c, Smac/Diablo,
Omi/HtrA2, AIF and Endonuclease G and once released into the cytosol, can
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trigger caspase-mediated or caspase-independent apoptosis. Cytochrome c
release from the mitochondria has been extensively studied. Once this protein is
released, it binds to an adaptor molecule, Apoptotic Protease Activating Factor 1
(APAF1), which then oligomerizes and recruits pro-caspase-9, in the presence of
ATP, through the caspase recruitment domain (CARD); this allows autoactivation of caspase-9 and this complex is known as the apoptosome, which is
essential for the activation of downstream effector caspases, like caspase-3
(Fulda & Debatin, 2005; Elmore, 2007).
Intrinsic apoptosis is able to follow a caspase-independent pathway,
following the release of the apoptosis-inducing factor (AIF) and the endonuclease
G (EndoG) from the inner mitochondrial space. AIF translocates to the nucleus,
where it participates in DNA degradation, while EndoG triggers caspaseindependent DNA fragmentation in cells following apoptotic stimuli (Ghobrial et
al., 2005; Fulda & Debatin, 2006). Both pathways have various inhibitors that
prevent the downstream signaling involved in apoptosis, including inhibitors of
apoptosis proteins (IAPs) and Flice inhibitory proteins (FLIPs) (Fadeel &
Orrenius, 2005).
Evasion of apoptosis is considered a major hallmark of cancer cells and
therefore the understanding of this process has enabled the development of
several forms of therapy. However, as cancer cells are notorious for developing
resistance mechanisms (Rebucci & Michiels, 2013), it is also essential to further
assess other forms of PCD, in the hopes of better developing better forms of
cancer therapeutics.
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Figure 3: The Pathways of Apoptosis that can be induced, following differential
apoptotic stimuli. The two main pathways of apoptosis include the intrinsic
pathway that requires an internal stimulus, such as toxins and DNA damaging
agents. The stimulus promotes the expression of proteins like p53, which lead to
downstream signaling that permeabilizes the mitochondrial membrane and allows
the release of pro-apoptotic factors, such as cytochrome c, the activation of
caspase-9 and the subsequent activation of caspase-3. In the extrinsic pathway,
a death ligand binds to its specific death receptor, recruits n adaptor domain and
leads to the activation of caspase-8. Active caspase-8 could directly activate
caspase-3 or could link to the intrinsic pathway through the cleavage of proapoptotic Bid, which ultimately leads to the permeabilization of the mitochondrial
membrane. Cancer cells overexpress inhibitors of both apoptotic pathways,
including IAPs (XIAP) and FLIPs (cFLIP). (Adapted from Ghobrial et al., 2005;
Fulda & Debatin, 2006; Coates et al., 2010)
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AUTOPHAGY (PROGRAMMED CELL DEATH TYPE II)
Autophagy, the process of ―self-eating,‖ is a lysosomal degradative
process, known to play a significant role as a tumor suppressive mechanism in
the development and progression of cancer, as defective autophagy has been
shown to be one of the numerous causes of tumorigenesis (Hippert et al., 2006).
Along with apoptosis, autophagy is involved in maintaining cellular homeostasis,
as it functions in nutrient recycling, energy generation, and the clearance of
damaged proteins and organelles (He et al., 2013).
The ability of cancer cells to evade apoptosis is one of the true hallmarks
of cancer and this property is vital to chemotherapeutic and radiotherapeutic
resistance as characterized by the most aggressive forms of human cancers
(McKenzie & Kyprianou, 2006). The introduction of autophagy in research has
introduced an alternative way to induce cell death in cancers that are resistant to
apoptosis and therefore chemotherapy. Autophagy is induced by a variety of
stimuli, including stress, starvation and the inhibition of the mTOR pathway and is
responsible for non-selective degradation of long-lived proteins, large aggregates
and defective organelles (Kim et al., 2008). This process involves the formation of
a double membrane vesicle around the protein/organelle to be degraded. This
double membrane vesicle, known as the autophagosome, then fuses with the
lysosome and the contents of the autophagosome are degraded (Figure 4)
(Hippert et al., 2006). This formation of the autophagosome and the subsequent
degradation of proteins and organelles are dependent on the selective
combination of several Atg (AuTophaGy) proteins. Some of these proteins play
similar roles to the enzymes in the ubiquitination cascade (Lee et al., 2012),
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suggesting that the autophagic process and the ubiquitination process are not
mutually exclusive.
The emergence of the process of autophagy is controversial. Depending
on the cell type and conditions, autophagy is believed to have dual roles (Hippert
et al., 2006; Dalby et al., 2010). Autophagy is a catabolic process that serves as
both a quality control process and a mechanism to replenish intracellular
nutrients and provide materials needed for protein synthesis, under conditions of
poor nutrient availability (Dalby et al., 2010; Yecies & Manning, 2011). These
suggest a pro-survival role in normal homeostasis and that autophagy could also
play a similar role in cancer, protecting tumor cells under stressful conditions (like
hypoxia and acidity, through overproduction of lactate), by providing the
necessary materials needed for required protein synthesis. For instance, there
are known anticancer agents, like tamoxifen and etoposide, which induce prosurvival autophagy (Dalby et al., 2010). This pro-survival form of autophagy is
usually accompanied by an inhibition of other forms of cell death, including
apoptosis (Hippert et al., 2006; Thorburn, 2008). On the other hand, many
studies have focused on the pro-death role of autophagy, especially in cancer
cells, as it has been observed that defects in autophagic processes promote
carcinogenesis (Yecies & Manning, 2011).
Furthermore, important connections between apoptosis and autophagy
have been identified, indicating an important link between the two main forms of
PCD (Figure 5) (Rosenfeldt & Ryan, 2011). For instance, p62 (also known as
sequestosome-1, SQSTM-1) has been found to interact with death receptors,
DR4 and DR5, for the activation of TRAIL induced extrinsic apoptosis. The fact
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that it also interacts with the autophagy regulator, Atg8/LC3, through its LC3interacting region, also indicates its importance in autophagy. The involvement of
p62 in the process of autophagy has been well established, and although
autophagic degradation is considered non-selective, the ability of p62 to
specifically recognize polyubiquitinated, misfolded and aggregated proteins and
organelles for selective autophagic degradation points to the importance of this
protein in autophagy. These findings provide substantial evidence of a molecular
link between autophagy and apoptosis, through the modulation of p62 (Moscat &
Diaz-Meco, 2009).
The Bcl-2 family of proteins not only have important roles in the
progression of apoptosis, but they also play a role in autophagic initiation and
progression (Thorburn, 2008). Pro-survival Bcl-2 interacts with pro-apoptotic Bax
to inhibit the induction of apoptosis and it has also been found to interact with
Beclin 1, to inhibit its role in the formation of the autophagosome (Figure 5).
Furthermore, the autophagic protein, Atg5, an E3 ubiquitin ligase-like protein,
involved in the elongation of the autophagosome, has also been found to interact
with FADD, resulting in apoptotic cell death through extrinsic apoptosis. Cleavage
of Atg5 by calpain leads to the translocation of the truncated Atg5 to the
mitochondria, where it promotes the release of cytochrome c (Thorburn, 2008;
Zhivotovsky & Orrenius, 2010; Kuang, Qi, & Ronai, 2013).
Overall, there is overwhelming evidence that autophagy functions as PCD
type II in some cancer cells where apoptosis is defective and, as such, it is not
difficult to infer that the induction of pro-death autophagy selectively in cancer
cells could be used as an anti-cancer therapeutic strategy.
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Figure 4: The Process of Autophagy that leads to autophagic degradation,
through the interaction with the lysosome. Cellular stresses, such as ER stress
and starvation, lead to the inhibition of the mammalian target of rapamycin
(mTOR), which leads to the induction of autophagy. The AuTophaGy related
proteins (ATGs) and Beclin-1 and Beclin-2 trigger downstream events that leads
to the complex assembly of the membrane structure of the phagophore. The
formation of this complex facilitates the conjugation of LC3-I onto
phosphatidylethanolamine in the lipid bilayer of the membrane, converting it to
LC3-II, and allowing the phagophore elongate and engulf target proteins and
organelles, via adaptor proteins like p62 and form the autophagosome. The
autophagosome fuses with the lysosome and acidic compartment that promotes
the fusion and degradation of the contents, through the aid of lysosomal
enzymes, such as cathepsins. (Adapted from Hippert et al., 2006).
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Figure 5: The Connections Between Apoptosis & Autophagy: Regulation of
apoptosis and autophagy is required to prevent deregulation of these processes
and their roles in disease initiation and progression. A) The Bcl-2 family of
proteins regulate both autophagy and apoptosis, where Bcl-2, MCl-1 and Bcl-xL
inhibit apoptosis by blocking Bax activation to prevent mitochondrial
permeabilization and the release of pro-apoptotic factors. Alternatively, these
proteins interact with Beclin-1’s BH3 domain to inhibit mTOR and activate
autophagy. B) Several key players in autophagy (ATG5, Beclin-1 and p62) also
play a significant role in apoptotic induction, through the activation of caspases
and the permeabilization of the mitochondrial membrane. Some death ligands,
like TRAIL have also shown significant effect in targeting the autophagic
pathways for the induction of autophagic degradation. (Adapted from Thorburn,
2008; Moscat & Diaz-Meco, 2009; Rosenfeldt & Ryan, 2011).
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THE ROLE OF PROGRAMMED CELL DEATH IN CANCER
Both apoptosis and autophagy have been implicated in the initiation and
progression of carcinogenesis. Cancer cells are notorious for up-regulating prosurvival signaling pathways that inhibit the induction of apoptosis, while mutations
in tumor suppressors, e.g. p53, and pro-apoptotic proteins are rampant
(Zhivotsovsky & Orrenius, 2010). Although it has been recognized that autophagy
could play dual roles, as a pro-survival or pro-death mechanism, it has been well
established that pro-survival autophagy plays an integral role in carcinogenesis,
providing cancer cells with the nutrients and energy they require for survival.
Furthermore, this form of autophagy has been correlated with a decrease in the
levels of other forms of PCD, especially apoptosis (Hippert et al., 2006).
The importance of both forms of PCD, especially in carcinogenesis is well
established. Various anti-cancer therapies have been shown to, not only induce
apoptosis in cancer cells, but to be efficacious in the induction of autophagy; for
instance, tamoxifen induces pro-survival autophagy in breast cancer cells in invitro models and ionization radiation has been found to induce pro-death
autophagy in various cancer cell type, to name a few (Coates et al., 2010). This
suggests that further understanding of PCD processes (type I and II) could be
beneficial anti-cancer strategies.
PCD, especially apoptosis, is designed as a safeguard against
carcinogenesis in normal cells. Most chemotherapeutic treatments attempt to reignite apoptosis in cancer cells. Unfortunately, available therapies also target
non-cancerous cells (as described below) and as such, there is a need to
develop more selective and thus safer forms of therapy.
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CURRENT CANCER THERAPY
The incidence of cancer is constantly increasing as the aging population
increases (Jemal et al., 2011). Substantial research has gone into developing
effective forms of treatments to halt the progression of cancer, usually by
stimulating the induction of various forms of programmed cell death (PCD) in
cancer cells by targeting mitotic machinery (Chabner & Roberts, 2005, Zhou &
Giannakakou, 2005); in more recent years, the focus has shifted to targeting
cancer cell metabolism (Zhao et al., 2013). Advances in research have
successfully introduced various forms of therapy into cancer care and their
effectiveness and drawbacks will be discussed further below;
SURGERY
Currently, cancer therapy designs are usually based on the organ in which
the cancer originates and the localization of that organ or cancer in the body
(Cortés et al., 2013). In the case of solid tumors, early detection is essential for
successful treatment, as it enables surgical removal, as primary treatment, of the
tumor or the organ in which it is located (if possible). Over the past decade,
substantial advances have been made to improve the early detection of various
cancers, thereby improving the outcome of surgical resection of tumors, as has
been observed with improved colorectal cancer screenings (Desantis et al.,
2014). Studies show that survival rates for non-small cell lung cancer (NSCLC)
greatly decrease as the cancer stages increase, going from 80% at stage I to less
than a 20% 2-year survival rate at stage III (Hussain & Nguyen, 2014).
Although surgery is associated with an increase in the survival rate of
some cancer patients, there are still cases where surgery, as a mode of therapy,
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is still not effective. Surgical resection is limited to patients in the early detection
category, usually before the tumor has invaded and metastasized into other
tissue locations. Furthermore, surgery is not without adverse effects. Long-term
side effects include tingling and tightness at the site of surgery along with later
development of chronic pain; although in some cases, this pain is not considered
severe. In prostate cancer patients, surgery is associated with urinary
incontinence, erectile dysfunction and bowel complications, while in thyroid
tissues, surgery can damage the nerves in the larynx. Furthermore, it has been
established that cancer recurrence is common in patients that underwent surgery,
with almost half the patients having a recurrence within 3 years of surgery; hence
many cancer patients usually undergo some other form of therapy, usually
chemotherapy and radiation therapy, alongside surgery (Desantis et al., 2014).
RADIATION THERAPY
Due to the aggressiveness and poor prognosis associated with many
cancers, the addition of other therapeutic forms, before or after surgical resection,
has been implemented in several cancer types. Radiation therapy has often been
employed to improve response and survival rates in cancer patients (Shaw et al.,
2002; Desantis et al., 2014). This form of therapy, along with surgery, improves
survival of cancer patients by potentially inhibiting further implantation of
metastasized tumors, allowing for better focused treatment to the localized site of
the primary tumor (Jagsi, 2014).
Normally, double stranded DNA breaks (for instance, as caused by
radiation, hypoxia and the presence of free radical scavengers), induces cell
cycle arrest and an enzymatic repair program for the repair of DNA damage.
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Inability to repair this damage leads to one of two pathways, the induction of
senescence and the induction of apoptosis or necrosis, through the up-regulation
of the tumor suppressor, p53 (Ross, 1999). Rapidly dividing cancer cells are
targeted by increasing doses of ionizing radiation, triggering apoptotic induction.
Due to the common target that is DNA and other mitotic machinery, however,
ionizing radiation also causes DNA damage in normal, non-cancerous cells,
leading to severe side effects observed in cancer patients in this treatment
regimen. As radiation therapy does not trigger cell death programs immediately
following treatment, it has been shown to induce cell death programs days or
even weeks following treatment. Slow growing tissues can remain unaffected for
weeks or months following treatment and, as such, the side effects in these
tissues are only observed months after the treatment regimen has been
concluded (Pawlik & Keyomarsi, 2004).
Genomic instability, as a result of DNA damage, is usually a contributing
factor to carcinogenesis. Coupled with the fact that cancer cells are notorious for
having mutations in the tumor suppressor p53, it can be concluded that DNA
damage and the inability to repair the damage and evade PCD processes
contributes to the process of carcinogenesis (Gorgoulis et al., 2005). As
ionization radiation induces DNA damage in order to trigger these cell death
processes, it can therefore be inferred that a resulting effect of ionizing radiation
is the accumulation of new tumors in a patient already undergoing treatment. This
suggests that a more effective mode of therapy is required, one that does not
come with the chances of inducing further carcinogenesis.
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CHEMOTHERAPY
Prior to the 1940’s, surgery and radiation therapies dominated the world of
cancer therapy. Since the beginning of the 20th century, various forms of
chemotherapy have also been in play (Chabner & Roberts, 2005; DeVita & Chu,
2008). Chemotherapy began with the use of nitrogen mustards and anti-folates,
the latter of which was used to inhibit the effect of folic acid on the proliferation of
leukemia cells; and over the years, has evolved to include several classes of
drugs (Chabner & Robert, 2005).
Cancer chemotherapy was developed to circumvent some of the side
effects observed in patients undergoing radiation therapy, particularly the DNA
damaging aspect that leads to PCD or development of secondary malignancies.
Newer chemotherapy introduced agents that target microtubules, which are a
major component of all eukaryotic cells and are vital for the maintenance of cell
shape, polarity, cell division and intracellular transport. Vinca alkaloids (e.g.
vincristine) and taxanes (e.g. paclitaxel) are the major groups of microtubule
targeting drugs, obtained from natural products, that have shown success as
microtubule destabilizing agents (Vinca alkaloids) and microtubule stabilizing
agents (taxanes). Both classes of microtubule targeting agents inhibit the
progression of cells through the cell cycle, inhibit mitosis and lead to the induction
of PCD. Besides their abilities to affect microtubule formation, these agents have
also been found to inhibit the formation of new blood vessels, a process known
as angiogenesis (Zhou & Giannakakou, 2005).
Although there have been major advances in the development of these
chemotherapies, the principles and limitations that have governed the discovery
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of new chemotherapeutic agents still apply today (Chabner & Robert, 2005). For
instance, neurological and hematological side effects are usually observed in a
dose-dependent effect in patients undergoing treatment with microtubule
targeting

agents.

Immunosuppression,

the

development

of

secondary

malignancies, and even death resulting from other side effects is usually
associated with majority of the currently available chemotherapies (Zhou &
Giannakakou, 2005; Desantis et al., 2014). Altogether, this information indicates
that a better target for cancer therapy is needed, in order to bypass some of the
severe side effects that are observed in cancer patients undergoing treatment.
TARGETED THERAPY
The limitations associated with the previously discussed forms of cancer
therapy, along with the many molecular defects in cancer cells, led to the
introduction of targeted therapies. These therapies were introduced in a bid to
target the multiple hallmarks of cancer (Hanahan & Weinberg, 2011), as well as
the metabolic changes within cancer cells (Zhao et al., 2013), in order to develop
more effective treatment regimens that do not come with such severe side
effects. These targeted therapies include targets such as growth factors,
signaling molecules and pathways, cell-cycle proteins, modulators of apoptosis
and proteins involved in angiogenesis (Chabner & Robert, 2005).
One of the most famous examples of targeted therapy was the
development of the Bcr-Abl tyrosine kinase inhibitor, imatinib (Gleevec), for the
treatment of chronic myeloid leukemia, with the characteristic Philadelphia
chromosome (Chabner & Robert, 2005; DeVita & Chu, 2008). This innovation
was a stepping-stone for the introduction of monoclonal antibodies against
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receptors and growth factors in cancer therapy, such as those against the
epidermal growth factor receptor (EGFR), like cetuximab (Martinelli et al., 2009).
Unfortunately, targeted therapies are not without their own obstacles. Cancer cell
resistance to chemotherapy is still a major limitation to cancer therapy
development; intrinsic and acquired resistance is usually observed following
numerous genetic and epigenetic changes in cancer cells (Rebucci & Michiels,
2013). Common resistance mechanisms involve drug efflux, using the multidrug
resistance (MDR) transporter, changes in DNA damage responses and mutations
in several pathways, allowing cancer cells develop the previously discussed
hallmarks of cancer (Chabner & Robert, 2005; Rebucci & Michiels, 2013). Cancer
cell resistance to targeted therapies have led to the introduction of combination
therapies, in a bid to overcome the resistance associated with targeted therapies,
while still attempting to reduce therapy-associated toxicity (Li et al., 2014).
The huge toxicity associated with cancer cell therapy is due to nonselective targets and the ―by-stander‖ effects. Emerging evidence indicates a role
of natural health products in the possible development of non-toxic alternatives
for cancer therapy. This begs further research and scientific validation of such
products for cancer treatment.
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NATURAL HEALTH PRODUCTS (NHPs)
Natural health products (NHPs) and natural products (NPs) play a leading
role in the discovery and the development of drugs for the treatment of human
diseases. Traditional medicines in the Native American, Chinese, and Indian
cultures have utilized numerous natural products, including dozens of spices and
plant extracts. NHPs are becoming increasingly popular and are used widely for
their promising therapeutic effects and fewer side effects. Scientific research into
the validity of these traditional products has shown that many do indeed have
potent anticancer effects (Zhi et al., 2007; Ganesan, 2008; Newman & Cragg,
2012). For instance, an extract from the Mayapple, Podophyllum peltatum, was
traditionally used by Native Americans to combat skin cancers and other
malignant neoplasms, as well as a host of other ailments. The major component
of this extract was podophyllotoxin, which was the first in a series of effective
anticancer agents called podophyllins (Mann, 2002). Likewise, numerous natural
products used by traditional Indian Ayurvedic medicine have been shown to have
strong anti-inflammatory and anticancer properties.
Even with all the incoming evidence, herbal drugs and other NHPs and
NPs are usually shunned during systemic therapy because of herb–drug
interaction and exaggeration of therapy-related toxicity. Current research is
focused on the development of new and more effective therapeutic agents that
have little to no associated toxicity to the patient. Lately, this focus has been
centered on NHPs and herbal formulations, mainly in the form of plants and other
biological sources around the world. NHPs have been used for centuries by a
variety of cultural backgrounds for various illnesses, some of which continually
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provide new medicinal applications and intriguing anecdotal evidence, which
merit further investigation. Today, there are numerous natural products that fall
under the umbrella of alternative medicine (Aggarwal et al., 2007; Ganesan,
2008; Kumar et al., 2011).
NHPs, from various traditional medicines, have been used for centuries for
the treatment of various diseases and anecdotal evidence suggests that there is
some benefit to the claims that have been reported. Furthermore, the use of
these NHPs and NPs have not been associated with many side effects and
toxicities (Aggarwal et al., 2006; Efferth et al., 2007). NHPs are complex
mixtures, containing multiple components that could potentially have bioactivity in
the face of different diseases. The complexity of NHPs makes them a viable
option for the treatment of diseases, especially chronic diseases like cancer, as
they might be able to target multiple pathways in a disease, while acting together
to potentially reduce any toxicities associated with the use of the NHP or NP
(Mishra et al., 2000; Tabas & Glass, 2013).
Studies on various natural products have shown some efficacy and lack of
toxicities associated with the use of these herbal formulations. However, as with
many other forms of therapies, combinations of NHPs have also been studied,
focusing on the combination of NHPs and NPs at lower doses, to further reduce
chances of toxicities and improve efficacy (Huang et al., 2003; Mueller et al.,
2004). Such studies provide sufficient evidence for the introduction of NHPs to
the public, in order to provide safer and cheaper complementary treatments for
diseases, especially in chronic diseases like cancer.
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NATURAL HEALTH PRODUCTS IN CANCER
The toll of cancer on the population is continuously on the rise and the
efficacy and safety of available anti-cancer therapies has not yet caught up. The
role of NHPs in cancer treatment has been evaluated in several scientific studies,
leading to the development of a total of 27 anti-cancer drugs from natural sources
between 1940 and 2010 (Figure 6) (Newman & Cragg, 2012). A common
example is Camptothecin, a quinolone alkaloid, has been studied and used for its
anti-tumour activity in targeting and inhibiting DNA topoisomerase I. This
compound was isolated from extracts of the Camptotheca acuminate, which has
been used for years in traditional medicine. In the last decade, this NP has been
found to possess anti-cancer activity, and its derivatives, topotecan and
irinotecan, are routinely used in the treatment of ovarian and colon cancers
(Efferth et al., 2007).
The discovery of the anticancer activities of so many traditional medicines
and natural products has been supported by scientific evidence and validation.
This was in part successful due to the initiation of the Cancer Chemotherapy
National Service Center (CCNSC) in 1955, by the National Cancer Institute (NCI).
The mandate of this program was to ―screen for anti-tumor agents on a larger
scale by establishing a strict standardized protocol‖ for testing potential
anticancer compounds (DeVita et al., 2008).
Since the 1980s, research into the anti-cancer effects of natural products
has yielded many promising results. For example, resveratrol, a polyphenol
present in grapes, has been under investigation for years and these studies show
the potential of resveratrol as both a preventative and an anti-tumor agent (Lu et
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al., 1999; Kallantari & Das, 2010). Similarly, piperlongumine, extracted from Piper
longum and identified in the 1960s around the same time as Taxol, was found to
selectively induce generation of reactive oxygen species in cancerous cells by
targeting the oxidative stress response and leading to apoptotic cell death (Raj et
al., 2011). In the 1980s, Kenneth Bagshawe and Peter Senter developed a novel
use for natural products: the antibody-directed enzyme-prodrug therapy
(ADEPT). This technique used tumor-specific antibodies bound to an enzyme
that would convert non-cytotoxic prodrugs into their cytotoxic forms once in
contact with the tumor. Many natural products were successfully used as
prodrugs, including doxorubicin and Taxol (Mann, 2002).
The different hallmarks of cancer and tumor cells, which include evading
growth suppression signals, evading programmed cell death processes, inducing
angiogenesis and sustaining proliferative signaling, to name a few (Hanahan &
Weinberg, 2001; Hanahan & Weinberg, 2011), provide multiple means to target
cancer cells selectively. The study of NHPs against cancer cells and xenograft
models has therefore focused on identifying NHPs that can target pathways that
convey survival protection to cancer cells, so as to selectively and effectively
eradicate cancer cells.
These earlier studies have paved the way for the introduction of more
NHPs from traditional medicine to the forefront of modern medicine and
anecdotal evidence indicate that these NHPs merit further investigation and
scientific validation. The scientific validation of these NHPs in terms of their
efficacy, safety and mechanism of actions will seal their position in modern
medicine, especially in the field of cancer research and therapy.
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Figure 6: Sources of Anticancer Drugs from the 1940s to 2010.
* Legend: Natural product (N); Derived from a natural product-usually a synthetic
derivative (ND); Natural product ―Botanical (NB); Natural product mimic (NM);
Totally Synthetic Drug (S); Made by total synthesis, but the pharmacophore is/
was from a natural product (S*). (Adapted from Ganesan, 2008; Newman &
Cragg, 2012).
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DANDELIONS (TARAXACUM spp.)
Dandelions are perennial ―weeds‖ that belong to the Asteraceae family of
plants and are widespread throughout warmer temperate zones. This plant has
been used for centuries as a form of remedy for various diseases, including
treating abscesses, reducing inflammation and promoting diuresis in traditional
Chinese medicine (TCM). These health benefits are not only limited to Chinese
medicine; folk use and traditional medicinal uses for dandelions extend across
Europe and Africa (Sigstedt et al., 2008; Yarnell & Abascal, 2009). The various
health benefits attributed to the use of dandelions has been credited to specific
Taraxacum species, including T. japonicum, T. monogolicum, T. coreanum and
T. officinale (Sigstedt et al., 2008). Various parts of this plant have been used in
the treatment of different ailments, with the root having been used in
gastrointestinal diseases and the leaves, as a diuretic and digestive stimulant.
The whole plant has been taken as a cure for hepatitis and anorexia as well,
although some of the claims associated with this weed have gone
unsubstantiated (Schütz et al., 2006; Yarnell & Abascal, 2009).
Some preclinical research on dandelion has introduced this plant with
numerous properties to the scientific community. Research has shown the antiinflammatory, prebiotic, anti-angiogenic and anti-neoplastic properties of
dandelion root (Zhi et al., 2007; Yarnell & Abascal, 2009). Some of these studies
contradict each other, leading to the publication of conflicting reports on the
efficacy of dandelions, however, the one thing all these studies agree on is that
dandelions can induce cytotoxicity in several types of cell types, due to its effect
on oxidative stress, inflammatory response, the secretion and expression of TNF36

 and IL-the down-regulation of nitric oxide (NO) and cyclooxygenase-2 (COX2) (Hu & Kitts, 2003; Koo et al., 2004; Hu & kitts, 2005; Schütz et al., 2006; Jeon
et al., 2008). The flower extract of T. officinale was found to be both pro-oxidant
and anti-oxidant, as at low doses, anti-oxidant behaviour was observed, and
attributed to the presence of luteolin and luteolin-7-glucoside, while at higher
doses, this extract possess pro-oxidant activities in colon cancer cells (Hu & Kitts,
2003). It is essential to note that the production of ROS can have both proapoptotic and anti-apoptotic effects, depending on the conditions of the cells, as
well as the cell types (Simon et al., 2000). The investigation of the mechanism of
action of dandelion root extract in cancer cells is under study, with focus on the
identification of the possible apoptotic pathway in which this extract is selective to
cancer cells. The mechanistic efficacy of DRE will be discussed in later chapters
of this thesis.
The selective anticancer efficacy of dandelion root extract has been
attributed to its ability to induce death-receptor mediated extrinsic apoptosis in
cancer cells selectively, and this activity can be attributed to the presence of
sesquiterpene lactones (Zhang et al., 2005; Ghantous et al., 2010), and the
suppression of cellular FLICE- like inhibitory protein (cFLIP), which is highly
expressed in several cancer cell types, including pancreatic cancer cells, by the
triterpene, lupeol (Murtaza et al., 2009). This compound is one of the bioactive
components of dandelion extracts (Hata et al., 2000; Chatterjee et al., 2011). This
inhibition of cFLIP has been shown to render TRAIL-resistant cancer cells
sensitive to TRAIL therapy (Murtaza et al., 2009).
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These are important findings that show the versatility of natural health
products, especially dandelion root extract, in targeting several cellular pathways
and under different situations and conditions; they also provide significant
evidence for the efficacy use of NHPs, especially dandelions, in the fight against
cancer.
LONG PEPPER (PIPER Spp.)
Long pepper, from the Piperaceae family, have been used for centuries,
for the treatment of various diseases. The identification of several bioactive
species of long pepper have been identified and they include P. longum, P. betle
and P. retrofactum. A long list of benefits have been attributed to the extracts of
the different Piper spp, with reports indicating their efficacy in different ailments
(Kumar et al., 2011).

Historically, long pepper has been used as a topical

treatment for muscle inflammation but has shown efficacy in a number of
diseases and conditions including diabetes, cancer and obesity, as well as its use
as an analgesic, and digestive stimulant, without having any toxic effects (Kumar
et al., 2011; Bao et al., 2013). More recently, the plant has been studied as an
anti-inflammatory

for

Carrageenan-induced

paw

edema

in

rats,

where

researchers found significant decrease in paw inflammation of rats treated with
long pepper indicating its efficacy in acute and sub-acute inflammation (Kumari et
al., 2012).
In addition to this study, other work has been done on Piperlongumine
(PL), an important component of the long pepper fruit, as a therapy against
atherosclerosis. This study found that the anti-inflammatory and anti-platelet
aggregation properties of PL prevented artherosclerotic plaque formation in mice,
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demonstrating the efficacy of PL as a possible therapy for this inflammatory
disease (Iwashita et al., 2007; Tabas & Glass, 2013). Furthermore, studies in
various cancer cell lines showed the anticancer effect of PL in these cells, where
PL targeted the oxidative stress response of these cells, increased the levels of
reactive oxygen species (ROS) and activated the expression of several key proapoptotic proteins; PL’s effect on the oxidative stress response in cancer cells led
to its ability to induce apoptosis in these cancer cells, in a dose and time
dependent manner This anticancer effect was confirmed in in vivo models of
breast adenocarcinoma (Raj et al., 2011). More importantly, this effect on ROS
generation and oxidative stress pathway targeting was not observed in the noncancerous cells, suggesting a dependence on the oxidative stress response
pathway in cancer cells. These results confirm what has been previously known:
that targeting the mitochondria could provide a better selective target in cancer
cells (D’Souza et al., 2011) for more efficacious treatment.
Further studies have also shown the ability of PL to target receptors,
including the platelet derived growth factor (PDGF) receptors, for the inhibition of
angiogenesis, and treatment with this compound led to the depletion of androgen
receptor in prostate cancer cells, through a proteasome-mediated ROS
dependent pathway (Bezerra et al., 2012; Golovine et al., 2013). The results from
these studies not only suggests a role of PL as a receptor antagonist, but also
provides a link between oxidative stress and receptor targeting, for an alternative
path to cancer cell specific targeting, proving this usefulness of NHPs and NPs in
the fight against cancer.
The anti-inflammatory response associated with the use of long pepper
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extract is attributed to the presence of PL; however, the effect of this compound
alone is significantly decreased, when compared to the efficacy of the whole plant
extract in reducing inflammatory response. Some reports indicate that the use of
the whole extract of long pepper show better efficacy, when used at lower
concentrations, compared to individual components of the extract, like PL, which
had an effective concentration ≥ 10 μM (Vedhanayaki et al., 2003; Iwashita et al.,
2007; Raj et al., 2011).
There are, however, very few scientific validation studies to prove the
benefits associated with the use of long pepper extracts; most of these studies
have been carried out on the components present within the extract, including
piperines. Piperines have been shown to inhibit many enzymatic drug biotransforming reactions and plays a significant and specific role in the metabolic
activation of carcinogens, as well as in metabolic and mitochondrial energy
production (Golovine et al., 2013; Jarvius et al., 2013; Meghwal & Goswami,
2013). The presence of piperidine alkaloids show potent fungicidal activity (Lee et
al., 2001; Bao et al., 2013). Some of these compounds, including PL, have shown
potent anti-cancer activity (Bezerra et al., 2007), suggesting that long pepper
extract contains multiple bioactive components that could be beneficial in the
development of more efficacious therapies for the treatment of various diseases,
including cancer.
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HYPOTHESIS
There is sufficient evidence indicating the importance of NHPs in the
development of drugs. Anecdotal evidence, bring to the forefront, a need for
scientific validation of more NHPs. This research focused on scientifically
validating the mechanistic efficacy of two NHPs, Dandelion Root Extract (DRE)
and Long Pepper extract (PLX) in cancer cells.
Our hypothesis is that natural health products (NHPs), such as DRE and
PLX, contains multiple bioactive components that can efficiently target multiple
vulnerable aspects of cancer cells to act as a selective treatment against cancer
and possibly improve the quality of life (QoL) of diagnosed patients.
OBJECTIVES
To study this hypothesis, three major objectives were put forward;
•

Evaluation of the selective efficacy of Dandelion Root Extract (DRE) and
Long Pepper extract (PLX) in several in-vitro, in-vivo and ex-vivo models

•

Investigation into the mechanism of action and selectivity of DRE and PLX
in cancer cell models

•

Fractionation & phytochemical analysis of DRE and PLX to identify the
bioactive compound(s) involved in providing the selectivity and efficacy.

OVERALL SIGNIFICANCE
The toll of cancer on the human body and the society as a whole, indicates
a serious need for a better selective, more effective and relatively cheaper mode
of treatment. Unfortunately, at this time, most of the available forms of therapy
induce apoptosis or other forms of programmed cell death in both cancer and
non-cancer cell types. The purpose of this study is to identify NHPs with better
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selective efficacy against cancer cells, while attempting to provide a stepping
stone for further validation studies of NHPs. The scientific studies carried out with
dandelion root and long pepper extracts, as natural health products, will provide
evidence for introduction of these NHPs to the public, in order to provide
alternative, safer and cheaper complementary treatments for cancer therapy and
improve QoL in cancer patients.
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ABSTRACT
Dandelion extracts have been used in traditional Native American
Medicine and Traditional Chinese Medicine (TCM) for treatment of leukemia and
breast cancer; however, the mechanism of action remains unknown. Today, DRE
is mainly marketed for management of gastrointestinal and liver disorders. The
current study aims to determine the anti-cancer activity of dandelion root extract
(DRE) against human leukemia, and to evaluate the specificity and mechanism of
DRE-induced apoptosis.
The effect of DRE on cell viability was evaluated using the colorimetricbased WST-1 assay. Apoptotic cell death was monitored by nuclear
condensation and confirmed by exposure of phosphatidylserine to outer leaflet of
plasma membrane. Activation of caspases was detected using a fluorogenic
substrate specific to either caspase-8 or -3. Loss of mitochondrial membrane
potential was observed by microscopy using JC-1 dye. The apoptotic effect of
DRE was also evaluated on a dominant negative FADD (Fas-associated death
domain) cell line and non-cancerous peripheral blood mononuclear cells
(PBMCs).
Aqueous DRE effectively induces apoptosis in human leukemia cell lines
in a dose and time dependent manner. Very early activation of caspase-8 and the
subsequent activation of caspase-3 indicate that DRE may be inducing extrinsic
or receptor-mediated apoptosis. Caspase inhibition rendered this extract
ineffective, thus DRE-induced apoptosis is caspase-dependent. Moreover, the
dominant-negative FADD cells that are unable to form a complete DISC (deathinducing signaling complex) were resistant to DRE treatment, which further
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confirms our hypothesis that DRE induces receptor-mediated apoptosis.
Interestingly, non-cancerous peripheral blood mononuclear cells (PBMCs)
exposed to aqueous DRE under the same treatment conditions as leukemia cells
were not significantly affected.
Our results suggest that aqueous DRE contains components that act to
induce apoptosis selectively in cultured leukemia cells, emphasizing the
importance of this traditional medicine and thus presents a potential novel nontoxic alternative to conventional leukemia therapy.
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INTRODUCTION
Dandelions are one of the most common and recognizable weeds and are
found in almost every part of the world (Koo et al., 2004; Yarnell and Abascal,
2009). The Taraxacum spp. includes the species Taraxacum japonicum,
Taraxacum mongolicum and Taraxacum officinale, although the differences in
composition of each of these species remain vague (Jeon et al., 2008). This plant
has been used in Traditional Chinese Medicine (TCM) and traditional Native
American Medicine for its medicinal activity as treatment of diseases ranging
from diarrhea and digestive diseases to hepatitis and cancer (Jeon et al., 2008;
Yarnell and Abascal, 2009). More specifically, they have traditionally been used
for treatment of breast cancer and leukemia (Sweeney et al., 2005).
Dandelions are perennial weeds composed of a variety of chemical
compounds that are thought to act alone or in combination to increase the activity
of the plant extracts (Schutz et al., 2006). The chemical composition of dandelion
extracts has been observed and some of the important components of the extract
include sesquiterpene lactones and phenylpropanoids, which are believed to
have anti-inflammatory, anti-oxidative and anti-cancer properties leading to the
diverse observed effects of dandelion extracts (Yarnell and Abascal, 2009). Other
components have not been fully characterized and therefore their activities
remain unknown (Schutz et al., 2006).
There are limited scientific studies investigating the anti-cancer activity of
dandelion extracts and very little is known about the mechanism of action; reports
on the effect of dandelion extracts and the production of cytokines have remained
ambiguous to date (Kim et al., 2000; Koo et al., 2004).
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Recently research has been focused on developing anti-cancer drugs that
interfere with metabolic pathways of cancer cells to induce apoptosis, a highly
regulated physiological process of cell death that has a wide range of implications
in disease (Kekre et al., 2005; Ghobrial et al., 2005). It is an important
mechanism by which cells undergo cell death to control cell proliferation (Kerr et
al., 1972; Gewies, 2003; Fadeel and Orrneius, 2005). Apoptosis is characterized
by DNA fragmentation, cell shrinkage and nuclear condensation, and
phosphatidylserine flipping from the inner to the outer leaflet of the plasma
membrane (Kekre et al., 2005).
Development of an effective chemotherapy that selectively induces
apoptosis in cancer cells is of great importance. One major pitfall of current
chemotherapeutics is that the majority cause severe side effects in noncancerous cells. In the current study, the activity of dandelion root extract (DRE)
against a human acute T-cell leukemia cell line (Jurkat) was evaluated in parallel
to its effect on non-cancerous peripheral blood mononuclear cells (PBMCs).
Our novel findings indicate that DRE is capable of inducing apoptosis at
low concentrations specifically in cancer cells with no toxicity to PBMCs. DRE
treatment caused very early activation of caspase-8 and subsequent activation of
caspase-3. Moreover, it was observed that Jurkat cells expressing a dominantnegative FADD (Fas-associated death domain) protein were insensitive to
apoptosis induced by DRE, indicating involvement of the extrinsic pathway of cell
death (Hueber et al., 2000).
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MATERIALS & METHODS
Standardized dandelion root extraction
Freshly obtained dandelion roots (from open grassy areas) were
thoroughly and repeatedly washed with water; final wash with distilled water.
Dandelion roots (100 g) were homogenized in 200 ml of distilled water at 25 ◦C
using a domestic blender. Total homogenate was filtered through a NITEX nylon
mesh filter (LAB PAK; Sefar BDH Inc., Chicoutimi, QC, CA) and the filtrate was
centrifuged at 8000 x g for 5min at 25°C. The supernatant was filtered using 0.45
μm filters, followed by filtration through 0.22 μm filters. The final filtrate was used
directly or lyophilized and reconstituted as needed into stock solutions of 100
mg/ml in water.
Cell culture
The Human acute T-cell leukemia (Jurkat clone E6-1) cell line and
dominant-negative FADD Jurkat cells (clone I 2.1) were purchased from ATCC
(Manassas, VA, USA). These cells were cultured in RPMI-1640 medium
supplemented with 15% fetal bovine serum (FBS) and 40 mg/ml gentamicin (Life
Technologies, Mississauga, ON, CA). These cells were maintained at 37◦C and
5% CO2. Nucleated blood cells were isolated from peripheral blood obtained
from healthy volunteers (University of Windsor REB# 04-060). Whole blood (12
ml) was collected a BD Vacutainer CPT Tube (Becton Dickinson, Franklin Lakes,
NJ, USA) and centrifuged at 2900 x g for 30 minutes at 25°C. Mononuclear cells,
platelets and plasma was collected and cultured in a 1:1 dilution of RPMI media,
supplemented and maintained in similar conditions as the Jurkat cell lines.
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Cell treatment
Cells were grown to 70% confluence and then treated with freshly
prepared water extract or lyophilized extract at concentrations ranging from 0.2
mg/ml, the lowest dose with minimal activity, to 1mg/ml, the most effective dose.
Cell staining and viability assay
Viability of Jurkat cells after DRE treatment was examined by Trypan Blue
Exclusion assay. Trypan Blue stain (Life Technologies, Carlsbad, CA, USA) was
added to cell Suspension and live cells (Trypan negative) were counted using a
Fisher Hemacytometer. Percent viability was calculated as the number of live
cells per ml. Cell proliferation was determined in Jurkat cells following exposure
to DRE using the colorimetric WST-1 assay (Roche, Laval, QC, Canada)
according

to

previously

published

protocols

(Maekawa

et

al.,

2003;

Ngamwongsatit et al., 2008). Absorbance readings were obtained using a Perkin
Elmer Victor Spectrophotometry machine; a decrease in absorbance indicates
reduced proliferation. To examine apoptotic morphology, cells were treated with
DRE and stained with cell-permeable Hoechst 33342 dye (Molecular Probes,
Eugene, OR, USA), at a final concentration of 10 M and incubated for 10
minutes at 37°C. Nuclei were examined using a fluorescent microscope (Leica
DM IRB, Germany) and corresponding phase-contrast and fluorescence images
were taken.
Annexin-V binding assay
To observe phosphatidylserine exposure, an early marker of apoptosis,
Jurkat cells were treated and collected after indicated periods then washed 2X
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with PBS and resuspended in Annexin-V binding buffer (10mM HEPES/NaOH pH
7.5, 140mM NaCl, 2.5mM CaCl2), containing 1:50 Annexin-V Alexa Fluor 488
conjugate (Molecular Probes) for 15 minutes at 25°C. Cells were then examined
under a fluorescent microscope; cells that bind Annexin-V in a calciumdependent manner are considered apoptotic.
Apopercentage apoptosis assay
Apoptosis was also detected using the apopercentage Apoptosis Kit
(Biocolor Life Science Assays, County Antrim, United Kingdom). This is an
additional assay based on the surface exposure of phosphatidylserine, which
permits the uptake of the apopercentage dye into the apoptotic cell. Cells were
grown in a gelatin layer and then treated as described above. After treatment of
Jurkat cells, cells were collected, washed in PBS and incubated with the
apopercentage dye for 30 minutes and multiple representative pictures were
taken for each well using a light microscope.
Measurement of mitochondrial membrane potential
To monitor mitochondrial membrane depolarization in cells following DRE
treatment,

JC-1

dye

(5,5’

6,6’

-tetrachloro-1,1’

3,3’

tetraethylbenzimidazolylcarbocyanine iodide from Invitrogen, Burlington, ON, CA)
was used. JC-1 forms aggregates in healthy mitochondria, and fluoresces red. In
apoptotic and necrotic cells, JC-1 does not aggregate and the monomeric form
(green fluorescence) indicates loss of mitochondrial membrane potential. Jurkat
cells were incubated with 2 μL/ml JC-1 dye for 15 minutes at 37°C and examined
with a fluorescent microscope.
Caspase activity
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Caspase-8 and -3 activity assays were performed using a previously
published method (Naderi et al., 2003). Briefly, total protein from Jurkat cell
lysates was incubated with fluorogenic substrates corresponding to the substrate
cleavage site specific for each caspase (DEVD-AFC for caspase-3 and IETDAFC for caspase-8). Fluorescence was measured at Ex. 400nm and Em. 505nm
with a Spectra Max Gemini XS fluorometer (Molecular Devices, Sunnyvale, CA,
USA). Caspase activity was calculated per μg protein and protein concentration
was determined with BioRad protein reagent (BioRad, Mississauga, ON, CA)
using bovine serum albumin as a standard.
Statistical analysis
All experiments were performed in triplicates and the results expressed as
mean ± S.D. Statistical analysis was performed with GraphPad Prism 5.0 288
software.
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RESULTS
Induction of Apoptosis in Human Leukemia Cells by Aqueous Dandelion
Root Extract in A Dose and Time Dependent Manner
In order to determine the effect of DRE on cancer cells, human leukemia
(Jurkat) cells were exposed to increasing concentrations of dandelion extract
(either as freshly prepared extract or lyophilized powder dissolved in water), for
48 h. Hoechst dye was used to detect apoptotic nuclei, which are condensed and
brightly stained. Increasing percentage of apoptosis corresponded with
increasing concentrations of DRE (Figure 1A and B). The fresh water extract
showed better efficiency at inducing apoptosis in Jurkat cells than the lyophilized
extract, although the lyophilized extract had a significant effect on these cells
even at 0.2 mg/ml (Figure 1B). For further confirmation of the ability of DRE to
induce apoptosis in Jurkat cells, WST-1 cell proliferation assay was carried out at
0.4 mg/ml and 0.6 mg/ml DRE after 48 h (Figure 1D). DRE was effective in
reducing cellular viability by approximately 60% of the control untreated cells at
0.6 mg/ml. Figure 2A indicates that at 96 h treatment, ∼70% of Jurkat cells had
undergone apoptosis. In order to study the time course of the DRE effect, Jurkat
cells were exposed to 0.6 mg/ml DRE. As shown in Figure 2A and B, there was
increased apoptosis with ∼80% of cells were apoptotic after 96 h with DRE.
To address whether non-apoptotic cells remaining after 48 h DRE
treatment are able to resume cell division after removal of DRE, Jurkat cells were
exposed to 0.6 mg/ml DRE over 48 h then washed and incubated with fresh
media (without DRE) for another 48 h. Figure 3 shows that cells initially exposed
to DRE were unable to grow after media refreshment.
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Figure 1: Induction of apoptosis by DRE in Jurkat cells. (A) Jurkat cells
stained with Hoechst and Annexin V after 48 h treatment with increasing
concentrations of dandelion root extract. (B) Increasing concentrations of
lyophilized dandelion extract induced more marked apoptosis in Jurkat cells after
48 h treatment. (C) Crude dandelion extract 100 L induced apoptosis in
approximately 50% of the cells as determined by manual counting of Hoechst
images. (D) The effect of DRE on the viability of Jurkat cells at 0.4 and 0.6 mg/ml
as determined by WST-1 cell proliferation assay, as a measure of absorbance at
450 nm. Decreased cell metabolic viability (as a % of control) is observed with
increasing concentrations of DRE.
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Figure 2: Effect of dandelion extract on Jurkat cells over time. (A) Effect of
dandelion extract on morphology of Jurkat cells exposed to DRE as can be seen
by fluorescence and phase contrast pictures after incubation with 0.6 mg/ml DRE
for extended periods. (B) Apoptosis increased with time from 3 to 96 h with ∼40%
of cells being apoptotic after 48 h and almost 80% after 96 h. Cell death was
quantified using the Trypan Blue exclusion assay.
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Figure 3: Exposure of Jurkat cells to DRE for 48 h inhibits growth even after
removal of DRE. Jurkat cells were exposed to 0.4 mg/ml and 0.6 mg/ml DRE for
48 h. The cells were then incubated in DRE free media and were allowed to grow
for 48 h. Trypan Blue exclusion assay was used to quantify the growth of Jurkat
cells after fresh media replacement for 48 h.
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Confirmation of Apoptosis by Annexin-V and Apopercentage Assays
In order to further confirm the apoptotic mode of cell death, additional
biochemical

characteristics

were

monitored.

During

apoptosis,

there

is

reorganization of the cell membrane, which leads to the flipping of
phosphatidylserine from the inner to the outer leaflet of the cell membrane (Martin
et al., 1995). This feature of apoptotic cells enabled us detect and confirm the
induction of apoptosis after exposure to DRE. Jurkat cells were exposed to 0.6
mg/ml DRE for 48 h and were either assayed using Annexin-V binding or
apopercentage dye, both of which take advantage of membrane reorganization.
Annexin-V binds with high affinity to exposed phosphatidylserine on apoptotic
cells (Martin et al., 1995). Apopercentage dye is selectively imported into the cells
undergoing apoptosis. Results shown in Figure 4 indicates that indeed, there is
an increased number of Annexin-V and apopercentage positive cells after DRE
exposure compared to control, thus further confirming that DRE induced
apoptosis in Jurkat cells.
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Figure 4: Confirmation of apoptosis by Annexin-V and apopercentage.
Annexin-V and apopercentage assays were carried out to confirm apoptosis by
the flipping of the phosphatidylserine to the outer leaflet of the cell membrane
during apoptosis as described in the materials and methods. Both assays
indicate that DRE treatment caused externalization of phosphatidylserine as
observed by Annexin V (green fluorescence) and apopercentage (pink cells).
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Dandelion Root Extract Induces Activation of Caspase-8 Followed by
Caspase-3 in Jurkat Cells
Activation of aspartate-specific cysteine proteases also known as
caspases, is an important biochemical event of apoptosis (Fadeel and Orrneius,
2005; Kekre et al., 2005). Different caspases are activated at the initiation and
execution phases of apoptosis. To determine the effect of DRE on the activation
of caspases, the activities of caspase-8 and caspase-3 were assayed in Jurkat
cellular extracts at different time periods following DRE treatment. Results shown
in Figure 5A indicates that DRE treatment caused very early activation of
caspase-8 at 6 minutes following DRE exposure followed by subsequent
activation of caspase-3 at 6h (Figure 5B).
Generally caspase-8 is activated following assembly of death inducing
signaling complex (DISC) in receptor-mediated apoptosis and thus our result
indicated that receptor-mediated apoptotic pathway might be involved in DREinduced apoptosis. The Fas associated death domain (FADD) is a cytosolic
adaptor protein that binds to Fas-receptor following its engagement with Fas
ligand, and recruits pro-caspase-8 leading to activation of caspase-8. Dominantnegative FADD Jurkat cells are unable to assemble functional DISC, and thus are
resistant to receptor-mediated apoptosis. To determine if DRE requires the FADD
receptor for activation of caspase-8, we tested dominant-negative FADD Jurkat
cells under the same conditions as wild-type Jurkat cells. Results indicated that
there was no response to increasing concentrations of DRE at 48 h compared to
the control untreated cells (see figure 5, chapter 4). This suggested that indeed,
DRE-induced apoptosis is receptor mediated.
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Figure 5: Dandelion root extract induces early activation of caspases in
Jurkat cells. Fluorometric caspase activity assay using caspase-3 (A) and
caspase-8 (B) specific peptide was performed as described in the methods
section. The results here are reported as activity per g of protein (in fold) and
the average of three experiments are shown. Early activation of caspase-8 and
ensuing activation of caspase-3 in Jurkat cells upon exposure to DRE at various
time intervals.
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Destabilization of Mitochondrial Membrane Potential by Dandelion Root
Extract
The mitochondria are known as the powerhouse of the cell and play an
essential role in apoptosis (Armstrong, 2006). Recent research has been focused
on mitochondria as a target for chemotherapy because destabilization of
mitochondria membrane potential leads to the release of apoptotic factors
thereby allowing apoptosis to occur (Bell et al., 2008; Ralph and Neuzil, 2009).
To determine the effect of DRE on Jurkat mitochondria, we exposed these cells
to 0.4 mg/ml DRE for 48 h. Mitochondrial destabilization was observed by JC-1
staining with increasing concentrations of DRE (Figure 6).
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JC-1

CONTROL

0.4 MG/ML

Figure 6: Destabilization of mitochondrial membrane potential by dandelion
extract. Jurkat cells were treated with DRE at 0.4 mg/ml and incubated with JC-1
dye. Red fluorescence indicates cells with intact mitochondrial potential.
Exposure to 0.4 mg/ml DRE led to the loss of mitochondrial membrane potential.
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Dandelion Root Extract is Non-Toxic to Non-Cancerous Peripheral Blood
Mononuclear Cells (PBMCs)
Dandelion extracts have been traditionally used for various ailments and
no toxic effects have been reported; we wanted to investigate its effect on noncancerous peripheral blood mononuclear cells (PBMCs). PBMCs were incubated
with various concentrations of DRE for 48 h, under the same conditions as Jurkat
cells and apoptotic nuclei were monitored by Hoechst staining.
Results indicated that there were no differences between control untreated cells
and DRE treated cells (Figure 7).
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Figure 7: Effect of DRE on non-cancerous peripheral mononuclear blood
cells (ncPBMCs). ncPBMCs, from healthy volunteers, were treated at the
indicated concentrations for 48 hours before being stained with Hoechst 33342
dye and imaged on a fluorescence microscope (A). (B) Nontoxic effect of DRE on
PBMCs. PBMCs treated in (A) were quantified by manual counting of brightly
stained apoptotic nuclei.
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DISCUSSION
The major setbacks of most available chemotherapies are that they cause
severe side effects due to toxicity of non-cancerous tissue, and often become
ineffectual due to chemo-resistance (Kekre et al., 2005; Ma et al., 2009). The
holy grail of cancer therapy is to develop a novel alternative that has high
specificity to induce apoptosis in cancer cells. In the last decade there has been a
surge of anti-cancer drugs introduced, with about half of them derived from
natural sources (Koo et al., 2004; Lee, 1999).
Although aqueous dandelion extracts have been used in traditional
medicine throughout Asia, Europe, and North America (Yarnell and Abascal,
2009) for treatment of many diseases including leukemia and breast cancer, the
mechanism by which the root extract acts is unknown. Most of the components of
dandelion extract have been isolated and identified but their functions remain
uncharacterized (Schutz et al., 2006). Reports on the scientific use of this extract
in the treatment of cancer have been unclear and/or conflicting (Sweeney et al.,
2005). In a study conducted by Koo et al. (2004), dandelion extract was shown to
induce cytotoxicity in the HepG2 human hepatocellular carcinoma cell line by
inducing production of cytokines such as TNF-α and IL-1β. Conversely, Kim et al.
(2000) reported that dandelion extract has anti-inflammatory activity in astrocytes
through inhibition of IL-1β and TNF-α production. In a recent study by Sigstedt et
al. (2008) both dandelion leaf and root extracts were shown to inhibit proliferation
and invasiveness of cancer cell lines by decreasing MMP-2 and MMP-9
expression, indicating a possible mechanism by which dandelions act to inhibit
the progression of cancer.
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Here we report the cancer-specific apoptosis activity of dandelion root
extract (DRE) and the possible mechanism by which this extract works. A
previous study has shown some effect on the viability of HepG2 cells, with
minimum effect using 0.2 mg/ml (Koo et al., 2004). We used a range of
concentrations between 0.2 mg/ml and 1.0 mg/ml for the induction of apoptosis in
Jurkat cells and the EC50 was observed at 0.6 mg/ml DRE. Apoptosis was
evident within 48 h at 0.6 mg/ml of DRE by chromatin condensation and
exposure of phosphatidylserine on the outer leaflet of the cell membrane (Figures
1 and 4). Increase in apoptosis, confirmed by a WST cell viability assay, was
observed in a dose and time-dependent manner (Figures 2 and 3).
Interestingly, we observed very rapid activation of initiator caspase-8
(within minutes) in Jurkat cells treated with DRE (Figure 5A), which was followed
by activation of executioner caspase-3 within 12 h of treatment (Figure 5B). This
indicated that DRE induces the death receptor mediated extrinsic pathway of
apoptosis (Figure 5A). To confirm this mechanistic hypothesis dominant-negative
FADD Jurkat cells, which have a truncated non-functional FADD protein, were
exposed to DRE. These cells were found to be resistant to DRE-induced
apoptosis; DnFADD cells are unable to assemble the death-inducing signaling
complex responsible for activation of caspase-8 and thus unable to undergo
extrinsic apoptosis (see figure 5, chapter 4; Marini et al., 2003).
Furthermore, we demonstrated that DRE-induced apoptosis is caspase
dependent as pre-treatment with the pan-caspase inhibitor ZVAD-fmk inhibited
cell death in Jurkat cells (Malyshev et al., 2004). Exposure to DRE (0.4 and 0.6
mg/ml) for 48 h led to the destabilization of mitochondrial membrane potential, as
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observed by a decrease in JC-1 dye accumulation (Figure 6). Decreased
mitochondrial membrane potential is thought to result from truncation and
activation of the pro-apoptotic protein Bid caused by activated caspase-8 (Belka
et al., 2000). Truncated BID protein binds to pro-apoptotic protein Bax, which
inserts into the mitochondrial outer membrane causing collapse of the
mitochondrial membrane potential (Li et al., 1998).
Over the years there has been no report of toxicity in people taking
dandelion extracts. To test the selectivity of our aqueous dandelion root extract,
non-cancerous peripheral blood mononuclear cells were treated with DRE under
the same conditions as Jurkat cells and examined for apoptotic morphology.
Interestingly, these normal non-cancerous cells were unaffected by DRE
treatment (Figure 7). This outcome may be due to the fact that the expression of
Fas receptors is far greater in human leukemia cells than in normal cells (Kekre
et al., 2005). This increased expression in leukemia cells may be the sensitizing
factor for apoptosis induction in Jurkat cells by DRE, which is consistent with our
results that DRE induces the death-receptor mediated pathway of apoptosis.
Our results clearly indicate that components of dandelion root extract act
either alone or in combination with each other to induce formation of the death
inducing signaling complex and subsequent extrinsic apoptosis selectively in
human leukemia cells (Figure 8). The mechanism by which this extract induces
apoptosis is being studied further to determine possible genomic interactions and
to delineate the active component of DRE. These in-vitro results are a steppingstone for the development of a more efficient mode of therapy and present a
novel non-toxic alternative to conventional leukemia therapy.
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Figure 8: Graphical Representation of the Mechanism of Action of DRE in
Human T Cell Leukemia (JURKAT). Following DRE treatment, there was rapid
activation of caspase-8 in Jurkat cells, indicating the targeting of the death
ligand/receptor dynamic. This presence of the Fas-Associated Death Domain
(FADD) was required for the activation of caspase-8, which led to the activation
of caspase-3 (directly or indirectly, through the truncation of Bid and the
destabilization of the mitochondrial membrane). The subsequent activation of
caspase-3 preceded the induction of apoptosis, characterized by known
morphological and biochemical features of apoptosis.
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ABSTRACT
Pancreatic cancer has a 100% mortality rate; the aim of this study is to
evaluate the efficacy of Dandelion Root Extract (DRE) in inducing apoptosis and
autophagy in aggressive and resistant pancreatic cancer cells. The effect of DRE
was

evaluated

using

WST-1

(4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-

tetrazolio]-1,3-benzene disulfonate) assay. Apoptotic cell death was confirmed by
nuclear

condensation

by

Hoechst

staining,

and

externalization

of

phosphatidylserine to the outer leaflet of the plasma membrane by Annexin-V
binding assay. Loss of mitochondrial membrane potential was observed using the
JC-1 (5, 5’, 6, 6’-tetrachloro-1,1’, 3,3’ tetraethylbenzimidazolylcarbocyanine
iodide) dye. The induction of autophagy was detected using an MDC assay and
this was confirmed by immunofluorescence for LC3-II.
BXPC3 and PANC-1 pancreatic cells were sensitive to aqueous DRE. This
extract induces selective apoptosis in a dose and time-dependent manner. DRE
caused the collapse of the mitochondrial membrane potential, leading to prodeath autophagy. Normal Human and Fetal Fibroblasts were resistant at similar
doses.
In this study, we demonstrate that DRE has the potential to induce
apoptosis and autophagy in human pancreatic cancer cells with no significant
effect on non-cancerous cells.

This will provide a basis upon which further

research in the field of cancer treatment through DRE can be executed.
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INTRODUCTION
In Canada, it is estimated that approximately 173 800 new cases of cancer
will be diagnosed and 76 200 Canadians will die of cancer in 2010 (Canadian
Cancer Society, 2010). The risk of developing this disease increases with age;
nonetheless it can affect all ages. Pancreatic cancer, a very aggressive and
highly resistant form of cancer, is a cancer that originates in the pancreas
(Canadian Cancer Society, 2010). It is the fourth leading cause of cancer-related
deaths in the world today (Castellanos et al., 2011). In 2010, it was estimated
that 4000 new cases would be diagnosed and 3900 deaths due to pancreatic
cancer in Canada.
Treatment for pancreatic cancers include the already known forms of
chemotherapeutics such as 5-fluorouracil and gemicitabin (Skinner, 2010),
surgery and radiation therapy. Although they show initial efficacy, these
treatments do not remain effective for extended periods of time and are usually
accompanied by severe side effects (Poplin et al., 2009; Kindler et al., 2010).
Furthermore, in the early stages of pancreatic cancer there are no clear signs or
symptoms (Tuvesan & Hanahan, 2011). Depending on the location of the tumour
in the pancreas, signs and symptoms begin to appear once surrounding tissues
become affected and surgical resection of the tumour is only successful if the
disease is diagnosed in its early stages when the cancer has not metastasized
(Castellanos et al., 2011). Early prognosis is therefore one of the leading areas of
research in this field due to its difficult identification (Canadian Cancer Society,
2010). Most commonly, pancreatic cancer is diagnosed in very late stages and
survival is dismal at best. With one of the highest mortality to incidence rate ratios
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(Tempero et al., 2011), there is an important need to introduce a safe and
effective mode of targeting both early and late stage pancreatic cancers.
One of the most common hallmarks of cancer involves the ability to evade
the physiological process of programmed cell death, also known as apoptosis
(Johnstone et al., 2002; Hanahan & Weinberg, 2011). Cancer cells have also
been found to utilize autophagy, a catabolic process used to degrade cytoplasmic
materials, as a pro-survival technique to overcome stressors such as starvation
and chemotherapy (Rosenfeldt & Ryan, 2011). There has been a lot of
controversy surrounding the field of autophagy, where it has been shown to play
dual roles, as both a pro-survival and pro-death phenomenon (Rosenfeldt &
Ryan, 2011). Recent studies have shown that pro-death autophagy and
apoptosis have interconnected pathways and can be regulated by the same
proteins, including the pro-apoptotic Bcl-2 family of proteins (Thorburn, 2008). It
is therefore necessary to investigate these pro-death pathways so as to harness
their properties for targeting various types of cancers.
In current cancer therapies, natural compounds such as Taxol (Paclitaxel)
and Navelbine, have been widely utilized. However, many of these compounds
are genotoxic or non-selective and therefore cause damage to normal cells as
well (Mukherjee et al., 2001). Dandelions are very common weeds found in
almost every part of the world (Koo et al., 2004), the leaves and root of which,
have been studied for their effects on digestion and gastrointestinal diseases
(Yarnell and Abascal, 2009). Recent investigations have shown that dandelion
root extract (DRE) has the ability to selectively induce apoptosis in human
melanoma and leukemia cells, with no toxicity to non-cancerous peripheral blood
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mononuclear cells (Chatterjee et al., 2011; Ovadje et al., 2011). Whether DRE
can induce programmed cell death in highly aggressive and resistant human
pancreatic carcinoma cell lines remains unknown.
In this study, we show the efficacy of Dandelion Root Extract in inducing
apoptosis in a dose and time dependent manner in aggressive human pancreatic
cell lines (BxPC-3 and PANC-1). In parallel, similar experiments in noncancerous Normal Human Fetal Fibroblasts indicate that DRE selectively targets
human pancreatic cancer cells, confirming results from previous studies
(Chatterjee et al., 2011; Ovadje et al., 2011). Early activation of caspase-8 and
subsequent activation of caspase-3 indicate that apoptosis induction by DRE is
due to activation of the extrinsic pathway of apoptosis. Interestingly, we observed
that DRE induced a pro-death form of autophagy in human pancreatic cancer
cells. This induction of autophagy corresponds with the destabilization of the
mitochondrial membrane potential, which was observed after treatment with
DRE.

Through revival experiments, it was shown that the signal to commit

suicide was retained once the cells had been exposed to DRE. Although we are
unsure of the active ingredients in DRE responsible for the induction of cell death,
our work provides novel evidence of the selective anti-cancer effects of DRE in
human pancreatic cancer cells.
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MATERIALS & METHODS
Dandelion Root Extraction and Cell Treatment
Dandelion root extract (DRE) was prepared from the roots of collected
dandelion weeds found in localized open grasslands.

Following repeated

washing with water, the roots were air dried and ground to a fine powder. The
powder was then homogenized in 200 mL of distilled water and filtered at room
temperate using NITEX nylon mesh filters (LAB PAK; Sefar BDH Inc., Chicoutimi,
Quebec, Canada). The filtrate was then spun down at 8000 x g at 25°C for 5
minutes and the supernatant was filtered by 0.45 μm and 0.22 μm filters. The
final filtrate was lyophilized and 100mg/ml stock aqueous extract was prepared.
Cell Lines and Cell Culture Maintenance
The cancer cell line used this study was human pancreatic cancer BxPC3
and PANC-1which were purchased from the American Type Culture Collection
(ATCC), Manassas, VA, USA. The normal cell line used were normal human
fibroblasts (NHF) cells, which were obtained from Coriell Institute for Medical
Research, USA. BxPC3 cells were grown in RPMI-1640 media supplemented
with 15% fetal bovine serum (FBS) and 10 mg/mL Gentamicin (Gibco BRL, VWR,
Mississauga, ON, Canada).

The normal human fibroblasts were cultured in

Dulbecco’s modified Eagle’s medium (DMEM) obtained from Sigma Chemical
Company, Mississauga, Ontario, Canada, supplemented with 10% FBS, 2mM LGlutamine, and 10 mg/mL Gentamicin (Gibco BRL, VWR, Mississauga, ON,
Canada). PANC-1 cells were grown in DMEM media supplemented with 15%
fetal bovine serum (FBS) and 10 mg/mL Gentamicin (Gibco BRL, VWR,
Mississauga, ON, Canada). All cell lines were grown and maintained at 37°C,
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95% humidity, and 5% CO2 in a Forma Scientific CO2 incubator equipped with a
HEPA filter (Forma Scientific Inc., Marietta, Ohio, USA). All cell lines were grown
to approximately 50% confluence and were treated with either Fresh water
Dandelion Root Extract or lyophilized extract (0.5 mg/mL to 7.5 mg/mL). Treated
cells were allowed to grow over time up to 96 hours after treatment and was
examined using several staining assays as described below.
CELL STAINING
Hoechst Staining
To visualize apoptosis in the cells, a photosensitive DNA-binding stain
called Hoechst 33342 (Sigma Chemical Company, Mississauga, Ontario,
Canada) was incubated with a final concentration of 10 μM with cells at room
temperature for approximately 10 minutes. Following incubation, the cells were
viewed with a Leica DM IRB inverted fluorescence microscope (Wetzlar,
Germany) and Northern Eclipse Version 8.0 Imaging software at 100X and 400X
objective. Apoptotic cells are characterized by brightly stained, condensed nuclei
as compared to larger, round and less-brightly stained non-apoptotic cells. The
average percent apoptosis was calculated by counting and averaging the number
of brightly condensed nuclei over the total number of cells observed over 5 fields
at 400X objective.
Annexin-V Binding Assay
An early marker of apoptosis is the flipping of phosphatidylserine from the
inner leaflet to the outer leaflet of the plasma membrane, which can be visualized
through the use of an Annexin-V binding assay. Cells treated with various doses
of DRE were scraped using a rubber policeman to removed adherent cells from
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the plate bottom and washed twice in phosphate buffered saline (PBS).
Following washing with PBS, the cellular pellet was resuspended in Annexin-V
binding buffer (10mM HEPES, 10mM NaOH pH 7.5, 140mM NaCl, 2.5mM CaCl2,
50 nM Sucrose), along with the Annexin-V Alexa Fluor® 488 conjugate (Sigma
Chemical

Company,

Mississauga,

Ontario,

Canada),

which

binds

to

phosphatidylserine, at 1:50 with respect to the buffer. This was allowed to
incubate in low light conditions at room temperature for approximately 15
minutes. Hoechst 33342 dye was also incubated with the cells for the final 10
minutes in order to visualize nuclear morphology of positively stained Annexin-V
cells.

The cells were then visualized and images were taken using a

fluorescence microscope (Leica DM IRB) at 400X objective.
Trypan Blue Exclusion assay
In order to quantify the number of viable Pancreatic Cancer cells, Trypan
blue staining was used to visualize the cells. Trypan blue is a dye, which stains
only dead cells whose plasma membranes are permeable to the dye. A 1:1
mixture of cell suspension and 0.4% Trypan blue dye (Sigma Chemical
Company, Mississauga, Ontario, Canada) was loaded onto a haemocytometer
(Hausser Scientific, USA) where non-viable blue-stained cells and viable
unstained cells were counted.

The average number of viable cells was

expressed as number of cells/mL.
Cell Viability Assay
In order to determine cell viability, a colorimetric dye called WST-1 ([2-(4Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium,

Roche

diagnostics, Mannheim, Germany) was used. In metabolically active, viable cells,
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WST-1 produces formazan, which can be measured for absorbance. First, a
Trypan blue count was done in order to seed equal number of cells into 96 well
plates. Approximately 5000 cells were seeded with a total volume of 200μL in
each well and treated following attachment of the cells overnight.

Following

treatment, WST-1 dye was added to each well (20µL per 200 µL) and incubated
at 37°C for 4 hours.

Absorbance was read at 590nm with a Victor™ Plate

Reader (Wallac, Turku, Finland). Absorbance values of the treated cells were
calculated as a percentage of absorbance values of control.
Mitochondrial Membrane Potential
In order to visualize mitochondrial membrane permeability in BxPC-3 cells,
JC-1 dye (5, 5, 6, 6-tetrachloro-1, 1, tetraethylbenzimidazolocarbo-cyanine
iodide, Sigma Chemical Company, Mississauga, Ontario, Canada) was incubated
with treated the cells.

JC-1 forms aggregates in mitochondria with intact

membrane potential. The dye was diluted 2:50 in PBS to a concentration of 0.5
μM and was incubated with treated cells for 45 minutes at 37°C. During the final
10 minutes of incubation, Hoechst dye was added to the cells.

Following

incubation, the cells were then visualized and images were taken using a
fluorescence microscope at 400x objective. Tetramethylrhodamine methyl ester
(TMRM) (Gibco BRL, VWR, Mississauga, ON, Canada) was used for PANC-1
cells to measure Mitochondrial Membrane Potential. PANC-1cells were grown on
coverslips. After treatment period, the cells were incubated for 45 minutes with
200 nM TMRM at 37°C. The coverslips were then placed on microscope slide
and pictures were taken at 40x objective using inverted fluorescence microscope
(Leica DM IRB).
87

MDC Assay
To detect autophagy, an MDC (monodansylcadaverine, Sigma Chemical
Company, Mississauga, Ontario, Canada) assay was preformed.

MDC is a

fluorescent compound that is incorporated into autophagic vacuoles and
produces a bright punctate stain. Propidium iodide (PI) is used as a co-stain with
MDC to visualize dead cells. First, 100μM MDC is diluted 1:25 in PBS and added
to the cells along with PI, then incubated at 37°C for 15 minutes. Following
incubation, the cells were visualized and images were taken using a fluorescence
microscope at 400X objective.
Immunocytochemical Analysis
BxPC3 cells were plated on poly-l-lysine coated coverslips and treated
with DRE for 48 hours to stimulate the induction of autophagy. Treated cells were
fixed in cold methanol, then cold acetone for 5 seconds and allowed to air dry.
Following fixation, the cells on the coverslips were incubated with PBS containing
0.05% Tween 20 and 5% Normal Goat Serum for 10 minutes. Cells were then
incubated with anti-LC3 antibody (1:500 dilution) (Novus Biologicals, Cat. No.
NB100-2220, Littleton, CO, USA), overnight at 4°C. The following day the cells
were subjected to two five-minute washes with PBS containing 0.05% Tween20
and then incubated with anti-rabbit antibody, Alexa Fluor® 488 conjugate (1:1000)
(Cell signaling Technologies, Cat. No. 4412, Pickering, ON. CA), for an hour at
room temperature. Following two washes with PBS-Tween20 for 5 minutes, cells
were counterstained with Hoechst for 10 minutes and visualized and images
were taken using a fluorescence microscope at 400x objective.
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Caspase Activity
The Caspase assays were performed using a previously published method
(Naderi et al., 2003). To determine caspase activity, the total protein from BXPC3 and PANC-1 cell lysates were incubated with the fluorogenic substrates
corresponding to the substrate cleavage site, specific for each caspase, DEVDAFC for Caspase-3 and IETD-AFC for Caspase-8 and 9. The fluorescence was
measured at an excitation wavelength of 400 nm and emission wavelength of 505
nm using a Spectra Max Gemini XS (Molecular Devices, Sunnyvale, California).
Caspase activity was calculated as activity per µg protein and protein
concentration was determined with BioRad protein assay reagent (BioRad,
Mississauga, Ontario) using bovine serum albumin (BSA) as a standard.
Readings were analyzed using GraphPad Prism 5.0 288 software.
Statistical analysis:
All experiments were performed in triplicates and the results expressed as
mean ± S.D. Statistical analysis was performed with GraphPad Prism 5.0 288
software.
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RESULTS
Effect of Dandelion Root Extract on Highly Aggressive Pancreatic Cancer
Cells.
In order to determine the effect of DRE on pancreatic cancer cells, two
different pancreatic cancer cell lines (BxPC-3 and PANC-1) were treated with
DRE at doses of 0.5, 1, 2.5, 5, and 7.5 mg/mL and examined at different time
points. To visualize morphological features of apoptosis induction in BxPC3 and
PANC-1 following DRE treatment, Hoechst, a dye that binds to the minor groove
of DNA, was used to observe nuclear condensation. An increase in nuclear
condensation was observed with an increase in concentration, as well as an
increase in the time of exposure to DRE (Figure 1A). Apoptotic cells and nonapoptotic cells were manually counted and quantified as average percentage
apoptosis in both cell lines. The average percent apoptosis was found to increase
with increasing concentration of DRE over time (Figure 1B).
An early marker of apoptosis is the reorganization of the cell’s membrane,
which leads to externalization of the phosphatidylserine from the inner leaflet to
the outer leaflet of the cell membrane. This can be observed with Annexin V
binding assay. Following 72-hour treatment with DRE, there is an increase in
bright green fluorescence indicative of apoptosis in a dose and time dependent
manner in DRE treated BxPC-3 cells. Annexin-V positive staining was observed
as early as 24 hours in DRE treated PANC-1 cells (Figure 1C).
Quantitative cell viability as a function of cell metabolism was assessed
through WST-1 assay. DRE led to a 60% decrease in cell viability 48 hours
following treatment with only 20% of BxPC-3 cells remaining viable after 96 hours
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of exposure to DRE. Similar results were observed in PANC-1 cells; with a
gradual decrease in cell viability with an increase in dose of DRE compared to
untreated control cells (Figure 1D).
According to results of both qualitative and quantitative analyses, the EC50
for both pancreatic cancer cell lines is around 5.0 mg/mL.
In order to investigate the fate of cells exposed to DRE but show no
apoptotic morphology following treatment for 48 hours (40%), BxPC-3 cells were
plated and treated for 48 hours at 5.0mg/ml and 7.5mg/ml DRE. After 48 hours,
equal numbers of BxPC-3 cells were seeded and allowed to grow in drug-free
media, with growth observed every 24 hours by trypan blue exclusion assay. The
untreated control cells were able to maintain constant growth over time. However,
the DRE treated cells were unable to revive growth in fresh media as time
progressed. Analysis reveals a significant decrease in the number of cells per
mL at 96 hours post-treatment from 700 000 to 10 000 cells between the
untreated control cells and the cells treated with DRE, respectively (Figure 1E).
Similar results were observed for the PANC-1 cell line following revival after
treatment with DRE for 48 hours.
These results indicate that DRE led to the loss of cell viability and
effectively induced apoptosis in human pancreatic cancer cells in a dose and time
dependent manner. More importantly, cells that had been exposed to DRE
retained the signal to commit suicide even after the removal of DRE.
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A

B

Figure 1: Efficacy of Dandelion Root Extract in inducing apoptosis in
human Pancreatic cancer cells. (A). An increase in brightly stained, condensed
nuclei indicative of apoptosis, is seen with increasing doses and time periods
following treatment with DRE. (B). Manual quantification of Hoechst pictures. In
comparison to the results seen in A, there is an increase in the average %
apoptosis in a dose and time dependent manner.
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D

E

Figure 1: Efficacy of Dandelion Root Extract in inducing apoptosis in
human Pancreatic cancer cells. (C). Brightly stained apoptotic cells seen in
Hoechst images are visualized by Annexin-V binding to exposed
phosphatidylserine in the lower panel of images in both BxPC-3 and PANC-1
cells. (D). Treatment with DRE led to a drastic decrease in the percent of
metabolically viable cells (as a % of control) after treatment at the indicated time
points; (i) BxPC-3 (*p<0.05; *#p<0.0001) and (ii) PANC-1 (*p<0.05; **p<0.0001)
hours with DRE. (E). Exposure to of BxPC-3 cells to DRE for 48 hours halted
the cell growth following removal of treatment. Cells were unable to revive growth
after exposure to DRE and retained the signal to commit suicide after removal of
DRE (**, #@p<0.0001).
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Repeated Doses of DRE at Lower Concentrations is More Effective than a
Single Low/High Dose in Inducing Apoptosis in Human Pancreatic Cancer
Cells
Any treatment at high doses can be toxic and as can be observed from our
previous results in figure 1, higher doses of DRE were required to induce
apoptosis in both pancreatic cancer cell lines. Treatment of these cells with
repeated doses of low concentrations of DRE showed a higher efficacy than one
single high dose. Exposure of BxPC3 (Figure 2A) and PANC-1 (Figure 2B) to low
concentration (0.5, 1.0, and 2.5mg/mL) of DRE for 48 hours and then a second
treatment for another 48 hours reveals that two treatments are more effective
than treating once with a high dose.

Comparing the control and 2.5mg/mL

treated phase images shows a drastic difference in the number of dead cells
following the second 48 hour treatment (Figure 2). These results indicate multiple
doses of low concentrations of DRE are more effective in inducing apoptosis than
one single high dose in human pancreatic cancer cells.
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A

BxPc-3

B

PANC-1

Figure 2: Repeated doses of DRE at lower concentrations in human
pancreatic cancer cells: Treating BxPC-3 (A) and PANC-1 (B) twice for 48
hours at doses of 0.5, 1, and 2.5mg/mL has a significantly higher effect than a
single treatment for 48 hours. Following the second 48 hour treatment, cells were
stained with Hoechst 33342 and fluorescence images were obtained at 400X
magnification.
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DRE Destabilizes the Mitochondrial Membrane Potential in Human
Pancreatic Cancer Cell Lines
In order to determine the mechanism of action of DRE, we wanted to
observe the effect of DRE on the mitochondria of human pancreatic cancer cells.
Both the extrinsic and intrinsic pathways of apoptosis converge on and
permeabilize the mitochondria leading to the release of pro-apoptotic factors
(Fadeel & Orrenius, 2005). Evaluation of mitochondrial membrane potential is
done through visualization of red fluorescence of JC-1 or TMRM mitochondria
permeable dyes in healthy, intact mitochondria. DRE led to the destabilization of
the mitochondrial membrane potential in BxPC-3 cells as observed by the loss of
red aggregates of JC-1 dye in DRE treated cells after 48 hours of treatment
(Figure 3A). Similar results were observed in DRE treated PANC-1 cells, stained
with TMRM (Figure 3B). These results indicate that the mitochondria of highly
aggressive pancreatic cells are vulnerable to DRE, leading to permeabilzation of
the mitochondrial membrane potential, characteristic of apoptosis.
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A

BxPc-3

B

PANC-1

Figure 3: DRE destabilized the mitochondrial membrane potential of human
pancreatic cancer cells. Pancreatic cancer cells were grown on coverslips and
treated with DRE for 48hours and stained with either JC-1 (A) or TMRM (B),
which are mitochondrial permeable dyes that aggregate in healthy mitochondria
and fluoresce red or remain in the cytosol in their monomeric form (Green).
Fluorescence microscopy was used to assess membrane potential. The loss of
dye aggregation is observed in DRE-treated BxPC-3 (A) and PANC-1 (B) cells.
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DRE activates the death-receptor mediated extrinsic pathway of apoptosis
The loss of mitochondrial membrane potential in itself does not provide us
with information regarding the pathway of apoptosis induction. In order to get
more information on the pathway of apoptosis induction, which would shed more
light on the mechanism of induction of apoptosis by DRE, we analyzed the
chronological activation of caspases. BxPC-3 cells were treated with 2.5 mg/ml
DRE, at the indicated time points, and subsequently analyzed for the activation of
caspases, using substrates specific to each type of caspase. Our results show
that there is a very rapid activation of caspase 8 in BxPC-3 cells (Figure 4),
suggesting an extrinsic mode of cell death. Similar results were observed in
PANC-1 cells.
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Figure 4: DRE induces extrinsic apoptosis in human pancreatic cancer
cells. BxPC-3 cells were treated with DRE at the indicated time points.
Subsequently, cells were collected, washed and incubated with lysis buffer to
obtain cell lysate. The cell lysate was incubated with caspase substrates, specific
to each caspase (3, 8 and 9) and incubated for an hour. Fluorescence readings
were obtained using a spectrofluorometer. An average of 6 readings per well and
a minimum of three wells were run per experiment. The results here are reported
as activity per µg of protein (in fold) and the average of three experiments are
shown
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DRE Induces Pro-Death Autophagy in Human Pancreatic Cells
Along with apoptosis, autophagy is a physiological process of cell death
involved in the maintenance of cellular homeostasis (Gottlieb et al., 2009). Cells
undergoing autophagy form autophagic vacuoles, which can be visualized
through the use of MonoDansylCadaverine stain (Niemann et al., 2000). The
corresponding PI stains reveals which of the autophagic cells are dead,
suggesting a pro-death capacity of DRE in pancreatic cancer cells.
Tamoxifen is known to induce pro-survival autophagy (Qadir et al., 2008),
and therefore is used as a positive control. We observed a clear induction of
autophagy in the treated cells at increasing doses of DRE over time as compared
to the positive tamoxifen control in BxPC-3 cells. (Figure 5A). When autophagy is
induced, microtubule-associated protein 1 light chain 3 (LC3-I), usually localized
in the cytosol, is conjugated to phosphatidylethanolamine. This conjugation
results in the lipidated protein LC3-II that is recruited to autophagosomal
membranes and can be used as another marker for autophagy detection (Ma et
al., 2011).
To

confirm

the

results

of

autophagy

seen

by

MDC

staining,

immunocytochemical analysis was used to detect the conversion of LC3-I to LC3II. BxPC-3 treated with DRE at 2.5mg/mL had a similar effect on the conversion
of LC3-I to LC3-II, compared to the tamoxifen treated cells. Both the tamoxifen
and DRE treated cells incubated with antibody against LC3-II gave positive
results, which confirmed the autophagy observed in 5a (Figure 5B). Treated
PANC-1 cells with DRE doses of 2.5 mg/mL showed similar results.
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Figure 5. DRE induces pro-death autophagy in human pancreatic cancer
cells. (A). BxPC-3 cells were seeded onto coverslips in six-well plates and
treated with DRE at 2.5mg/mL for 48 hours. Tamoxifen is a known inducer of prosurvival autophagy and was used as a positive control for autophagic induction in
pancreatic cancer cells. Following treatment, cells were stained with
monodansylcadaverine and counterstained with Propidium Iodide to indicate the
dead cells. (B). BxPC-3 cells were plated on coverslips and treated with DRE or
Tamoxifen for 48 hours. Following treatment, coverslips were incubated with
primary antibody specific to LC3-II overnight at 4°C, then incubated with
appropriate secondary antibody for an hour at room temperature. The cells were
counterstained with Hoechst and imaged.
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DRE is not Toxic to Non-Cancerous Normal Human Fibroblasts
Dandelions have been used as an herbal medicine for centuries and there
has been no reported evidence of toxicity (Kemper et al., 1999). In order to
further investigate whether DRE selectively targets cancerous cells, Normal
Human Fibroblasts (NHFs) were treated with DRE under the same conditions as
the pancreatic cancer cells. Treatment of non-cancerous NHFs with DRE at
doses of 1.0, 2.5 and 5 mg/mL for 96 hours reveals no morphological signs or
characteristic of apoptosis as seen by Hoechst staining (Figure 6; top panel). In
comparison to pancreatic cancer cells treated with DRE, NHFs retain their
viability in the presence of DRE as seen through WST-1 cell viability assay
(Figure 6; bottom panel). However, the treated cells are not as viable as the
untreated control cells and plateaus at approximately 70% cell viability. The noncancerous NHF cells do not undergo apoptosis in the presence of DRE. These
results reveal that DRE is non-toxic to non-cancerous cells and selectively targets
cancerous cells.
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Figure 6: DRE has selective toxicity to human pancreatic cancer cells:
Normal Human Fibroblasts were treated with DRE at increasing concentrations
(1.0 to 5.0 mg/ml) for 96 hours. The cells were then stained with Hoechst dye for
nuclear morphology and fluorescent images were obtained. No nuclear
condensation, characteristic of apoptosis, is observed in NHF treated cells (Top
panel). NHFs were seeded in a 96-well plate at 4000 cells/well and treated with
increasing concentrations of DRE, before incubating with the WST-1 viability dye.
WST-1 cell viability assay was then used to monitor the viability of NHFs after
treatment with DRE every 24 hours, to a maximum of 96 hours subsequent to
treatment (Bottom panel). Unlike in pancreatic cancer cells, increasing doses of
DRE did not drastically affect the viability of normal human fibroblasts.
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DISCUSSION
Natural compounds have shown significant anti-cancer activity, with
reports showing their potential to inhibit the progression of several cancers by
interfering with several key mechanisms employed by cancer cells (Boik, 2000).
In this study, we have shown that the root extract of the very common weed,
dandelions, have the ability to selectively induce apoptosis and autophagy in very
aggressive human pancreatic cancer cells.
The high mortality rate of pancreatic cancer patients is most likely due to
the fact that the disease is usually asymptomatic until it metastasizes and
becomes invasive, at which point it is incurable (Koostra et al., 2008; Maitra &
Hruban, 2008). Therefore, a majority of pancreatic cancer patients presented in
this state of advanced and/or metastatic condition are inoperable (Maitra &
Hruban, 2008). A lot of chemotherapeutic agents have been tested for their
efficacy in treating this disease but only a few of them have shown moderate
activity and produce very little survival benefit and severe side effects (Longo et
al., 2008).
We observed that the exposure of pancreatic cancer cells to Dandelion
Root Extract (DRE) led to the loss of cell viability followed by the induction of
apoptosis in a dose and time dependent manner. More importantly, we looked at
the effect of initial exposure to DRE on the ability of these cells to revive growth.
After treatment for 48 hours, cells were removed from the treated media and replated in fresh, drug-free media and allowed to grow. We observed that this initial
exposure to DRE halted the ability of the cells to revive growth, indicating that
these aggressive pancreatic cells retained the signal to commit suicide, induced
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by DRE (Figure 1).
Over the ages, people have relied on dandelions for therapeutic benefits in
the treatment of various diseases ranging from diarrhea and other gastrointestinal
diseases to more serious diseases, like hepatitis. To date, there has been no
report of toxicity linked to usage of dandelion extracts (Sigstedt et al., 2008;
Yarnell & Abascal, 2009). Previous studies in our lab have shown that DRE is
non-toxic to non-cancerous peripheral blood mononuclear cells obtained from
healthy volunteers (Chatterjee et al., 2011). To confirm these results, as well as
corroborate what has been seen for centuries, we tested DRE on non-cancerous
Normal Fetal Fibroblasts (NFF) in parallel experiments. As expected, there was
no significant effect on the viability of NFFs. These cells did not show apoptotic
morphology, characterized by nuclear condensation and fragmentation (Figure
6). These results indicate that DRE is specific in its targeting of human cancer
cells, without affecting the normal cells tested.
It is very well known that a lot of chemotherapies have very severe side
effects, mostly due to the fact that these drugs are not specific to cancer cells and
are sometimes only effective at very high doses. Also, cancer cells, especially
pancreatic cancer cells, develop resistance to conventional chemotherapies
(Maitra & Hruban, 2008). As mentioned earlier, the EC50 for DRE in highly
aggressive pancreatic cancer cells is between 1.0 (BxPC-3) and 2.5 mg/mL
(PANC-1) between 24 and 48 hours. Interestingly, we found that repeated
treatment of pancreatic cancer cells with lower doses of DRE led to a greater
induction of apoptosis than the single high dose (Figure 2A and B). This might
indicate that the active ingredient in the extract are not stable or effective for long
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periods in the cells and a second dose may be required to effectively induce
apoptosis in the cells that remain after the first treatment. In this way, repeated
treatment with low dose may overcome the aggressiveness and resistance of
these cells to DRE. Although DRE has shown no significant toxicity to noncancerous cells, these results indicate that giving a repeated dose of DRE at
lower concentrations is more effective as well as reducing the chance of side
effects (if any) seen in high dose chemotherapies.
Not many studies have been done to elucidate the mechanism of action of
natural extracts, specifically DRE, for their efficacy for disease treatment. We
have previously shown that DRE targets the death receptor mediated pathway of
apoptosis in human leukemia (Ovadje et al., 2011) and aggressive human
melanoma cells (Chatterjee et al., 2011). Previously, pancreatic cancer cells have
been shown to express Fas and TRAIL receptors (Hasel et al., 2001; Siegmund
et al., 2007). We hypothesize that some components of DRE may imitate death
ligands and might interact with the death receptors, activating the extrinsic
pathway of apoptosis. In this study, we also confirmed this by observing the
activation of caspases after DRE treatment (Figure 4). These results corroborate
the previous results obtained. Both the extrinsic and intrinsic pathway of
apoptosis converges on the mitochondria (Fulda & Debatin, 2006).
The activation of both pathways leads to the permeabilization of the
mitochondrial membrane for the release of pro-apoptotic factors such as
apoptosis inducing factor (AIF), cytochrome C and endonuclease G, which are
involved in the execution of apoptosis (Fulda & Debatin, 2006). In this study, we
observe the loss of mitochondrial membrane potential after caspase-8 activation,
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following treatment with DRE (Figure 3A and B). This loss was seen as early as
48 hours, before we see the bulk of apoptotic cells, indicating that DRE may
indirectly involve mitochondria destabilization in pancreatic cancer cells for the
execution of apoptosis. Mitochondrial destabilization could lead to increased
Reactive Oxygen Species (ROS) (Fulda & Debatin, 2006).
Autophagy could be induced by the presence of such dysfunctional
mitochondria, a process of ―self-eating‖ activated under conditions of starvation
and stress. Under these conditions, the cells attempt to deal with stress (such as
damaged organelles and proteins) by engulfing and degrading these organelles
and proteins and recycling the materials obtained from the degradation.
Prolonged exposure to stressors lead to prolonged degradation of organelles and
proteins eventually leading to cell death caused by autophagy (Rosenfeldt &
Ryan, 2011). There are also studies that have shown that molecular pathways
involved in programmed cell death type I (apoptosis) and type II (autophagy) are
interconnected and proteins involved in one pathway, could be involved in the
other (Thorburn, 2008). Indeed, we observed the induction of autophagy by DRE
in both pancreatic cancer cells, concurrent with mitochondrial membrane
destabilization (Figure 5).
We therefore hypothesize that components found in DRE activate the
death receptor mediated extrinsic pathway of apoptosis, which involves the early
activation of caspase-8, followed by activation of the executioner caspase-3 as
well as cleavage of BID and mitochondrial destabilization. Damaged mitochondria
and the generation of ROS could therefore lead to the induction of pro-death
autophagy, coupled with apoptosis for the cell death we observe 96 hours after
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exposure of highly aggressive and resistant human pancreatic cancer cells to
DRE.
At this point of the study, we are aware of some limitations to this work.
The active ingredient responsible for the anticancer activity in DRE has not yet
been identified; although natural products are usually considered to be complex
botanicals and activity is not due to a single active ingredient (Foster et al., 2005).
It is possible that the crude aqueous dandelion root extract contains multiple
compounds working together in unison to promote its selective anticancer
activity. We have standardized a protocol for extraction and after every extraction
process, we assay for activity of the extract. The different batches of root
extracted have shown similar activity throughout. More importantly, preliminary
HPLC analysis of our extract has shown the presence of compounds (triterpenes
and sesquiterpenes) previously reported to be present in dandelions (data not
shown). Since natural aqueous DRE has been used as a traditional medicine for
other ailments, and is not associated with any toxicity, it represents a safer
potential form of therapy for pancreatic cancer treatment.

In an attempt to

ensure that our experiments are well controlled, we have standardized an
extraction procedure so as to ensure we have approximately equal amounts of
extracts in each treatment. Enrichment of the apoptosis inducing fraction of DRE,
characterization of compounds in this fraction and evaluating its efficacy in an invivo model of pancreatic cancer, are the obvious next steps currently in progress
in our laboratory.
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ABSTRACT
Chronic Myelomonocytic Leukemia (CMML) is a heterogeneous disease
that is not only hard to diagnose and classify, but is also highly resistant to
treatment. Available forms of therapy for this disease have not shown significant
effects and patients rapidly develop resistance early on in therapy. These factors
lead to the very poor prognosis observed with CMML patients, with median
survival duration between 12 and 24 months after diagnosis. This study is
therefore centered around evaluating the selective efficacy of a natural extract
from dandelion roots, in inducing programmed cell death in aggressive and
resistant CMML cell lines.
To confirm the induction of programmed cell death in three human CMML
cell lines, nuclear condensation and externalization of the phosphatidylserine, two
main characteristics of apoptosis, were detected using Hoechst staining and
annexin-V binding assay. The induction of another mode of cell death,
autophagy, was determined using a monodansylcadaverine (MDC) stain, to
detect the formation of autophagy vacuoles.
The results from this study indicate that Dandelion Root Extract (DRE) is
able to efficiently and selectively induce apoptosis and autophagy in these cell
lines in a dose and time dependent manner, with no significant toxicity on noncancerous peripheral blood mononuclear cells. More importantly, we observed
early activation of initiator caspase-8, which led to mitochondrial destabilization
and the induction of autophagy, suggesting that DRE acts through the extrinsic
pathway of apoptosis. The inability of DRE to induce apoptosis in dominantnegative FADD cells, confirms the mechanism of action of DRE in in vitro models
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of CMML.
The results from this study indicate that natural products, in particular
Dandelion Root Extract, have great potential, as non-toxic and effective
alternatives to conventional modes of chemotherapy available today.
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INTRODUCTION
The risk of developing cancer increases with age; nonetheless it can affect
all ages (Attia et al., 2008). Chronic Myelomonocytic Leukemia (CMML) is a
highly aggressive and resistant form of leukemia with a highly variable natural
course of progression. The difficulty in diagnosing this disease contributes to its
aggressive and resistant nature. In recent years, the World Health Organization
(WHO) has classified this disease as both a myeloproliferative disease (MPD)
and a myelodysplastic syndrome (MDS) (Ramshaw et al., 2002; Foucar, 2009).
This classification system has improved diagnosis of CMML, although it can still
prove difficult.
Even with advances in chemotherapy research, the prognosis for CMML
still remains very poor with median survival of 12 to 24 months (Foucar, 2009).
The available forms of treatment come with very severe side effects, with patients
developing resistance early on during treatment. The only effective form of
treatment that has shown significant success in CMML patients is Hematopoietic
Stem Cell Transplantation, although very few studies have been done with CMML
MDS/MPD (Steensma & Bennett, 2006). It is therefore of utmost importance to
develop more modes of treatment that are not only safe, but also effective in
targeting CMML cells specifically.
Natural products have been used for centuries as a source of nutrition,
nourishment and for various forms of therapy for a wide range of diseases.
Recent reports indicate that over the past sixty years, more than 60% of the
approved anti-cancer drugs have been either natural or derived from natural
products (Gordaliza, 2008).
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Taraxacum officinale, commonly known as Dandelions, are perennial
weeds of the Asteracaea family, thought to have originated in central Asia, but
now known to grow almost anywhere in the world today. Traditional medicine,
especially Traditional Chinese Medicine, has encouraged the use of dandelion
extracts for the treatment of various diseases, ranging from diarrhoea and
digestive diseases to more serious ailments like hepatitis and anorexia (Schütz et
al., 2006; Yarnell & Abascal, 2009). There have been very few scientific studies
to ascertain many claims of the use of dandelion extracts in the treatment of
diseases, but recently, studies indicate this plant has anti-inflammatory, antioxidant and anti-carcinogenic activities (Schütz et al., 2006).
Our group is studying the anticancer effects of dandelion root extract
(DRE), by evaluating its ability to induce physiological programs of cell death in
aggressive, resistant CMML cells. Previous work done by our group showed that
DRE effectively induced apoptosis in human T cell leukemia (Jurkat) and
melanoma cells, by rapidly activating the death-receptor mediated extrinsic
pathway of apoptosis (Chatterjee et al., 2011; Ovadje et al., 2011).
In this study, the efficacy of DRE in more aggressive leukemia cell lines
was

assessed

to

determine

its

selectivity

and

efficacy

in

inducing

apoptosis/autophagy in CMML cells. Results indicate that DRE effectively
induces apoptosis and autophagy in a dose and time dependent manner. The
rapid activation of caspase-8, through the activation of the extrinsic pathway of
apoptosis, was observed in these cells, comparable to levels found in Jurkat cells
(Ovadje et al., 2011). Non-cancerous peripheral blood mononuclear cells
(ncPBMCs), treated with dandelion root extract in parallel, were not susceptible to
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apoptosis, demonstrating the selectivity of dandelion root extract in cell culture.
Results from this study indicate that dandelion root extract could potentially
represent a novel non-toxic alternative to conventional cancer therapy available
today.
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MATERIALS & METHODS
Standardized Dandelion Root Extraction
Freshly obtained Dandelion roots (from open grassy areas) were
processed according to a previously published protocol (Ovadje et al., 2011). The
roots were thoroughly washed with distilled water several times. One hundred
grams of dandelion roots were homogenized in 200 ml of distilled water at room
temperature using a domestic blender. Total homogenate was filtered through a
NITEX nylon mesh filter (LAB PAK; Sefar BDH Inc. Chicoutimi, Quebec CA) and
the filtrate was spun down, 8000 x g for 5 mins at 25°C. The supernatant was
filtered using 0.45 μm filters, followed by lyophilisation. The dry powder (% yield:
7.34%) was reconstituted in water to give a stock solution of 100 mg/ml DRE.
This was then filtered through 0.22 μm filters and used in the treatment of
Chronic Myelomonocytic leukemia cells.
Cell Culture and Treatment
Human CMML cell lines (MV-4-11, HL-60 and U-937 cells), as well as a
dominant negative FADD Jurkat cell line was purchased from ATCC (Manassas,
VA.). MV-4-11 and HL-60 cells were cultured in Iscove’s Modified Dulbecco’s
Medium, supplemented with 15% fetal bovine serum (FBS) and 40 mg/ml
gentamicin (Life Technologies, Mississauga, Ontario). The DnFADD cells were
cultured in RPMI-1640 medium supplemented with 15% FBS and 40 mg/ml
gentamicin. These cells were grown and maintained in an incubator set at 37°C
with an atmosphere containing 5% CO2 and 95% humidity.
Human nucleated blood cells were purified from whole blood obtained
from healthy volunteers, modified from a previously published protocol (Griffin et
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al., 2010), and as approved by the University of Windsor ethical committee,
REB# 04-060. Whole blood (12 ml) was collected into a BD Vacutainer CPT Tube
(Cell Preparation Tube) obtained from Becton Dickinson (Franklin Lakes, N.J.).
The whole blood was spun down in a tabletop lowspeed centrifuge at 2900 x g for
30 mins at 25°C. The red blood cells went through the polyester gel and the top
layer containing mononuclear cells, platelets and plasma was collected. These
cells were cultured under the same conditions as the CMML cells (37°C, 5% CO2
and 95% humidity) and cultured in AIM-V medium from Invitrogen (Burlington,
ON). For the induction of apoptosis and autophagy by treatment with Dandelion
Root Extract (DRE), cells were grown to 50–70% confluence and then treated
either with different concentrations of lyophilized extract (0.6 mg/ml to 5.0 mg/ml).
At different times after treatment, cells were analyzed for apoptotic markers as
described below.
Trypan Blue Exclusion Assay
To examine the ability of MV-4-11 cells to revive growth after previous
exposure to DRE, these cells were treated with DRE for 48 hours, after which the
cells were removed from media containing extract and equal number of cells
were re-plated and examined every day. After treatment, a cell suspension was
added (1:1) to Trypan Blue stain (Life Technologies, Mississauga, ON). Using a
hemacytometer (Fisher Scientific, Horsham, PA.), live cells (trypan blue negative)
were counted three times, calculated and tabulated as number of cells per ml
using GraphPad Prism 5.0 288 software.
Hoechst Staining
Cells were grown and treated, and then stained with cell-permeable
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Hoechst 33342 (Molecular Probes, Eugene, Ore.), at a final concentration of 10
mM and incubated for 10 mins at 37°C. The cells were then examined under a
fluorescent microscope (Leica DM IRB, Germany) and fluorescent pictures were
taken. Five fields of fluorescent pictures were used to count apoptotic versus live
cells (where brightly stained cells with condensed nuclei were considered
apoptotic). These results were then calculated and tabulated as percentage of
apoptotic cells using GraphPad Prism 5.0 288 software.
Annexin-V Binding Assay
To confirm the induction of apoptosis by staining for phosphotidylserine
exposed on the outer leaflet of the plasma membrane (a characteristic feature of
apoptosis), CMML cells were grown and treated with different concentrations of
DRE. The cells were collected after given periods as indicated, washed in
phosphate-buffered saline (PBS) and resuspended in annexin-V binding buffer
(10 mM HEPES/NaOH pH 7.5, 140 mM NaCl, 2.5 mM CaCl2), containing 1:50
annexin-V Alexa Fluor 488 conjugate (catalog no. A13201, Molecular Probes) for
15 mins at room temperature. Cells were then examined under a fluorescent
microscope (Leica DM IRB), and pictures were taken. All pictures were
processed using Adobe Photoshop 7.0 software.
Assessing Mitochondrial Membrane potential
JC-1 Mitochondrial Membrane Potential Detection Kit was applied to
monitor mitochondrial membrane destabilization in cells undergoing apoptosis. In
non-apoptotic cells with healthy mitochondria, JC-1 (5, 5’ 6, 6’-tetrachloro-1, 1’, 3,
3’

tetraethylbenzimidazolylcarbocyanine

iodide)

(Catalog.

No.

M34152,

Burlington, ON) exists as a monomer in the cytosol and also accumulates as
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aggregates in the mitochondria which fluoresce red. In apoptotic and necrotic
cells, JC-1 exists in its monomeric form, diffused in the cytosol where it
fluoresces green. MV-4-11 and DnFADD cells were collected after treatment and
incubated with 100 μL per ml JC-1 dye for 15 min at 37°C. The cells were
examined under fluorescent microscope (Leica DM IRB, Germany) and
fluorescent pictures (six fields per sample) were taken. All pictures were
processed using Adobe Photoshop 7.0 software.
Monodansylcadaverine (MDC) Staining
Monodansylcadaverine (MDC) (Sigma-Aldrich Canada, Mississauga, ON,
Canada) was used to visualize autophagic vacuoles. CMML cells were plated in
six-well plates and treated with different concentrations of DRE for 48 hours. After
treatment, cells were incubated with 0.1 mM MDC for 30 minutes. Fluorescent
pictures were acquired at 400X magnification on a Leica DM IRB inverted
fluorescence microscope.
Propidium Iodide Staining
Cell death was detected by cell lysis observed by staining with propidium
iodide (PI) dye (Sigma Aldrich, Canada, Missisauga, ON. Canada). After
incubating with
MDC dye for 30 minutes, cells also co-stained with PI at a concentration of 1.0
mg/mL for the last 15 minutes of incubation with MDC. Following incubation, the
cells were visualized and images were taken using a fluorescence microscope at
400X objective.
TUNEL staining
After treating MV-4-11 cells with DRE for the indicated time points, the
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Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay
was performed according to the manufacturer’s protocol (Molecular Probes,
Eugene, OR) and a previously published protocol (Negoescu et al., 1996), in
order to detect DNA damage. Cells were treated with DRE or VP-16 (as a
positive control) at indicated concentrations and time points and analyzed for the
fragmentation of DNA. Following treatment, cells were fixed by suspending them
in 70% (v/v) ethanol and stored at -20°C overnight. The sample was then
incubated with a DNA labeling solution (10 μL reaction buffer, 0.75 μL TdT
enzyme, 8 μL BrdUTP, 31.25 μL of dH2O) for 1 hour at 25°C. Each sample was
exposed to an antibody solution (5 μL Alexa Fluor 488 labeled anti-BrdU antibody
and 95 μL rinse solution). The cells were incubated with the antibody solution for
20 minutes and pictures were taken using a fluorescent microscope (Leica DM
IRB, Germany).
Cell viability Assay
To examine the viability of CMML cells after treatment, cells were
incubated with cell proliferation reagent WST-1 (Catalog No. 05 015 944 001,
Roche Diagnostics) for 4 h at 37°C, following treatment with DRE at indicated
doses and time points, using manufacturers protocol. WST-1 works by reacting
with the mitochondrial succinate-tetrazolium reductase forming the formazan dye.
The WST-1 reagent produces a water-soluble formazan product (Ngamwongsatit
et al., 2008). Fluorescence readings were obtained at 450 nm using a Perkin
Elmer Victor Fluorescence instrument. Viability readings were analyzed using
GraphPad Prism 5.0 288 software and expressed as percentages of the control
untreated groups.
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Assessment of Caspase Activity
The Caspase assays were performed using a previously published method
(Naderi et al., 2003). To determine caspase activity, the total protein from MV-411, HL-60 and DnFADD cell lysates were incubated with the fluorogenic
substrates corresponding to the substrate cleavage site, specific for each
caspase, DEVD-AFC for Caspase-3 and IETD-AFC for Caspase-8. The
fluorescence was measured at an excitation wavelength of 400 nm and emission
wavelength of 505 nm using a Spectra Max Gemini XS (Molecular Devices,
Sunnyvale, California).
Caspase activity was calculated as activity per μg protein and protein
concentration was determined with BioRad protein assay reagent (BioRad,
Mississauga, Ontario) using bovine serum albumin (BSA) as a standard.
Readings were analyzed using GraphPad Prism 5.0 288 software.
To further confirm the role of caspases in apoptosis induction by DRE, the
broad caspase inhibitor, ZVAD-fmk (Catalog No. 219007, EMD4Biosciences, San
Diego, California), was incubated with MV-4-11 cells an hour before treatment, as
described above. Some cells were collected, washed in PBS and stained with
Hoechst 33342 and annexin V. Others were analyzed for the activation of
caspases, using fluorogenic substrates described above, after DRE treatment.
Mitochondrial Isolation and Measurement of ROS Production
Mitochondria were isolated from untreated MV-4-11 and HL-60 cells for
analysis of ROS production. Cells were washed twice in cold PBS, resuspended
in hypotonic buffer (1 mM EDTA, 5 mM Tris–HCl, 210 mM mannitol, 70 mM
sucrose, 10 mM Leu-pep, 10 mM Pep-A, and 100 μM PMSF) and immediately
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homogenized, and centrifuged at 600 x g for 5 minutes at 4°C. The supernatant
was centrifuged at 15,000 x g for 15 minutes at 4°C. The resulting cytosolic
supernatant was discarded and the mitochondrial pellet was resuspended in cold
hypotonic buffer.
To measure the production of ROS, Amplex Red (Molecular Probes,
Eugene, OR) was used. The isolated mitochondria were resuspended in cold
hypotonic buffer and ≥ 20 μg of protein was added to wells of a 96-well opaque
plate. The isolated mitochondria was treated with 1.0 mg/ml DRE and as a
positive control, 250 μM paraquat (PQ) (Sigma Aldrich, Mississauga, ON.
Canada) was used. Amplex Red reagent was added to each well for a final
concentration of 50 μM; horseradish peroxidase (HRP) was added in the ratio of
6units per 200 μL. Fluorescence readings were taken every 5 minutes for a total
time of 4 hours at Ex. 560 nm and Em. 590 nm.
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RESULTS
DRE effectively induces apoptosis in Chronic Myelomonocytic Leukemia
cells:
To assess the effect of Dandelion Root Extract in aggressive and resistant
human chronic myelomonocytic leukemia cells, MV-4- 11, HL-60 and U-937 cells
were treated with increasing concentrations of DRE for increasing time points.
These cells were analyzed for the induction of apoptosis, using Hoechst and
Annexin-V binding assay. Apoptosis was characterized by condensation of the
nuclear chromatin and the externalization of the phosphatidylserine to the outer
leaflet of the cell’s membrane (Ziegler, 2004). Results indicate that DRE
efficiently induced apoptosis in these highly aggressive and resistant leukemia
cells in a dose- and time-dependent manner (Figure 1), as an increase in the
percentage of apoptotic cells corresponded to an increase in the dose and time of
exposure.
Another characteristic feature of apoptosis is nuclear DNA fragmentation
that can be observed after cleavage of caspase-3 (Fadeel & Orrenius, 2005). To
further confirm the induction of apoptosis, TUNEL assay was used to quantify
DNA fragmentation in these cells after exposure to DRE. Etoposide, a known
chemotherapy that targets topoisomerase II to induce double stranded DNA
breaks (Ziegler, 2004), was used as a positive control for DNA fragmentation.
Results indicate that DRE activated the apoptotic pathways leading to late stage
DNA fragmentation, compared to etoposide, which caused DNA fragmentation
that led to the induction of apoptosis (Figure 2).
For a more quantitative assessment of the effect of DRE on CMML cells,
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these cells were treated with DRE and analyzed for the effect of this extract on
the viability of these cells in a time-dependent manner. Results observed indicate
that treatment with DRE led to a decrease in the viability of MV-4-11 cells as a
function of metabolic activity, using a WST-1 cell proliferation assay (Figure 3A).
This extract led to a 60% decrease in the viability of treated cells compared to the
control, untreated cells, indicating that DRE could potentially affect the metabolic
activity of CMML cells, ultimately leading to cell death observed in figure 1A.
Since we observed an approximate decrease in metabolic activity of 60% of MV4-11 cells 96 hours after treatment with DRE, the next step was to determine if
DRE has any effect on the other 40% of cells that did not show any apoptotic
morphology 96 hours after treatment. MV-4-11 cells were treated with DRE and
after 48 hours the cells were removed, from media containing DRE, washed and
equal numbers of cells (200,000 cells/sample) were re-plated (for control and
treated cells) in fresh media without the extract. These cells were then analyzed
for their ability to revive growth after previous exposure to DRE.
Although MV-4-11 cells continued to grow in the absence of DRE, it was
observed that cells previously treated with DRE had reduced ability to revive
growth and therefore grew at a slower pace than the cells not treated with DRE
for 48 hours. More importantly, it was observed that treatment with a second
dose of DRE, after 48 hours, could induce apoptosis successfully in all the cells
that do not show apoptotic morphology after the first treatment (Figure 3B).
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Figure 1. DRE induces apoptosis in CMML cells in a dose dependent
manner: MV-4-11, HL-60 and U-937 cells were treated with increasing doses of
DRE and analyzed for the induction of apoptosis. (A) Hoechst and Annexin-V
staining of DRE-treated CMML cells 48 hours after treatment. Magnification
400X. (B) Manual quantification of three individual experiments of DRE-treated
cells, 48 hours after. 6 pictures were obtained for every sample and live versus
dead cells were counted to ascertain the percent apoptotic cell count for every
sample. Experiment was performed three times and the mean and standard
deviation of the three experiments were obtained
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Figure 2. DRE induces late stage DNA damage in MV-4-11 cells: MV-4-11
cells were treated with 1.0 mg/ml DRE and 10 µM VP-16 at the indicated time
points to determine if DNA damage was the cause or effect of apoptosis
observed in CMML cells. Following treatment, cells were fixed and
immunostained with anti-BrdU antibody to observe DNA damage. Increase in
TUNEL positive staining corresponds with an increase in levels of DNA damage
following treatment. More positively stained cells are observed in the final stages
of apoptosis caused by DRE, compared to the DNA targeting drug, VP-16.
Magnification: 200X

129

Figure 3. DRE reduces the viability of MV-4-11 cells in a time dependent
manner: (A). MV-4-11 cells were plated in 96-well clear bottom plates and
treated with DRE at indicated time points and analyzed for the ability of DRE to
reduce the metabolic viability of these cells, measured by a decrease in
metabolic activity. Following treatment, the WST-1 reagent was added to each
well, the absorbance readings were taken at 450 nm, and expressed at a
percentage of the control. The absorbance readings were analyzed using
GraphPad Prism version5.0 and values are expressed as mean ± SD from
quadruplicates of 3 independent experiments. (b). Following treatment with DRE
for 48 hours, MV-4-11 cells were removed from media containing DRE and equal
number of cells were replated in fresh media, with no extract and allowed to grow
for 96 hours, observing growth every 24 hours by trypan blue exclusion assay
(left). As a single dose of DRE slowed down growth of MV-4-11 cells but did not
completely halt this growth, MV-4-11 cells were treated with DRE for 48 hours,
then treated with a second dose of DRE after the first 48 hours. Subsequent to
the second treatment, cells were observed for growth ability (right), using trypan
blue exclusion assay.
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DRE activates the extrinsic pathway of apoptosis in CMML cells
The first step in determining the mechanism of DRE-induced apoptosis in
human CMML was to assess the chronological activation of caspases in DREtreated cells. This should give some insight to the pathway by which apoptosis is
induced in these cells. In order to observe the activation of caspases, MV-4-11
cells were treated with DRE for various time points, following which, caspase
activity was assayed, using substrates specific to caspases-3, -8 and -9. Results
indicate that DRE rapidly activates caspase-8, followed by subsequent activation
of caspase-3 at later time points (Figure 4A and B) similar results were observed
in HL-60 cells.
In order to determine if caspase activation is required for the induction of
DRE-induced cell death in CMML cells, a pan-caspase inhibitor, ZVAD-fmk, was
used to pre-treat the cells for an hour and then the cells were treated with DRE
for different time points and assayed for caspase-8 activation. Figure 4C confirms
the inhibition of caspase-8 activation by ZVAD-fmk and this inhibition correlates
with the inability of DRE to induce apoptosis in MV-4-11 cells following pretreatment with the pan-caspase inhibitor (Figure 4D). These results indicate that
caspases are required for the apoptosis-inducing effects of DRE, more
importantly, caspase-8 and -3.
From these results, we hypothesize that DRE activates the extrinsic
pathway of apoptosis and that the activation of caspases (caspase-8 and
subsequent activation of caspase-3) are required for this process. To confirm this
effect on the activation of the extrinsic pathway of apoptosis, we wanted to
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observe the effect of DRE on cells with a dominant-negative mutation in the FasAssociated Death Domain (FADD) protein, an essential component of the death
inducing signaling complex (DISC) (Fulda & Debatin, 2006). Dominant negative
FADD (DnFADD) cells were treated with DRE for 96 hours at increasing
concentrations and analyzed for the induction of apoptosis by nuclear
condensation and change in morphology. Results show that DRE did not induce
apoptosis in cells with a mutant FADD domain, nor did it lead to a change in the
morphology of these cells (Figure 5A). A trypan blue exclusion assay was used to
evaluate the effect of DRE on the number of cells after exposure to this extract,
compared to cells not treated with DRE. In figure 5B, we observe no significant
difference between the control untreated cells and the DRE-treated cells.
Furthermore, activation of caspase-8 and 3 were not observed in DRE treated
DnFADD cells (Figure 5D). These results indicate that DRE requires the FasAssociated Death Domain for its activation of the extrinsic pathway of apoptosis.
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Figure 4. DRE activates the death-receptor-mediated extrinsic pathway of
apoptosis: Following treatment with DRE, at indicated time points and
concentrations, MV-4-11 cells were collected, washed and incubated with lysis
buffer to obtain cell lysate. The cell lysate was incubated with caspase
substrates, specific to each caspase (3,8 and 9) and incubated for an hour.
Fluorescence readings were obtained using a spectrofluorometer. An average of
6 readings per well and a minimum of three wells were run per experiment. The
results here are reported as activity per µg of protein (in fold) and the average of
three experiments are shown (a,b). (c). Prior to DRE treatment, MV-4-11 cells
were pre-treated with a pan-caspase inhibitor, Z-VAD-fmk for an hour and then
treated with DRE at the indicated concentration for indicated time points. These
cells were then incubated with caspase-8 substrate and fluorescence readings
were obtained. These cells were also analyzed for the induction of apoptosis by
Hoechst and annexin-V staining (d). Magnification: 400X.
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Figure 5. DRE required the Fas-Associated Death Domain (FADD) for its
activity: (A). Dominant-negative FADD (DnFADD) cells were treated with DRE at
indicated concentrations, for 96 hours and analyzed for the induction of apoptosis
by nuclear condensation (Hoechst) and change in morphology (Phase contrast).
Magnification: 400X. (B). Following treatment with DRE, DnFADD cells were
collected and cell number was obtained using the trypan blue exclusion assay.
Live cells were impermeable to the trypan blue dye. (C). DnFADD cells were
treated with DRE for the indicated time points and analyzed for the activation of
caspase-8, using caspase-8 specific substrate and fluorescence readings were
obtained. An average of 6 readings per well and a minimum of three wells were
run per experiment. The results here are reported as activity per µg of protein (in
fold) and the average of three experiments are shown.
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DRE destabilizes the mitochondrial membrane of CMML cells
Due to the fact that the two different pathways of apoptosis can target the
mitochondria, the next step was to observe the effect of DRE on the mitochondria
of CMML cells affected by DRE. MV-4-11 cells were treated with DRE for 24
hours and analyzed for the destabilization of the mitochondrial membrane
potential, using a cationic lipophilic dye, JC-1, which aggregates in healthy
mitochondria with intact potential, to give off red fluorescence. A loss or decrease
in red fluorescence is therefore indicative of a loss of mitochondrial membrane
potential (MMP). Figure 6A shows the effect of DRE on the mitochondrial
membrane of MV-4-11 cells.
Here, we observed a loss of red fluorescence, indicative of a loss of intact
mitochondrial membrane potential, indicating that DRE has an indirect effect on
the mitochondria of CMML cells, by causing the dissipation of MMP. To further
implicate the extrinsic pathway of apoptosis in DRE-induced apoptosis, we
wanted to observe the effect on the mitochondria of DnFADD cells treated with
DRE. Figure 6B shows the effect of DRE on the mitochondria of DnFADD cells.
Here, we observed a consistency in the red fluorescence, indicating that the
mitochondria of DnFADD cells remained intact and were unaffected by treatment
with DRE. These results confirm that DRE does require FADD for its induction of
apoptosis.
Mitochondria are considered the major players in the production of
reactive oxygen species (ROS) under physiological conditions. The levels of the
ROS increase drastically under pathological conditions, thereby leading to the
induction of cell death (Adam-Visi & Chinopoulos, 2006). Furthermore, the
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production of ROS is known to have dual roles; it could be the cause or effect of
the induction of apoptosis. ROS has been shown to induce the activation of
certain death receptors, such as Fas and TNF (Simon et al., 2000). Therefore,
these points of evidence implicate the mitochondria in the initiation and/or
execution of apoptosis.
To further assess the effect of DRE on the mitochondria of CMML cells,
the production of ROS was studied. To do this, the mitochondria were isolated
from MV-4-11 and HL-60 cells and were treated directly with DRE. ROS
production was assessed by incubation with Amplex Red dye over 4 hours, with
readings taken at 5-minute intervals. Paraquat (PQ), is a known inducer of ROS
production in the mitochondria [14] and this was used as a positive control of
ROS production in both MV-4-11 and HL-60 cells. In both cell lines, it can be
observed that there is an increase in the production of ROS in DRE-treated cells
compared to the control untreated cells; in the MV-4-11 cells, this increase
surpasses that of the PQ treated cells (Figure 7A and B). Therefore, these results
are indicative of the mitochondria as an indirect target of DRE.
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Figure 6. DRE destabilizes the mitochondria membrane potential of MV-4-11
cells: (A). Following treatment with DRE, MV-4-11 cells were incubated with JC-1
dye to detect the loss of mitochondrial potential (ref to Materials and Methods).
Red fluorescence indicates only cells that have healthy mitochondria. The
mitochondria of MV-4-11 cells are completely destabilized by DRE treatment. On
the other hand, the mitochondria of DnFADD cells remained unaffected by DRE
treatment (B). Magnification: 400X
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Figure 7. DRE increases ROS production in isolated mitochondria from
CMML cells: Isolated mitochondria from (A) MV-4-11 and (B) HL-60 cells were
treated directly with 1.0 mg/ml DRE and ROS production was measured using
Amplex Red substrate in the presence of horseradish peroxidase (HRP). Results
were compared to control untreated mitochondria and positive control, paraquat
(PQ). Fluorescence readings were taken in 5 min intervals for 4 h at Ex. 560 nm
and Em.590 nm and expressed as relative fluorescence units (RFU). Analyses of
results were performed using GraphPad Prism version 5.0 and results shown are
representative of 3 independent experiments demonstrating similar trends.
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DRE induces pro-death autophagy in MV-4-11 cells
Autophagy, also known as ―self-eating‖, is an evolutionary conserved
process that is known to play a significant role in the maintenance of cellular
homeostasis. It is the primary degradation process by which cells can get rid of
long-lived or defective proteins, as well as, defective organelles (Thorburn, 2008).
It is reported to play a dual role, as it supports cell survival and cell death (in
extreme cases of ―self-eating‖) (Rosenfeldt & Ryan, 2011). Various cellular
stressors, such as hypoxia, starvation, protein aggregation and ROS production,
usually induce this process. The presence of these stressors leads to the
formation of the autophagosome, a double membrane vesicle, around the protein
or organelle to be degraded. The autophagosome will fuse to the lysosome and
its contents can be degraded (Liu & Lenardo, 2007; Dalby et al., 2010).
In order to assess the induction of autophagy in CMML cells, MV-4-11
cells

were

treated

with

DRE

for

48

hours,

then

stained

with

monodansylcadaverine (MDC) dye and counterstained with propidium iodide to
observe cell death. Tamoxifen (TAM), a known inducer of pro-survival autophagy
(Qadir et al., 2008), was used as a positive control. Results indicate that, unlike
TAM, DRE does induce a pro-death form of autophagy, as characterized by the
bright punctate MDC staining, as well as the propidium iodide positive staining, in
DRE-treated cells, comparable to the TAM-treated cells. These cells were more
brightly stained than the control untreated cells (Figure 8).
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Figure 8. DRE triggers pro-death autophagy in MV-4-11 cells but not in noncancerous Peripheral blood mononuclear cells (ncPBMCs): MV-4-11 and
ncPBMCs cells were treated with DRE for 48 hours and analyzed for the
induction of autophagy; Tamoxifen (TAM) was used as a positive control for the
induction of pro-survival autophagy. Following treatment, the cells were stained
with MDC to detect autophagic vacuoles and counterstained with PI to detect cell
death. Fluorescence images were captured. Magnification: 400X.
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DRE is selective to CMML cells, with little toxicity on normal, noncancerous cells
Dandelions have been used for centuries for nourishment and therapy,
with few reports of little to no toxicity, due to the lack of toxins and alkaloids
present in this plant. High doses have been reported to cause allergic contact
dermatitis, although this was shown in studies using dandelion extract as a
topical treatment [6]. In order to assess toxicity of DRE in the lab, non-cancerous
peripheral blood mononuclear cells (ncPBMCs) were isolated from the blood of
apparently healthy volunteers, according to a previously published protocol (Fuss
et al., 2009).
In assessing for the induction of autophagy in CMML cells, we observed a
distinct lack of autophagic vacuole in ncPBMCs, as well as a corresponding lack
of propidium iodide positive cells in these treated samples, compared to MV-4-11
cells, where we observed the induction of pro-death autophagy (Figure 7).
Following this comparison, we wanted to confirm this selectivity, by assessing for
the induction of apoptosis. Following isolation of PBMCs from healthy volunteers,
cells were plated into six-well culture plates and treated with DRE at increasing
concentrations for 96 hours, then analyzed for the induction of apoptosis. Results
show that DRE does not induce apoptosis in ncPBMCs, even at high doses
(Figure 9A and B). As ncPBMCs are not actively proliferating in culture, some
isolated PBMCs were pre-incubated with concanavalin A (conA), a plant mitogen
known to stimulate T cell proliferation in-vitro (Dwyer & Johnson, 1981). These
cells were then exposed to DRE treatment and analyzed for the induction of
apoptosis. As with the ncPBMCs not pre-treated with conA, those pre-incubated
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with conA and subsequently treated with DRE remained unsusceptible to DREinduced apoptosis (data not shown). These results have also been shown in
other non-cancerous cell lines, for example, normal human fibroblasts (NHFs)
(Chatterjee et al., 2011).
To further evaluate the selective induction of cell death in ncPBMCs, these
cells were treated with DRE for 48 hours and stained with MDC and PI to assess
the induction of pro-death autophagy, using tamoxifen as a positive inducer of
autophagy. Figure 8 (bottom panel) indicates that tamoxifen effectively induced
autophagy in ncPBMCs, ultimately leading to the cell death, observed with
propidium iodide staining. Importantly, there was no induction of autophagy in
these cells, as compared to the control, untreated cells. These DRE treated cells
were also impermeable to propidium iodide, confirming the lack of cell death in
ncPBMCs treated with DRE. These results suggest that DRE is non-toxic to noncancerous blood cells, making it selective to CMML cells.
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Figure 9. DRE does not target normal non-cancerous peripheral blood
mononuclear cells (ncPBMCs): (A). ncPBMCs were isolated from healthy
volunteers and plated in six-well plates. These cells were treated with DRE at
increasing concentrations for 96 hours and analyzed for the induction of
apoptosis by nuclear condensation (Hoechst) and externalization of the
phosphatidylserine (Annexin-V binding). Magnification: 400X. (B). Results from
three different experiments were quantified to determine the percentage of
apoptosis occurring in ncPBMCs treated with DRE.

143

DISCUSSION
The poor prognosis for Chronic Myelomonocytic Leukemia (CMML)
patients is a major indication that there is a serious need for a more effective and
non-toxic alternative to the conventionally available forms of chemotherapy and
surgical procedures (Steensma & Bennett, 2006). With the introduction of natural
products, not only as sources of nourishment, but also for their therapeutic
benefits, it is therefore necessary to study the vast array of natural products as
non-toxic and less expensive alternatives for the treatment of CMML. Apoptosis
and autophagy, two necessary modes of programmed cell death, are important
mechanisms, which cells utilize for the maintenance of cellular homeostasis
(Zhivotovsky & Orrenius, 2010). Cancer cells, however, have developed
mechanisms to evade these programs, so as to enable enhanced proliferation,
aggressiveness and resistance (Hanahan & Weinberg, 2000; Ghobrial et al.,
2005). In this study, we demonstrate the selective efficacy of dandelion root
extract in inducing apoptosis and autophagy in highly aggressive and resistant
CMML cell lines. We observed the induction of apoptosis in three of the CMML
cell lines used for this study (Fig. 1). More importantly, this effect was selective,
as non-cancerous PBMCs and NHFs remained unsusceptible to DRE-induced
apoptosis (Figure 9A and B).
Although various extracts of dandelions have been used for centuries for
the treatment of various diseases, there have been very few scientific studies
done to ascertain the mechanism by which these extracts act and although some
of the compounds present in dandelion extracts have been isolated and
identified, they still are not fully characterized (Schu¨tz et al., 2006; Yarnell &
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Abascal, 2009). The major aim of the study was therefore to determine the
mechanism of DRE-induced cell death in CMML cells.
In this study, we report a rapid activation of caspase-8 (within minutes)
and subsequent activation of caspase-3 in human CMML cells, indicative of a
rapid activation of the death receptor mediated extrinsic pathway of apoptosis
(Figure 4A and B). This activation has been shown to be necessary for the
induction of apoptosis observed after DRE treatment, as the inhibition of caspase
activity, using a pan-caspase inhibitor, ZVAD-fmk, prevented the induced cell
death observed (Figure 4C and D). These results suggest that caspases, more
importantly, caspase-8 and 3, are required for the induction of apoptosis by DRE.
The Fas-Associated Death Domain (FADD), as well as other death domains, are
highly important for activation of caspase-8 through extrinsic apoptosis (Elmore,
2007). The binding of the death ligand to its corresponding death receptor leads
to the recruitment of specific receptor death domains for the formation of the
death inducing signaling complex (DISC) (Fulda & Debatin, 2006). The absence
of FADD should therefore prevent the activation of the extrinsic pathway of
apoptosis through inhibition of the activation of caspase-8 (Shakibaei et al.,
2010).
To further confirm the effect of DRE on the extrinsic pathway of apoptosis,
DnFADD cells were treated with DRE and analyzed for apoptosis induction.
According to our results, no nuclear condensation and morphological changes
were observed with the treatment of DRE. There was no change in the number of
cells treated with DRE, compared to the control untreated cells, suggesting that
DRE did not have a significant effect on the cells with a truncated FADD protein
145

(Figure 5A and B). Furthermore, these cells were not susceptible to DRE-induced
rapid activation of caspases, specifically caspase-8 (Figure 5C). As we observed
late activation of caspase-3, we wanted to observe the connection between the
intrinsic and the extrinsic pathway of apoptosis.
It is known that the activation of caspase-8 could yield two main results.
First, the activated caspase-8 could lead directly to the activation of the effector
caspase, caspase-3 or it could lead to mitochondrial changes, through the
cleavage of pro-apoptotic protein, Bid. The truncation of Bid causes mitochondrial
membrane destabilization, which leads to the release of pro-apoptotic proteins for
the activation of caspase-3 [26]. In this study, we observed the destabilization of
the mitochondrial membrane potential 24 hours after treatment with DRE. This
destabilization of mitochondrial membrane potential was only observed in MV-411 cells, not in DnFADD cells (Figure 6A and B). These results suggest that DRE
indirectly targets the mitochondria after the activation of the extrinsic pathway of
apoptosis. It confirms the requirement of the adapter domain for DRE-induced
apoptosis, as we do not observe a similar loss of mitochondrial membrane
potential in DnFADD cells treated with DRE. As the mitochondria are major
players in the production of ROS (Chen et al., 2003), the next step was to
observe the effect of DRE on the production of ROS. Results confirm the
production of ROS from isolated mitochondria (Figure 7A and B), further
confirming the effect of DRE on the mitochondria of CMML cells.
The integrity of the mitochondria is essential for the maintenance of
cellular homeostasis and defects in the mitochondria caused by treatment with
DRE could provide sufficient signals for the induction of programmed cell death
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type II, also known as Autophagy, a process induced by the presence of
defective organelles, proteins and starvation (Gottlieb & Carreira, 2010).
Autophagy has been shown to play a significant role in cancer survival and
its role in programmed cell death has been controversial. In response to
stressors, cells undergo ―self-digestion‖ as a means of temporary survival, where
macromolecules are digested in order to provide an alternate energy source.
However, excessive exposure to stressors could lead to excessive autophagy,
ultimately resulting in cell death (Yu et al., 2006; Dalby et al., 2010). The loss of
mitochondrial membrane potential, observed after treatment with DRE, therefore
led us to determine if the stress induced by our extract, leading to mitochondrial
membrane destabilization was a sufficient signal for the induction of autophagy.
Our results indicate that treatment with DRE triggered the induction of a
pro-death form of autophagy in MV-4-11 cells (Figure 8; top panel). Comparing
this to treatment with tamoxifen, which is known to induce pro-survival autophagy
in cancer cells, treatment with DRE not only triggered autophagy, comparable to
TAM, the cells were also propidium iodide positive, indicative of cell death.
Moreover, ncPBMCs stained with MDC and PI showed no induction of autophagy
in these cells after DRE treatment (Figure 8; bottom panel). These results
suggest that DRE is effective in selectively inducing both forms of programmed
cell death in human CMML cells.
In conclusion, Dandelion Root Extract has shown selective efficacy in
inducing two forms of programmed cell death in highly aggressive and resistant
CMML cell lines. The rapid activation of caspase-8 not only activated the extrinsic
pathway of apoptosis, but also triggered pro-death autophagy selectively in these
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cells, suggesting that this extract has components that enhance its selective
efficacy in targeting CMML cells. These results indicate that within the vast array
of available natural products and compounds, there are non-toxic alternatives to
conventional chemotherapy that are safe and effective.
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ABSTRACT
Natural health products have formed the basis for the introduction of many
identified drugs in the treatment of various diseases, especially as anti-cancer
agents. Dandelion extracts have been studied extensively in recent years for its
anti-depressant and anti-inflammatory activity. Recent work in our lab, with invitro systems, have shown the anti-cancer potential of an aqueous extract of
dandelion root in several cancer cell models, with no toxicity to non-cancer cells.
The detailed analyses of the efficacy and toxicity of this extract in in-vivo and exvivo models, as well as, the mechanism(s) of action remains unexplored.
Furthermore, the pharmacologically active components within this extract,
involved in the anti-cancer activity are unknown.
In this study, we examine the role of an aqueous extract of dandelion root
in highly aggressive colon cancer cell lines, as well as its anti-cancer efficacy in
patient-derived ex-vivo samples of leukemia. Aqueous DRE induced significant
and selective programmed cell death (apoptosis) in colon cancer cells,
irrespective of their p53 status (HT-29 – p53 mutant and HCT116 – p53 wild
type). The anti-cancer efficacy of this extract was confirmed in in-vivo studies,
where the oral administration of DRE-supplemented drinking water halted the
continued growth of human colon tumors in xenograft models. More importantly,
we observed this cell death inducing ability of DRE in peripheral blood
mononuclear cells (PBMCs), isolated from the blood of newly diagnosed
leukemia patients in the Windsor-Essex area.
In this study, we also hypothesized that the complexity of this natural
extract is able to target more than one signaling pathway, and hence, more than
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one cancer cell vulnerability, in order to have a potent anti-cancer effect. We
determined the presence of bioactive ingredients, including -amyrin, -amyrin
and lupeol in bioactive fractions of aqueous DRE. This anti-cancer effect of DRE
hinged on the activation of multiple pathways, including the rapid activation of
extrinsic apoptosis, the destabilization of the mitochondrial membrane potential
and the induction of pro-death autophagy, following an increase in the expression
of genes involved in programmed cell death type I and II (apoptosis and
autophagy, respectively).
Our results show that aqueous DRE can potentially represent a non-toxic,
effective alternative, which could possibly reduce the occurrence of cancer cells
resistance, as it contains multiple bioactive components that can target multiple
signaling pathways, specifically in cancer cells. Furthermore, these findings have
led to the approval of dandelion root extract, as the first NHP in Canada, for
Phase I clinical trials, for hematological cancers in Canada.
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INTRODUCTION
The increase in the world’s aging population, as well as the adoption of
cancer-causing behaviours, are the major contributors to an escalation in the
incidence of different forms of cancers globally. There are over 12 million new
cancer cases arising annually and over 7 million cancer-related deaths
worldwide, and even with the introduction of many chemotherapy and
chemopreventative approaches, cancer is still one of the leading causes of
deaths in the world today, with a statistic of one in four deaths being attributed to
cancer alone (Jemal et al., 2011; Siegel et al., 2013).
Despite the progress made in the development and introduction of many
chemotherapy agents, the accompanying toxicities and side effects (Jemal et al.,
2011), indicate that further research is required to reduce the incidence of cancer
rates, and the amount of cancer-related deaths, as well as improve the quality of
life of patients already diagnosed with the disease.
Natural health products (NHPs) and natural products (NPs) have been
essential in the development of many drugs, with over 75% of the currently
available chemotherapies having been derive from natural sources (plants,
microbes and marine sources), with the common example being paclitaxel
(Mann, 2002). These NHPs have been used in various traditional medicines and
recent scientific studies in the use of these NHPs for specific diseases have
yielded some scientific validation to the use of these products (Ganesan, 2008;
Newmann & Cragg, 2012). Even with all the incoming evidence, herbal drugs and
other NHPs and NPs are usually shunned during systemic chemotherapy

155

because of herb-drug interaction and the exaggeration of chemotherapy-related
toxicity (Foster et al., 2005; Nobili et al., 2009).
Dandelions (Taraxacum spp) have been used for centuries for the
treatment of various ailments; surprisingly enough, it has received little research
attention. Some scientific studies have shown the efficacy of various parts of this
plant as anti-inflammatory, anti-oxidative and as a diuretic agent (Yarnell &
Abascal, 2009).
Recent studies in our lab have shown the anti-cancer activity of an
aqueous extract of dandelion root, selectively in cancer cells. In these studies, we
show that dandelion root extract (DRE) is able to selectively induce the rapid
activation of the death-receptor mediated extrinsic pathway of apoptosis in a
dose and time dependent manner, in several cancer cell types (Chatterjee et al.,
2011; Ovadje et al., 2011; Ovadje et al., 2012a; Ovadje et al., 2012b).
Furthermore, we observed a caspase-8 dependence, following DRE treatment.
This result showed that, following the inhibition of caspase activation, using a
pan-caspase inhibitor, zVAD-fmk, in chronic myelomonocytic leukemia cells,
there was a corresponding inhibition of the induction of apoptosis (Ovadje et al.,
2012b). These findings have led us to further investigate the mechanism of DRE
in cancer cells that enhance its selectivity, as evidenced by the lack of toxicity in
non-cancer cells.
In this study, we hypothesize that there are bioactive component(s) within
aqueous DRE that are able to target multiple vulnerabilities within a cancer cell,
in order to induce selective programmed cell death processes. In this study, we
delve further into the mechanism of action of DRE in highly aggressive, drug
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resistance colon cancer cells, where we observe the activation and localization of
active caspase-8 to the mitochondria and the peri-nuclear space. However, this
caspase-8 activation was not essential to the mechanistic efficacy of DRE in
colon cancer cells, as inhibition of caspase-8 activation did not have an effect on
the apoptosis inducing activity of DRE in these cell types, demonstrating the
versatility of this extract in in-vitro models. Further assessment of DRE in in-vivo
and ex-vivo models (with patient-derived samples of leukemia) suggests that this
extract could potentially represent a novel non-toxic alternative to conventional
cancer therapy available today, as it was well-tolerated in mice models but was
efficient in inducing apoptosis in ex-vivo samples. More importantly, we have
been able to identify three bioactive components, α-amyrin,β-amyrin and lupeol,
within this extract that could contribute to its overall bioactivity, demonstrating the
benefits of utilizing the whole complex extract of dandelion root.
These results further scientifically validate the use of NHPs, especially the
dandelion root species, as a potential anti-cancer agent, worthy of further
investigation.
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MATERIALS & METHODS
Dandelion Root Extraction & Preparation
The dandelion roots used for this study were obtained from Premier Herbal
Inc. (Lot No. 318121). The root extract was prepared, modified from a previously
published protocol (Ovadje et al., 2011). Dried dandelion root was immersed in
liquid nitrogen for about 5 to 10 minutes, until thoroughly frozen. The frozen
pieces were ground up in an impingement grinder to an average particle size of ≤
45 μm. Following grinding, dandelion root powder was extracted in boiling water
on low heat for 3 hours. The total extracted material was filtered through a NITEX
nylon mesh filter (LAB PAK; Sefar BDH Inc. Chicoutini, Quebec CA) and the
filtrate was spun down at 800 x g for 5 minutes at room temperature. The
supernatant was filtered through a 0.45 μm filter, followed by lyophilzation. The
dried extracted material was reconstituted in water to give a final stock solution of
100 mg/ml and then passed through a 0.22 μm filter, in a biological safety cabinet
and stored at 4°C. this material was used for the experiments described in this
study.
Cell Culture and Treatment
Human colon cancer cell lines (HT-29, p53 mutant and HCT116, p53 WT
(Muller et al., 2013) were purchased from ATCC (Manassas, VA). These cells
were cultured in McCoy’s 5a medium (ATCC, Catalog no. 30-2007),
supplemented with 10% fetal bovine serum (FBS) and 40 μg/ml gentamicin (Life
Technologies, Mississauga, ON). Normal human colon mucosal epithelial cell line
(NCM460, Incell Corporation, LLC, San Antonio TX) were subcultured in RPMI
1640 medium (Sigma Aldrich, Mississauga, ON), supplemented with 10% FBS
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and 40 μg/ml gentamicin. These cells were grown and maintained in an
incubator, set at 37°C, with an atmosphere containing 5% CO2 and 95%
humidity.
Peripheral blood mononuclear cells (PBMCs) were purified from whole
blood samples, obtained from either healthy volunteers (non-cancerous PBMCs –
ncPBMCs) or from newly diagnosed leukemia patients (prior to the administration
of chemotherapy). These cells were prepared according to a previously published
protocol (Griffin et al., 2010; Ovadje et al., 2012b) and as approved by the
University of Windsor’s research ethical committee, REB# 04-060. Whole blood
(~12ml) was collected into a BD Vacutainer CP Tube (Cell Preparation Tube)
obtained from Becton Dickinson (Franklin Lakes, NJ). The whole blood was spun
down by density gradient centrifugation in a tabletop lowspeed centrifuge at 2900
x g for 30 minutes at 25°C. The red blood cells went through the polyester gel
and the top layer containing mononuclear cells, platelets and plasma was
collected. These cells were washed twice in AIM-V medium (Invitrogen,
Burlington, ON), following which, cells were maintained in an incubator set at
37°C with an atmosphere containing 5% CO2 and 95% humidity. The cells were
cultured in AIM-V medium.
To assess the efficacy of DRE in our cell culture models, cells were plated
and grown to 50 – 70% confluence prior to treatment with dandelion root extract
(DRE), at increasing concentration (0.5 mg/ml – 6.0 mg/ml). Subsequent to
treatment, cells were analyzed for efficacy of DRE, as described below. All cells
were cultured for ≤ 4 months, before being discarded and fresh frozen cells were
used to continue studies, lasting longer than the 4-month period.
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Assessment of Cellular Metabolic Activity & Viability
To examine the viability of colon cancer and normal colon mucosal
epithelial cells after treatment, cells were incubated with cell proliferation reagent
WST-1 (Catalog No. 05 015 944 001, Roche Diagnostics) for 4 hours at 37°C,
following treatment with DRE at indicated doses and time points, using the
manufacturers protocol. WST-1 works by reacting with the mitochondrial
succinate-tetrazolium reductase, forming the water-soluble formazan product
(Ngamwongsatit et al., 2008). Fluorescence readings were obtained 450 nm
using a Perkin Elmer Victor Fluorescence instrument and viability readings were
analyzed using GraphPad Prism 6.0 288 software and expressed as a
percentage of the control untreated groups.
Assessment of Programmed Cell Death Induction
An early marker of apoptosis is the reorganization of the cell membrane to
expose phosphatidylserine fro the inner leaflet of the cell membrane to the outer
leaflet. This allows apoptotic cells to be taken up by phagocytic cells (Fadeel &
Orrenius, 2005). This characteristic can also be exploited to assess the induction
of apoptosis, according to a previously published protocol (Rieger et al., 2011).
Following treatment with DRE, cells were trypsinized (0.15% trypsin) to lift
adherent cells from the plates. The cells were washed twice in phosphate
buffered saline (PBS). After washes with PBS, the pellet was resuspended in
Annexin-V binding buffer (10 mM HEPES, 10 mM NaOH, PH 7,5, 140 mM NaCl,
2.5 mM CaCl2 and 50nM sucrose) and Annexin-V Alexa Fluor 488 conjugate
(Catalog No. A13201, Life Technologies, Burlington, ON), which binds to the
exposed phosphatidylserine, at a 1:50 ratio, with respect to the binding buffer.
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This reaction was incubated at room temperature for 15 minutes. Hoechst 33342,
a photosensitive DNA binding dye (Molecular Probes, Eugene, OR), was used as
a counterstain, at a final concentration of 10 μM, in the last 10 minutes of the
incubation at room temperature. Apoptotic cells will be characterized by brightly
stained, condensed nuclei, as compared to the larger, rounder and less brightly
stained non-apoptotic cells. At the time of Hoechst staining, cells were
counterstained with propidium iodide, a cell impermeable photosensitive DNA
binding dye (Sigma Aldrich, Mississauga, ON), at a final concentration of 1 μg/ml
(added at the same time as Hoechst 33342). Following the incubation, cells were
visualized and images were obtained using a fluorescence microscope (Leica
DMI 6000 fluorescence microscope, with a Leica DFC 360FX camera and Leica
STP6000 control board).
The images were obtained at 400X magnification and fluorescence
quantification was also carried out using a TALI image-based cytometer (Catalog
No. T10796, Life Technologies, Burlington ON), using a previously published
protocol (Remple & Stone, 2011; Chan et al., 2012).
Evaluation of Mitochondrial Membrane Potential
JC-1 Mitochondrial Membrane Potential Detection Kit was used to monitor
membrane destabilization in cells undergoing apoptosis. In non-apoptotic cells,
with

healthy

mitochondria,

tetraethylbenzamidazolylcarbocyanine

JC-1
iodide)

(5,5’,

6,6’-tetrachloro-1,1’,3,3’-

(Catalog

No.

M34152,

Life

Technologies, Burlington ON) exists as a monomer, which fluoresces green, in
the cytosol and also accumulates as aggregates in the mitochondria, which
fluoresces red. In apoptotic and necrotic cells, with defective mitochondria, JC-1
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only exists in its monomeric form, diffused in the cytosol, with no accumulation in
the mitochondria, leading to a distinct lack of red fluorescence. Treated cells were
incubated with JC-1 dye, at a final concentration of 200 nM, for 45 minutes at
37°C. the cells were counterstained with Hoechst staining and were examined by
fluorescent

microscopy

and

fluorescent

images

were

taken

at

400X

magnification. Samples were also observed using image-based cytometry.
Mitochondrial Isolation and Measurement of ROS Production
Mitochondria were isolated from untreated HT-29 and NCM460 cells for
analysis of reactive oxygen species (ROS) production. Cells were washed twice
in cold PBS, resuspended in hypotonic buffer (1 mM EDTA, 5 mM Tris-HCl, 210
mM mannitol, 70 mM sucrose, 10 μM Leu-pep, 10 μM Pep-A and 100 μM PMSF)
and immediately homogenized, before centrifuging at 600 x g for 5 minutes, at
4°C to get rid of nuclear pellet and unbroken cell debris. The resulting cytosolic
supernatant was discarded and the mitochondrial pellet was resuspended in cold
hypotonic buffer.
To measure the production of ROS, Amplex Red (Molecular Probes,
Eugene, OR) was used. Following resuspension in cold hypotonic buffer, ≥ 20 μg
of protein was added to wells of a 96-well opaque plate. Treatment was done with
2.5 mg/ml DRE, a positive control, 250 μM paraquat (PQ) (Sigma Aldrich,
Mississauga ON) and a negative control, 3 mM N-Acetylcysteine (N-AC) (Sigma
Aldrich, Mississauga ON). Amplex Red reagent was added to each well fro a final
concentration of 50 μM; horseradish peroxidase (HRP) was added in the ratio of
6units per 200 μL. Fluorescence readings were taken every 5 minutes for a total
time of 5 hours at Ex. 560 and Em. 590 nm on a spectrofluorometer (SpectraMax
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Gemini XS, Molecular Devices, Sunnyvale, CA). The readings were analyzed on
GraphPad Prism 6.0 288 software and expressed as relative fluorescence units
(RFU) per μg protein.
Evaluation of Caspase Activation
Cysteine-Aspartic Proteases (Caspases) are a major player in the initiation
and execution of apoptosis (Fadeel & Orrenius, 2005). The caspase assays were
performed and modified from a previously published method (Naderi et al., 2003).
Caspase activation was confirmed using an Image-iT Live caspase detection kit
(Catalog No. I35105, Life Technologies, Mississauga ON). Following treatment
for an hour with DRE, cells were stained with a cell permeable FLICA dye for the
detection of active caspases, at 150X dilution and incubated for 45 minutes at
37°C. Following incubation with the dye, cells were washed in 1X wash buffer
and counterstained with propidium iodide. The stained cells were visualized by
TALI image-based cytometry. To further confirm the role of caspases in apoptosis
induction by DRE, a caspase-8 specific inhibitor, IETD-fmk (Catalog No. 218759,
EMD4Biosciences, San Diego, CA) or a pan-caspase inhibitor, ZVAD-fmk
(Catalog No. 219007, EMD4Biosciences) were incubated with HT-29 cells, an
hour before DRE treatment, as described above. Cells were analyzed for
metabolic viability by the WST-1 viability assay.
Immunocytochemical Analysis of Caspase Activation
To confirm the activation of caspases and their localization upon
activation, HT-29 cells were plated onto poly-L-lysine (Sigma Aldrich, Canada)
coated coverslips in a 6-well plate and allowed to attach to the coverslips for 24
hours. These cells were then treated with DRE for different time points, ranging
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from 30 minutes to 24 hours, following which the cells were incubated with a
mitochondrial specific due, MitoTracker (Invitrogen, Canada) for 45 minutes,
before the cells were obtained for immunocytochemical analysis. Cells were fixed
in 3.7% paraformaldehyde (PFA) solution for 5 minutes at room temperature,
followed by a 1.4% formaldehyde/0.1% NP-40 solution for 1.5 minutes at room
temperature. Subsequent to fixation, cells were incubated with a blocking solution
of 5% goat serum in PBS, followed by incubation overnight at 4°C with antimouse primary antibody, specific to active caspase-8 (Santa Cruz Biotechnology,
CA). The following day, coverslips were incubated with a goat anti-mouse
secondary antibody, conjugated to AlexaFluor 488 (CellSignalling Technology,
MA) for an hour at room temperature. The coverslips were washed in PBS and
incubated with Hoechst 33342 for 10 minutes, at a final concentration of 10 μM
and mounted on slides, using 80% glycerol. The slides were stored at 4°C until
ready for visualization by fluorescent microscopy.
Gene Expression Profiling of DRE Treated Cells:
RNA extraction and cDNA synthesis
Following treatment of chronic myelomonocytic leukemia (CMML) cells,
HT-29 and NCM460 cells, with DRE, total cellular RNA was extracted using the
Qiagen RNeasy Mini Kit (Qiagen, Inc.), according to the manufacturer’s protocol.
The RNA quality was examined using gel electrophoresis and measuring the
A280/A260 ratio (NanoDrop 2000). The cDNA was synthesized from 500 ng of
total RNA by using the RE3 Reverse Transcriptase Mix first-strand synthesis
system. Following a denaturation step of 5 minutes at 42°C, RNA was reverse
transcribed to a single stranded cDNA using oligo(dT) primers (Qiagen, Inc.). The
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reverse transcription reaction was performed in a total volume of 20 μL at 42°C
for 15 minutes, immediately followed by 95°C for 180 minutes.
PCR Array (Cell Death Signaling Pathway).
The polymerase chain reaction (PCR) for the cell death signaling pathway
was performed, following the reverse transcription of isolated RNA, using the
RT2Proiler PCR array system from Qiagen, Inc. The PCR array was performed to
combine the quantitative performance of the SYBR Green based system, with
multiple profiling abilities of the pathway-focused gene expression (Ornatowska
et al., 2007). 384-well (4 x 96-well) plates containing gene-specific primer sets fr
84 relevant genes in the major programmed cell death pathways (Apoptosis,
Autophagy and Necrosis), 5 housekeeping genes, a positive control and a
negative control gene set was used (Catalog No. PAHS-212Z, Qiagen, Inc.
Toronto, ON).
Amplification of specific gene products was detected using the SYBR
Green PCR mastermix and the real time amplification data was gathered using
the ABI 7900HT software. The samples were amplified for 40 cycles for 15 s at
95°C and 60 c at 60°C. each curve was completed with a melting curve analysis,
to confirm the specificity of amplification. Gene expression was normalized to
internal controls (housekeeping genes) to establish fold change in gene
expression between the controls and treated samples by CT method (Qiagen RT2
Profiler PCR Array Analysis program).
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Fractionation & Phytochemical Analysis of Dandelion Root Extract
Analyses were carried out in collaboration with Dr. JT. Arnason and his
group, at the University of Ottawa, Ottawa ON. The protocol was carried out
following a previously published protocol (Guerrero et al., 2010). Ground
dandelion root (1.5 kg) was extracted twice in ethanol (95% in H2O) with a 24hour incubation for both extractions, at room temperature. The first extraction was
made using 10 L of solvent and the second extraction, using 8.0 L. the combined
extracts were evaporated in a vacuo and lyophilized to yield 93.3 g of a brown
residue (crude extract; 6.2% yield). Dried extract was chromatographed on a
glass column packed with silica gel (1.0 kg) eluting with 5% increments of polarity
gradients, starting from 100% hexane, to 100% ethylacetate, to 100% methanol
(hexanes-EtOAc (1:0 f 0:1) and EtOAc-MeOH (1:0 f 9:1). This yielded 210
fraction, which were then pooled to yield 25 primary fraction, by thin-layer
chromatography (TLC) analyses performed on a silica gel 60 F254 plate (Merck),
an visualization of plates was carried out using a ceric sulfate (10%) solution in
H2S. Bioactivity analyses led to the identification of 5 bioactive fractions.
Secondary fractionation yielded 24 secondary subfractions. Pre-fractionation of
secondary fractions with significant bioactivity was carried out and separated on a
preparative scale 1200 series Agilent preparative scale HPLC using a reversedphase Gemini Axia 250 x 21.2 mm column, particle size 10 μm (Phenomenex
Inc., Torrance CA), using an isocratic mobile phase composition of 45% THF in
55% water at 37.5mL.min to afford uvaol (12.0 mg, 0.0008%), botulin, (100 mg,
0.007%), α-amyrin (6.5 mg, 0.0004%), and betulinic acid (5.0 mg, 0.0003%) at
the monitoring wavelength of 210 nm, bandwith 4, reference off.
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The final preparative scale isolation of the phytochemicals was undertaken
using a reversed-phase Gemini Axia 250 x 21.2 mm column, particle size 10 μm
(Phenomenex Inc., Torrance CA), on an Agilent 1200 Series preparative HPLC
system comprising a binary pump, an autosampler with a 2 mL loop, a diode
array detector, with a flow cell (Path length 3 mm and maximum pressure limit,
120 bar), and a fraction collector (40 μL collection tubes). IR spectra were
recorded on a Shimadzu 8400-S FT/IR spectrometer. Optical rotations were
registered on a Perkin Elmer 241 digital polarimeter. NMR spectra were recorded
on a Bruker Avance 400 spectrometer in C5D5N, at either 400 MHz (1H) or 100
(13C) MHz, using tetramethylsilane (TMS) as an internal standard. EIMS and
HREIMS were obtained on a Kratos Concept IIH mass spectrometer.
Western Blotting Analysis
SDS-PAGE was performed on the protein samples. Treated cells were
lysed in lysis buffer (0.1% NP40, 20 mM Tris-HCl, 100 mM NaCl and 5 mM
EDTA), following which, the total protein was measured by Bradford assay.
Proteins were separated on a 10% gel and then transferred to a nitrocellulose
membrane. Following transfer, the membranes were blocked in a milk solution
(5% w/v milk in Tris-Buffered Saline with Tween-20 (TBST)) for 90 minutes.
Subsequent to the blocking step, membranes were probed with primary
antibodies, overnight at 4°C; anti-cFLIP, raised in rabbit (1:1000), (Catalog No.
GTX28421, GeneTex Inc. Irvin, CA) and anti-actin, raised in mouse (1:1000),
(Catalog No. sc-81178, Santa Cruz Biotechnology, CA). Following incubation with
the primary antibodies, membranes were washed in TBST (1X – 15 minute wash
and 2X – 5 minute wash) and following the washes, membranes were incubated
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with anti-mouse or anti-rabbit horseradish peroxidase conjugated secondary
antibody (1:1000) – (Catalog No. ab6728 and ab6802, respectively, Abcam,
Cambridge MA) for an hour at room temperature. The membranes were then
washed for 3 X 5 minutes in TBST, followed by band visualization with a Visiglo
Select HRP chemiluminescent substrate kit (Catalog No. CA11027-138, VWR
International, Mississauga ON). Densitometry analyses were performed using
Image J software.
In-vivo Assessment of Dandelion Root Extract:
Toxicity Assessment
Six week old Balb/C mice were obtained from Charles River Laboratories
and housed in constant laboratory conditions of 12-hour light/dark cycle, in
accordance with the animal protocols outlined in the University of Windsor
research ethics board (AUPP #10-17). Following acclimatization, mice were
divided into two groups (4 animals/control (untreated) and 4 animals/treatment
group). The control untreated group was given plain filtered water, while the
second group was given 5 mg/ml dandelion root in drinking water, resulting in
approximately 40 mg/kg/day of DRE in their drinking water, respectively for 75
days. During the period of the study, toxicity was measure by weighing mice
twice a week and urine was collected for protein urinalysis by urine dipstick and
Bradford assays. Following the duration of the study, mice were sacrificed and
their organs (Livers, kidneys and hearts) were obtained for immunohistochemical
and toxicological analysis by Dr. Brooke at the University of Guelph.
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Efficacy of DRE in Tumor Xenograft Models of Immunocompromised Mice
Six week old make CD-1 nu/nu mice were obtained from Charles River
Laboratories and housed in constant laboratory conditions of 12-hour light/dark
cycle, in accordance with the animal protocols outlined in the University of
Windsor research ethics board (AUPP #10-17). Following acclimatization, mice
were subcutaneously injected in the right and left hind flanks with a colon cancer
cell suspension (in PBS) at a concentration of 2 * 106 cells/ mouse (HT-29, p53-/in the left flank and HCT116, p53+/+ in the right flank). Tumors were allowed to
develop (approximately a week), following which, the animals were randomized
into treatment groups of 4 mice per group, as outlined in the toxicity studies
above. The mice were allowed to drink ad libidum, and treatment was replaced
everyday. All mice were assessed for toxicity, as well as efficacy of oral
administration on the growth of tumors. The tumors were assessed every other
day by measuring the length, width and height, using a standard caliper and the
tumor volume was calculated according to the formula π/6*length*width. The
mice were also assessed for any weight loss for the duration of the study, which
also lasted 75 day. Following the study, mice were sacrificed and their organs
and tissues (livers, kidneys, hearts and tumors) were obtained and stored in
formaldehyde for immunohistochemical and toxicological analysis.
Hematoxylin & Eosin (H & E) Staining
Mice organs were fixed in 10% formaldehyde, following which the organs
were cryosectioned into 10-micron sections and placed on a superfrost/Plus
microscope slides (Fisherbrand, Fisher Scientific). Sections of organs were
stained according to a standardized H & E protocol (Fischer et al., 2008).
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Statistical Analyses
All experiments were repeated at least three independent times. Statistical
analysis was performed using GraphPad Prism 6.0 288 software. Statistical tests
included the Students T-test, one- and two-way Anova.
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RESULTS
Efficacy of Dandelion Root Extract in Various Cancer Cell Models:
Dandelion Root Extract Induces Apoptosis in Aggressive Colorectal Cancer
Cells
Previous results with dandelion root extract (DRE) have implicated this
extract as a possible anti-cancer agent in various leukemia, melanoma and
pancreatic cancer cell models (Chatterjee et al., 2011; Ovadje et al. 2011; Ovadje
et al., 2012a; Ovadje et al., 2012b). The capacity of DRE’s apoptosis-inducing
activity prompted further studies into the efficacy of this aqueous extract in highly
aggressive colorectal cancer cells.
To determine if this water extract of dandelion root shows potency against
colon cancer cells, HT-29 and HCT116, were used in this study. Along with these
cell types, normal mucosal colon epithelial cells (NCM460) were used to assess
any levels of toxicity associated with DRE treatment. Following treatment with
DRE, at increasing concentrations and time points, we observed a resultant
decrease in the viability of both HT-29 and HCT116 colorectal cancer cells,
irrespective of p53 status (Figure 1A). Employing the WST-1 cell viability assay,
we determined the EC50 of DRE in both colon cancer cell lines; 2.0 mg/ml in
HCT116 cells and 3.5 mg/ml in HT-29 cells. The selectivity of DRE to caner cells
was once again confirmed, as we did not observe as similar trend in the response
of NCM460 cells, treated in parallel with the colon cancer cells. (Figure 1A).
Further investigation into the anti-cancer efficacy of DRE in colon cancer
cells indicates that DRE efficiently induces apoptosis in colon cancer cells
selectively. Following treatment, cells were stained with Hoechst 33342,
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propidium iodide and Annexin V dye to observe the nuclear morphology, cell
membrane integrity and externalization of phosphatidylserine respectively.
Following DRE treatment, we observed a corresponding increase in propidium
iodide and Annexin V positive staining, by fluorescence microscopy, indicative of
apoptosis in colon cancer cells, while NCM460 cells again remained unaffected
(Figure 1B). Image- based cytometry was used to quantify the amount of
apoptosis induced by DRE. Treatment with DRE led to an approximately 40%
increase in Annexin V positive cells and a corresponding 97% increase in
propidium iodide cells (Figure 1C). These results confirm the anti-cancer potential
of dandelion root extract and demonstrates its efficacy in aggressive colorectal
cancer cells.

172

173

Figure 1: Dandelion Root Extract Induces Apoptosis in Aggressive
Colorectal Cancer Cells: Colon Cancer cells (HT-29 [p53-/-] and HCT116
[p53+/+]) and normal colon mucosal epithelial cells (NCM460) were treated with
increasing doses of DRE and analyzed for anticancer effects. A) Cells were
plated in 96-well clear bottom plates and treated with DRE at indicated time
points and analyzed for the ability of DRE to reduce the viability of these cells,
measured by a decrease in metabolic activity. Following treatment, the WST-1
reagent was added to each well, the absorbance readings were taken at 450 nm,
and expressed at a percentage of the control. The absorbance readings were
analyzed using GraphPad Prism version5.0 and values are expressed as mean ±
SD from quadruplicates of 3 independent experiments. B) Hoechst (Blue),
Annexin V (Green) and Propidium Iodide (PI) (Red) staining of DRE-treated cells,
48 hours after treatment. Fluorescence images were obtained at 400X
magnification.
174

Figure 1: Dandelion Root Extract Induces Apoptosis in Aggressive
Colorectal Cancer Cells: Colon Cancer cells (HT-29 [p53-/-] and HCT116
[p53+/+]) and normal colon mucosal epithelial cells (NCM460) were treated with
increasing doses of DRE and analyzed for anticancer effects. C) Following
treatment, cells were stained with Annexin V and PI and image-based cytometry
was used to assess the induction of apoptosis apoptosis. Experiments were
repeated three independent times and the data was quantified to determine the
percentage of apoptotic and necrotic cells, as measured by annexin V and PI.
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Dandelion Root Extract Can Halt the Growth of Colon Tumors in Xenograft
Models
As alluded to previously, the anticancer efficacy of DRE has been
observed in various cancer cell types, including the reported colorectal cancer
cell types mentioned above. The in-vitro results indicated a need for further
studies into the anticancer efficacy of DRE. Dandelions have been used for
centuries for the treatment of various diseases; and the different parts of the plant
have been used to treat ailments, including dyspepsia, spleen and liver
complaints, hepatitis and anorexia (Schütz et al., 2006; Yarnell & Abascal, 2009).
These reports also outline a lot of the anecdotal evidence surrounding the use of
various parts of the plant. However, there is a distinct lack of reports indicating
toxicities associated with its use. Our in-vitro studies further prove that DRE is
able to distinguish between cancer and non-cancerous cells to cause a decrease
in the viability of cancer cells and induce apoptosis, with no toxicity to noncancerous cells.
To further scientifically evaluate and validate the safety of DRE, the first
step was to assess the toxicity to regular mice in a toxicological study. Balb/c
mice were orally administered DRE, at a dose of 40 mg/kg/day, in their drinking
water and allowed to drink ad libidum, for a period of 75 days; these mice were
observed for signs of toxicity for the duration of the study. To measure toxicity,
mice were weighed twice a week and urine was collected, for protein urinalysis
studies, to determine any damage to the kidneys of the animals on DRE regimen.
Results showed no significant difference between the control, untreated group
and the DRE supplemented water group in terms of weight of the mice in each
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group. No significant difference was observed between the control and DRE-fed
groups, suggesting a lack of toxicity (Figure 2A). These results were further
confirmed by a distinct lack of difference in protein levels in the urine of mice
collected from each group in the last four weeks of the study. The protein
urinalysis was performed using a urine dipstick kit, as well as a Bradford protein
concentration assay. The results indicate that there were trace amounts of
protein in the urine of mice from both groups (Figure 2B).
Following the duration of the study, mice were sacrificed and their organs
were obtained for histopathological analysis, by a certified pathologist at the
University of Guelph. Hematoxylin and eosin staining of the hearts, livers and
kidneys showed no gross morphological differences in tissue slices between the
control and the DRE treated group (Figure 2C). These results indicate a lack of
toxicity associated with DRE, through oral administration in our animal studies
and results from the pathologist further confirmed our results. The results from
the pathologist were accompanied by a statement, indicated that the presence of
any lesions in the tissues are minimal or mild and interpreted as either
background or incidental lesions and the lack of lesion type and frequency was
sufficient to conclude no toxicological effect of DRE to the balb/c mice (Table 1).
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Table 1: Summary of Histological Lesions in Balb/C Mice on DRE regimen
No Treatment
(Plain-filtered water)

Liver:
-Infiltration, leukocyte,
predominantly mononuclear,
minimal
-Focal mineralization, minimal
-Hepatocyte necrosis, minimal
-Focus of cellular alteration,
eosinophilic, minimal
-Hepatocyte vacuolation, lipid
type, minimal
- Hepatocyte vacuolation, lipid
type, mild
Fibrin thrombus

M1 M2 M3 M4 M5

X

M1

M2

M3

M4

X
X

X

X

X

X

X

X
X

X

X

X

X

Heart:
-Infiltration, leukocyte,
predominantly mononuclear,
minimal
Myofiber separation and
vaculation, minimal (suspect
artifact)
Kidney:
- Infiltration, leukocyte,
predominantly mononuclear,
minimal
Tubule vacuolation, minimal
Fibrin or other extracellular
matrix, glomerulus

X

Treatment group
(DRE-Supplemented
water)

X
X

X

X

X
X

X

X

X
X

X

X
X
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Figure 2: Dandelion Root Extract is Well Tolerated in Animal Models: Balb/C
mice were separated into two groups, one group on plain filtered water and the
other, on DRE-supplemented water (40 mg/kg/day) for a period of 75 days. Mice
were assessed for toxicity of DRE. A) Weight of mice in each group for the
duration of the study. B) Urine was obtained from mice every week for the last 4
weeks of the study. Protein urinalysis was carried out using urine dipstick and the
Bradford protein assay. C) Following the period of the study, mice were sacrificed
and their tissues (hearts, kidneys and livers) obtained for histopathological
studies; Hematoxylin and Eosin staining of tissues. Images were obtained on a
brightfield microscope at 63X Objective.
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Following toxicity studies, we wanted to further evaluate the efficacy of
DRE in animal tumor models. For this part of the study, CD-1 nu/nu
immunocompromised mice were subcutaneously injected with HT-29 cells (left
flank) and HCT116 cells (right flank). Following the establishment of colon
tumors, mice were separated into two groups (same as the toxicity study). Mice
were observed for the duration of 75 days, while the weights and tumor volumes
were measured twice a week. The results obtained demonstrate that oral
administration of 40 mg/kg/day of DRE in the drinking water did not have an
effect on the weights of the mice (as observed in the toxicity studies) and was
efficient in suppressing the growth of both p53 WT (HCT116) and p53 mutant
(HT-29) tumors in-vivo (Figure 3A – C). Additionally, H & E staining revealed less
nuclei in the DRE treated group, compared to the control group, however, as
observed in the toxicity studies, there were no gross morphological differences in
the livers, kidneys and hearts of the control and DRE treated groups (Figure 3D).
These results not only indicate that oral administration of DRE is not toxic to
animal models, but is efficacious in halting the growth of colon tumors in
xenograft models.
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Figure 3: Dandelion Root Extract Halts the Growth of Colon Tumor
Xenografts: Following the toxicity studies, immunocompromised CD-1 nu/nu
mice were subcutaneously injected with 2*106 colon cancer cells (HT-29 on the
left flank and HCT116 on the right flank). Following the establishment of tumors,
mice were separated into the same groups, as described in the toxicity studies.
A) Mice were weighed every other day for the duration of the study. B) The tumor
volumes were measured using a standard caliper and the tumor volumes were
calculated according to the formula π/6*length*width. C) Images of mice tumors
week 9 of the study, showing differences in the tumor sizes between the control,
untreated group and the DRE group. D) Following the period of the study, mice
were sacrificed and their tissues (hearts, kidneys and livers), as well as tumors,
were excised for histopathological studies; Hematoxylin and Eosin staining of
tissues. Images were obtained on a brightfield microscope at 63X Objective.
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Dandelion Root Extract Induces Apoptosis in Clinical Samples of PatientDerived Peripheral Blood Mononuclear Cells
The next phase of this study was to determine if DRE could be taken
further, as a potential anticancer agent in a clinical setting. Blood samples were
obtained from newly diagnosed leukemia patients. Table 2 provides details about
patient age, leukemia type at time of diagnosis, along with their response to DRE
treatment in ex-vivo conditions. All of the diagnoses are first occurrence, unless
otherwise stated. Patients were diagnosed in the clinic with: Acute Myeloid
Leukemia (AML), subtyped as M0 - M7 or MDS (myelo- dysplastic syndrome);
Acute Lymphoblastic Leukemia (ALL), sub- typed as Burkitt's (L3); Chronic
Myelogenous Leukemia (CML); or Chronic Myelomonocytic Leukemia (CMML)
and Chronic Lymphocytic Leukemia (CLL). All samples (n = 11) showed an
increase in apoptosis (by Hoechst, Annexin-V and propidium iodide staining in
fluorescence microscopy and image-based cytometry) in a dose and timedependent manner, with > 80% of apoptotic cells at the highest dose of 5.0 mg/ml
DRE at 48 hours (Figure 4A-C). These results were distinctly dissimilar to results
obtained with ncPBMCs, which showed no influence on apoptotic induction by
DRE treatment (Ovadje et al., 2012b). These results demonstrate that DRE is
selectively toxic to cancer cells in in-vitro, in-vivo and ex-vivo models, irrespective
of cancer type, with little to no associated toxicity to non-cancerous cell models.
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Table 2: Patient-Derived Samples of Leukemia, with Response to DRE
Treatment
Patient #

Age

Clinical
Diagnosis

% Apoptosis

CLL

Time of
Exposure to
DRE
48 H

1

42

2

72

AML

48 H

56 ± 7.8

3

78

48 H

97.9 ± 1.1

4

58

ALL

48 H

70 ± 3.9

5

56

AML – M4

48 H

37.7 ± 5.3

6

69

48 H

39.03 ± 5.4

7

52

ALL

48 H

76 ± 10.4

AML

48 H

57.9 ± 3.6

9

48 H

87.2 ± 13.7

10

48 H

66.4 ± 3.2

11

48 H

89.3 ± 4.5

8

44 ± 10.2

**Spaces; Information was withheld.
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N = 11

Figure 4: Dandelion Root Extract Induces Apoptosis in Clinical Samples of
Patient-Derived Peripheral Blood Mononuclear Cells (PBMCs): PBMCs were
isolated from the blood of newly diagnosed patients. Cells were treated with
increasing concentrations of DRE and analyzed for the induction of apoptosis. A)
Representative Hoechst (white), Annexin V (Green) staining of DRE-treated cells,
48 hours after treatment. Fluorescence images were obtained at 400X
magnification. B) Quantification of apoptotic cell death in PBMCs treated DRE (n
= 11). C) Following treatment of PBMCs, cells were stained with PI and analyzed
by image-based cytometry. Representative results are shown here.
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Mechanism of Dandelion Root Extract in Selectively Targeting Cancer Cell:
Dandelion Root Extract Targets the Mitochondria of Colon Cancer Cells
Few scientific studies have attempted to delineate the mechanism of
dandelion extracts, especially in cancer cells. Some studies have suggest that
dandelion flower extracts (DFE) have antioxidant, pro-oxidant and cytotoxic
activity in colon adenocarcinoma cells, Caco-2, while being able to scavenge
reactive oxygen species in mouse macrophage cells, RAW264.7 (Hu & Kitts,
2003; Hu & Kitts, 2005). These effects have been attributed to the presence of
flavonoids within the water and ethylacetate extracts of the flower. However, there
is still a lot to be done regarding the presence of other compounds within these
extracts and how they influence the activities. Previous studies in our lab have
shown that aqueous DRE does not induce its cytotoxicity by inducing double
stranded DNA breaks, by TUNEL labeling, in chronic myelomonocytic leukemia
(CMML) cells, in order to induce apoptosis in these cell types (Ovadje et al.,
2012b). These results have a confirmation in already published work, by other
groups, indicating that DFE was efficient at reducing DNA damage, by decreasing
the breakage of supercoiled DNA strands, even in the presence of oxidative
stress (Hu & Kitts, 2003). These results therefore suggest a lack of genotoxicity
associated with DRE use. However, as with previous studies, we observed a
disruption of the mitochondrial membrane potential following DRE treatment, by
JC-1 staining, in HT-29 cells. On the other hand, the mitochondria of NCM460
cells remained unaffected (Figure 5A). These results were quantified and
confirmed by image-based cytometry, where we observed a decrease in the
intensity of red fluorescence, indicative of a loss of mitochondrial membrane
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potential in HT-29 cells, with no difference between the control and DRE treated
samples in NCM460 (Figure 5B). These data suggest that DRE is able to target
multiple significant vulnerabilities in cancer cells selectively and that such targets
might include the mitochondria. To further investigate the role of the mitochondria
in DRE induced PCD, mitochondria was isolated from HT-29 and NCM460 cells
and the isolated mitochondria was directly treated with 2.5 mg/ml DRE. In the
presence of Amplex Red and HRP, fluorescence readings were obtained every 5
minutes. Results obtained showed that DRE treatment led to a significant
increase in the levels of reactive oxygen species (ROS) produced in HT-29 cells,
compared to the control, untreated mitochondria. In parallel, it can be observed
that treatment of isolated mitochondria from NCM460 cells, with DRE, did not
lead to the same increase in the levels of ROS (Figure 5C), further confirming
that DRE has multiple targets in cancer cells, leading to the selective targeting to
self-destructive processes. These results further suggest that, like DFE, DRE
might also contain both antioxidant and pro-oxidant properties (Hu & Kitts, 2003).
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Figure 5: Dandelion Root Extract Targets the Mitochondria of Colon Cancer
Cells: Following treatment with DRE, HT-29 and NCM460 cells were incubated
with JC-1 dye. Red fluorescence intensity was measured by fluorescence
microscopy (Magnification: 400X) (A) and image based cytometry (B) to detect
the loss of the mitochondrial membrane potential. The mitochondria of HT-29
cells were completely destabilized, while those of the NCM460 cells remained
intact.
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Figure 5: Dandelion Root Extract Targets the Mitochondria of Colon Cancer
Cells: C) Isolated mitochondria from HT-29 and NCM460 were treated directly
with DRE; ROS production was measured using Amplex Red substrate in the
presence of horseradish peroxidase (HRP). Results were compared to the
control, untreated mitochondria, the positive control, Paraquat (PQ) and the
negative control, N-Acetylcysteine (N-Ac). Fluorescence readings were taken in
5-minute intervals for 5 hours at Ex. 560 nm and Em. 590 nm and expressed as
relative fluorescence units (RFU) per μg protein. Analyses of results were
performed using Graphpad Prism and results shown are a representative of 3
independent experiments.
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Dandelion Root Extract Activates Caspase-8 in Human Colorectal Cancer
Cells
Previous studies in our lab have shown that DRE efficiently and rapidly
activates the extrinsic pathway of apoptosis in leukemia and pancreatic cancer
cells, with a dependence on the activation of caspase-8 for the subsequent
induction of apoptosis, as cells with a dominant-negative Fas-Associated Death
Domain (Dn-FADD) were unresponsive to DRE treatment (Ovadje et al., 2012b).
This part of this study was aimed at further investigating the role of the extrinsic
pathway in DRE-induced apoptosis. Using substrates specific fluorescent labeled
inhibitors of caspases (FLICA) for each caspase (DEVD – Caspase-3; IETD –
Caspase-8), the chronological activation of caspases could be monitored in HT29 and NCM460 cells that had been treated with DRE for increasing time points,
ranging from 15 minutes to 48 hours. Our results by image-based cytometry
show that DRE induced a 68% increase in caspase-8 activation in HT-29 cells
treated with 2.5 mg/ml DRE for an hour, with a corresponding 30% increase in
propidium iodide staining. Furthermore, these results were specific to HT-29
cancer cells, as NCM460 normal cells did not respond to DRE treatment in the
same manner (Figure 6A). Our results show that NCM460 cells had no increase
in caspase-8 activation or propidium iodide staining, confirming the selectivity of
DRE to cancer cells. These results also further confirm that DRE acts through the
extrinsic pathway of apoptosis in cancer cells.
To further investigate the role of extrinsic apoptosis in DRE’s mechanism
of action, the localization of activated caspases, following DRE treatment, was
studied. Caspases are crucial for the initiation, propagation and execution of
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apoptosis (Loo et al., 2002), and therefore their activation and localization has
been a focus of much research, with many conflicting reports. Some reports
suggest that before activation, pro-caspases are located in the cytosol, and
following apoptotic stimuli and activation, these caspases remain in the cytosol
(Loo et al., 2002). Some other reports on the other hand have determined that
following activation, caspases localize to the mitochondria, where they interact
with other pro-apoptotic proteins for the progression of apoptosis (Chandra et al.,
2004). A third option also indicates that inactive caspases are kept in the
mitochondria, and following apoptotic stimuli and activation, these caspases are
released out of the mitochondria into the cytoplasm and surround the peri-nuclear
space (Qin et al., 2001). The aim of this part of the study was to confirm the
activation of caspase-8, following DRE treatment and to determine the
localization of caspase-8, before and after apoptotic stimuli and activation.
In order to do this cells that were plated onto coverslips were treated with
DRE for 30, 60, 180 and 360 minutes and assessed for the activation and
localization of caspase-8. These cells were incubated with MitoTracker dye for 45
minutes, prior to immunocytochemical analysis, described in the materials and
methods. The results show that there was a progressive destabilization of the
mitochondrial membrane following treatment of DRE, as early as 30 minutes, but
more importantly, it was observed that pro-caspase-8 (green) localized with the
mitochondrial dye (red) in the control untreated samples and following activation
after DRE treatment, the now active caspase-8 was released out of the
mitochondria as indicated by the dispersed green dye associated with caspase-8
(Figure 6B). These results indicate that, not only is DRE able to efficiently
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activate the extrinsic pathway of apoptosis, by the rapid activation of caspase-8, it
is also leads to the destabilization of the mitochondrial membrane in treated
samples.
In our previous studies, we show that the activation of caspases was
essential to the induction of apoptosis by DRE. To confirm this dependence of
caspase activation, cells were pre-incubated with either a pan-caspase inhibitor,
Z-VAD-fmk or a caspase-8 specific inhibitor, IETD-fmk for an hour, before DRE
treatment. Following treatment, cells were analyzed by WST-1 viability assay.
Results show that in the presence of caspase inhibitors, Z-VAD-fmk (results not
shown) and IETD-fmk, there was still a corresponding decrease in the viability of
HT-29 cells, in response to an increase in dose and time of exposure to DRE
treatment. These results were comparable to the same studies carried out in the
absence of caspase inhibitors (Figure 6C), suggesting that in HT-29 colorectal
cancer cells, DRE’s mechanism of action is caspase independent.
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Figure 6: Dandelion Root Extract Triggers the Activation of Caspase-8: A)
Following DRE treatment, HT-29 and NCM460 cells were incubate with FLICA
substrates specific to caspase-8 and incubated for an hour and counterstained
with propidium iodide. Fluorescence intensity was measured with image-based
cytometry.
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Figure 6: Dandelion Root Extract Triggers the Activation of Caspase-8: B)
To determine the localization of caspase-8 following activation, treated cells were
incubated with MitoTracker (Red), fixed and then incubated with the anticaspase-8 antibody, followed by a secondary antibody conjugated to AlexaFluor
488 (Green). Cells were also counterstained with Hoechst 33342 (blue) to detect
the nuclear morphology. Images were obtained at 63X objective. White arrows
indicate the dispersion of MitoTracker Red, indicative of a loss of mitochondrial
membrane potential and the magenta arrows show the presence of active
caspase-8 in the nucleus following DRE treatment. Scale bars = 20 m. C). Prior
to DRE treatment, HT-29 cells were pre-treated with a caspase-8 specific
inhibitor, IETD-fmk, for an hour at indicated concentrations and analyzed for cell
viability, using the WST-1 assay as a measure of absorbance at 450 nm.
Decreased cell metabolic viability (as a % of control) is observed with increasing
concentrations of DRE.
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Dandelion Root Extract Promotes the Expression of Cell Death Genes in
Cancer Cells
Due to the inability of caspase-8 specific inhibitors to prevent the
anticancer activity of DRE in HT-29 colon cancer cells, which was contrary to the
results observed in our previous studies with leukemia and pancreatic cancer
cells, the next step was to further investigate the different aspects of cell death
processes that could be induced/activated, following DRE treatment. Using the
RT2 Profiler Cell Death Pathway Finder PCR system, we were able to profile the
expression of 84 key genes in the central mechanisms for apoptotic, autophagic
and necrotic cell death. In CMML cells, we observed that DRE treatment led to
high expression of several cell death genes, with ≥ 70% of genes being
expressed before cycle 30 in the treatment group, compared to ≥90% of genes
over cycle 30 (Figure 7A). Further analysis of the data showed 22 genes with
over a 10-fold increase in expression, following DRE treatment (Table 3; Figure
7B). Table 3 further lists the gene functions of these highly expressed genes. It is
important to note that treatment of CMML cells with DRE led to increased
expression of ≥ 70% of genes (≥ 59 out of 84 genes) in this cell death pathway
finder. The results reported in this study are for the genes that had over a 5-fold
increase in gene expression, as compared to the control untreated sample. This
increase in gene expression was not confined to one major pathway, however,
we observed increases in expressions of genes involved in apoptosis and
autophagy, indicating that DRE has multiple targets in cancer cells, especially
leukemia cells. This further confirms the connections between the programmed
cell death processes of apoptosis and autophagy.
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Figure 7: Fold Change in Expression of Cell Death Genes in Chronic
Myelomonocytic Leukemia (CMML) Cells – (MV-4-11): The effect of DRE on
cell death gene expression in CMML cells were evaluated using the RT2 profiler
PCR assay. Following treatment of CMML cells with DRE, RNA was isolated,
converted to cDNA and incubated with oligodT primers. PCR microarray analysis
was carried out on an ABI 7900HT. A) Percentage of genes highly expressed or
not detected in the control and DRE treated samples of CMML cells. B) Fold
change in gene expression of cell death genes in CMML cells treated with DRE,
compare to the control untreated cells (Fold expressions in control are set at 1
and treated samples are expressed as fold increases from the control).
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Table 3: Fold Change in Expression of Cell Death Genes in Chronic
Myelomonocytic Leukemia (CMML) Cells – (MV-4-11)
Gene

Fold
Change

APAF 1 (Apoptotic
Protease Activating
Factor 1)

38.54

APP (Amyloid beta
(A4) Precursor
Protein)

26.02

ATG12 (Autophagy
related 12)

12.41

ATG16L1
(Autophagy related
16-like 1)

15.72

ATG5 (Autophagy
related 5)

27.70

ATG7 (Autophagy
related 7)

24.09

BAX (BCL-2
Associated XProtein)

308.06

BCL2L1 (Bcl-2 like
1)

7.00

BCL2L11 (Bcl-2
like 1)

18.57

BECN1 (Beclin 1)

43.44

Gene Function
A central component of the intrinsic pathway of
apoptosis. Forms the apoptosome with
cytochrome c and pro-caspase-9 (Yoshida et al.,
1998; Gu et al., 2014)
Increased expression of APP is involved in
caspase-3
dependent
and
independent
apoptosis (Nishimura et al., 2002)
Plays a distinct role in the early steps of
autophagosome formation during autophagic
degradation, especially mitophagy (Radoshevich
et al., 2010)
Essential for the elongation of isolation
membranes during autophagy; interacts with
ATG12-ATG5 to determine the site of LC3
lipidation (Fujita et al., 2008; Ishibashi et al.,
2011)
Interacts with ATG12 and ATG16L1 for the
formation of the autophagosome in autophagic
degradation (Fujita et al., 2008; Radoshevich et
al., 2010; Ishibashi et al., 2011)
An E1-like enzyme; Activates ATG12 and ATG8;
Essential for the ATG conjugation system and
the formation of the autophagosome (Xue et al.,
2010)
Pro-apoptotic member of the Bcl-2 family;
interacts with the mitochondrial voltagedependent anion channel (VDAC), leading to the
loss of membrane potential. (Pawlowski et al.,
2000)
Also known as Bcl-xL; Considered an antiapoptotic member of Bcl-2 family. Its
phosphorylation (as a result of increase in ROS)
is associated with a decrease in its anti-apoptotic
and anti-autophagic activity (Song et al., 2012;
Kim et al., 2014)
Apoptosis facilitator, also known as Bim;
Activates Bax and Bad (other pro-apoptotic
proteins); Can override apoptotic resistance
caused by overexpression of anti-apoptotic Bcl-2
members (Plötz et al., 2013)
Caspase-mediated cleavage of BECN1 is
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CASP1 (Caspase1)

27.30

CASP2 (Caspase2)

51.48

CASP3 (Caspase3)

41.10

CASP6 (Caspase6)

122.45

CASP9 (Caspase9)

9.45

COMMD4 (COMM
domain containing
4)
FAS (Fatty acid
synthetase
receptor)

133.81
12.34

FASLG (Fatty acid
synthetase ligand)

1

GRB2 (Growth
factor receptorbound protein 2)

192.01

MAPK8 (Mitogen
Activated Protein
Kinase 8)

22.60

MCL1 (Myeloid
Cell Leukemia 1)

44.70

involved in the cross-talk between apoptosis and
autophagy; dysfunction is BECN1 is implicated
in many disorders, including cancer (Kang et al.,
2011).
Cleaves a variety of substrates (121 substrates),
including
pro-inflammatory
cytokine
prointerleukin
(IL)-1
to
induce
apoptosis
(pyroptosis) (Denes et al., 2012)
Can be activated in the absence of extrinsic and
intrinsic apoptotic stimuli, although it is also a
direct downstream target of caspase-8, even
though it is an initiator caspase (Olsson et al.,
2009; Soo-Hyun & Crispin, 2012)
Effector caspase; involved in the cleavage of
Poly-(ADP-ribose) Polymerase (PARP) (Olsson
et al., 2009)
Considered an effector caspase of the extrinsic
pathway, but could also be an activator of
caspase-8 for a positive feedback loop (Cowling
& Downward, 2002; Olsson et al., 2009)
Initiator caspase in the intrinsic pathway of
apoptosis; forms the apoptosome with APAF1
and cytochrome c; activates effector caspases,
such as caspase-3 (Yoshida et al., 1998; Olsson
et al., 2009)
Inhibits NF-B activation (Jin et al., 2012)
The extrinsic pathway of apoptosis requires the
binding of death ligands, e.g. Fas ligand, to its
specific death receptor, triggering downstream
effects, which include the activation of initiator
caspase (e.g. caspase-8) and the subsequent
activation of effector caspases (Elmore, 2007)
Has a dual role in receptor kinase signaling. Can
actively inhibit the phosphorylation of receptor
tyrosine kinases involved in cell proliferation
(Belov & Mohammadi, 2013)
Also known as BCL2-associated agonist of cell
death; involved in a variety of cell processes,
including cell proliferation and apoptosis,
especially in intrinsic apoptosis (Show et al.,
2008; Bjørkøy et al., 2009)
Alternative splicing results in multiple variants; a
longer variant which is anti-apoptotic and a
shorter variant, which promotes apoptosis
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SQSTM1 (p62)
(Sequestosome 1)

345.39

RefSeq, Oct 2010
Autophagy receptor; shown to activate caspase8
mediated
apoptosis;
interacts
with
ubiquitinated proteins/organelles and facilitates
that translocation to the lysosome for autophagic
degradation (Zhang et al., 2013)
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To further determine the differences in how colorectal cancer cells respond
to DRE, and to further investigate the selectivity of DRE to cancer cells, the gene
expression study was carried out in HT-29 and NCM460 cells. Table 4 outlines
the results obtained from this part of the study, emphasizing the differential
expression of genes between HT-29 colon cancer cells and NCM460 normal
colon epithelial cells. It was observed that treatment with DRE had opposite
effects in cancer and non-cancerous cells, when it came to how they express cell
death genes, as cell death genes overexpressed in HT-29 cells, following
treatment, with down-regulated in NCM460 cells, under the same conditions and
vice versa (Figure 8). These results further show that DRE is able to distinguish
between cancer and non-cancer cells (colon) in order to induce selective
cytotoxicity to cancer cells, without associated toxicity to the non-cancer cells.
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Table 4: Differential Fold Change in Expression of Cell Death Genes in
Human Colorectal Cancer (HT-29) Versus Normal Colon Mucosal Epithelia
Cells (NCM460)
Gene

Fold
Change
(HT-29)
Bcl-2 (B-Cell -2.2 ± 0.23
Lymphoma
2)

Fold
Change
(NCM460)
+3.2 ± 0.44

Bcl-2A1 (Bcl- -1.5 ± 0.21
2
related
protein A1)

+15.5 ± 1.1

CD40LG

-1.4 ± 0.11

+11.2 ± 0.7

GALNT5
(polypeptide
Nacetylgalacto
saminyltransf
erase 5)

-1.8 ± 0.23

+8.5 ± 0.75

-1.2 ± 0.15

+2.2 ± 0.25

SYCP2
-1.3 ± 0.16
(Synaptonem
al Complex
2)

+2.0 ± 0.22

PARP2 (poly
(ADP-ribose)
polymerase 2

Gene Function
An integral outer mitochondrial
membrane protein that blocks the
apoptotic death by interacting and
inhibiting pro-apoptotic proteins, e.g.
BAX, APAF1 (Tsujimoto & Croce,
1986)
BCL2A1 is a target of NF-kB
activation,
in
response
to
inflammatory signals. This gene
exerts pro-survival functions and is
generally overexpressed in several
cancers (Vogler, 2012)
An integral membrane protein and a
member of the TNF superfamily,
overexpressed
in
several
carcinomas. Enhances cytokine
production and promotion of cell
proliferation (Banchereau et al.,
1994)
A
member
of
the
TNF
superfamily. They are responsible
for
the
altered
O-linked
glycosylation occurring during the
development of various cancers and
their progression via altering Oglycan biosynthesis (He et al., 2014)
Induced by double stranded DNA
breaks, as a cellular response to
DNA damage. It is involved in DNA
repair and transcriptional regulation.
PARP inhibitors are an emerging
field in cancer therapy (Liang et al.,
2013; Yelamos et al., 2014)
A major component of synaptic
complexes
during
meiosis
(prophase). May be involved in the
organization of chromatin by
temporarily binding to DNA scaffold
attachment regions (Schalk et al.,
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TMEM57
-1.4 ± 0.25
(Transmembr
ane Protein
57)

+1.6 ± 0.25

ULK1 (Unc- -1.3 ± 0.16
51
Like
Autophagy
Activating
Kinase
1)/
ATG1

+3.1 ± 0.2

BMF (Bcl-2 +1.4 ± 0.23
modifying
factor)

+7.2 ± 0.55

DEFB1
(Defensin,
Beta 1)

-40 ± 7.54

+1.3 ± 0.09

GAA
(Acid +1.2 ± 0.22
alpha
glucosidase)

+9.9 ± 0.34

HSPBAP1
+1.1 ± 0.11
(Heat shock
protein
27kDa
associated
protein 1)
IFNG
+3.3 ± 0.25
(Interferon
Gamma)

+2.5 ± 0.3

NFKB1
(Nuclear

-2.3 ± 0.3

+1.1 ± 0.11

+1.5 ± 0.5

1999)
A target of Jun Kinase signaling.
Has been shown to interact with
several proteins, including the
transcription regulators HTT and
SMAD9). Its function is still being
studied
A serine/threonine protein kinase
involved in autophagy in response
to starvation by phosphorylating
Beclin-1. Transcriptional activation
of ULK1 is involved in cancer cell
survival (Pike et al., 2013; Russell et
al., 2013)
A Bcl-2 family membrane that might
activate apoptosis and anoikis.
Interacts with other members of the
Bcl-2 family for apoptosis induction
(Grespi et al., 2010; Hausmann et
al., 2011)
Found to be down-regulated in
several cancer types and plays a
significant role in innate and
adaptive immune response to
promote cytotoxicity (Donald et al.,
2003)
Active in the lysosomes for the
breakdown
of
glycogen
into
glucose. Plays a role in autophagic
induction by encouraging the
degradation of p62 conjugated
cargo (Nascimbeni et al., 2012)
May play a role in cellular stress
response. Knockdown of this gene
is associated with an increase in
caspase-3/7 activation (Smirnov et
al., 2012)
Coordinate various cell response
programs, including macrophage
activation,
inhibition
of
cell
proliferation and activation of
apoptosis (Schroder et al., 2004)
Has both pro- and anti-apoptotic
activities; a major transcription
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factor kappa
B)
TNFRSF1A
(Tumor
Necrosis
Factor
Receptor
Superfamily,
Member 1A)
CASP1
(Caspase-1)

+1.5 ± 0.15

-2.2 ± 0.3

+12.3 ± 2.1

-2.5 ± 0.25

SNCA (Alpha +3.0 ± 0.14
synuclein)

-4.8 ± 0.45

TNF

-7.5 ± 0.55

+8.3 ± 0.32

factor in various cell signaling
pathways (Kaltschmidt et al., 2000;
Stark et al., 2007)
Member of the TNF superfamily.
Recruits adapter domains such as
FADD and TRADD for activation of
extrinsic apoptosis (Schall et al.,
2014)
Cleaves a variety of substrates (121
substrates),
including
proinflammatory
cytokine
prointerleukin
(IL)-1
to
induce
apoptosis (pyroptosis) (Denes et al.,
2014)
A biomarker of colorectal cancer,
and overexpressed in various other
cancers; might be involved in cell
death activation in certain cell types
(Devine et al., 2011; Bethge et al.,
2014)
A cytokine that binds to its receptors
(TNFR1, TNFRSF1A) and promotes
extrinsic apoptosis under ideal
conditions (Hassan et al., 2014)
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Figure 8: Differential Fold Change in Expression of Cell Death Genes in
Human Colorectal Cancer (HT-29) Versus Normal Colon Mucosal Epithelial
Cells (NCM460): The differential effect on gene expression in colon cancer and
normal colon epithelial cells was evaluated using the RT2 profiler array. Following
48-hour treatment with DRE, RNA was isolated from HT-29 and NCM46 cells,
converted into cDNA and incubated with oligodT primers. Following PCR
analysis, data was analyzed, using Qiagen PCR data analysis software. A) Cell
death genes down-regulated in HT-29 cells and up-regulated in NCM460 cells,
following treatment. B) Cell death genes, with no significant change in fold
expression in HT-29 cells, with a corresponding increase or decrease in fold
expression in NCM460 cells. C) Cell death genes overexpressed in HT-29 cells,
but down regulated or unchanged in fold expression in NCM460 cells.
**** P<0.0001
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Fractionation and Phytochemical Analysis of Dandelion Root Extract:
Identification of Bioactive Fractions & Components within Dandelion Root
Extract
To commence the phytochemical analysis, dandelion root was extracted
twice in anhydrous ethanol and rotor evaporated to obtain the extracted material
and analysis was carried out according to the flowchart (Figure 9A). Some of this
material was kept aside for bioactivity testing, while the rest of the extracted
material was fractionated in a glass column packed with silica gel. The primary
fractions (210) obtained were pooled together by thin-layer chromatography,
based on similarities in their profiles to obtain 26 fractions. These fractions were
then tested for bioactivity, by WST-1 cell viability assay. The results from the
fraction studies were compared to those obtained from the bioactivity testing of
the ethanolic extract of dandelion root. Bioactivity testing identified 6 out of 26
fractions with significant activity, comparable to the whole ethanolic extract
(Figure 9B – shows results from two of the bioactive fractions and results from a
fraction with barely adequate bioactivity).
Following the identification of bioactive fractions, these active fractions were
further fractionated to obtain secondary fractions (25) by a preparative HPLC
column. Further bioactivity testing narrowed down the number of bioactive
fractions. The identified bioactive fractions were analyzed by HPLC-MS, using a
standard mix, to identify the different compounds within the fractions (Figure 9CD). This led to the identification of three major components within two of the
bioactive fractions (Fraction #5 and #6); -amyrin, -amyrin and lupeol (Figure
10A). These data confirms the presence of multiple pharmacologically active
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components within DRE. Assessment with WST-1 indicate that further analysis is
essential to determine if any of the identified components could potentiate the
anti-cancer activity of DRE observed with the whole complex mixture in cancer
cells.
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Figure 9: Identification of Bioactive Fractions & Components within
Dandelion Root Extract: A) Flowchart of the steps outlining the fractionation and
phytochemical analysis of DRE. Following ethanolic extraction of DRE,
fractionation, followed by chromatographic analyses, were carried out to identify
bioactive compounds within DRE. B) Effect of crude ethanolic extracts and
secondary fractions on the metabolic viability of HT-29 colon cancer cells. 5
active fractions were further analyzed to identify the components within. C)
UPLC-DAD-MS chromatogram of bioactive fraction #5 and #6, along with a
standard mix of known compounds.
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Anticancer Activity of Identified Bioactive Compounds within Dandelion
Root Extract
To test the hypothesis that DRE contains multiple bioactive compounds
that could potentiate its cytotoxicity, and following the identification of 3
compounds, within 2 of the bioactive fractions, the next phase of this study was to
determine if any of these compounds had significant cytotoxicity to cancer cells,
comparable to DRE as a whole. Each compound was tested alone in HT-29 cells,
at increasing concentrations and for increasing time points, and the viability of
these cells, as a function of their metabolism was measured, using the WST-1
viability assay. We observed a decrease in the viability of cells treated with amyrin, with 10 M as the most effective concentration. At the concentrations
used (≤ 10 μM), β-amyrin and lupeol did not show significant viability reducing
properties (Figure 10B). To further test our hypothesis that the components within
DRE are able to act in synergy to provide better efficacy at lower doses, we
tested these components, in combination studies (α-amyrin + β-amyrin; α-amyrin
+ lupeol; β-amyrin + lupeol). Results show that α-amyrin and β-amyrin, when
used in combination, showed a combined additive effect on the ability to affect
the metabolic activity of HT-29 cells, than when used individually (Figure 10C).
These results strongly suggest that the multiple bioactive components within DRE
could act in synergy to show better anticancer efficacy, especially in highly
aggressive cancer cell types
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Figure 10: Anticancer Activity of Identified Bioactive Compounds within
Dandelion Root Extract: A) Identified compounds (by ChemDraw) in bioactive
fractions #5 and #6. These triterpenes are isomers (MW = 427 g/mol). B)
Following treatment, HT-29 cells were analyzed for the ability of αamyrin,βamyrin and lupeol to reduce the viability of these cells, measured by a
decrease in metabolic activity. Following treatment, the WST-1 reagent was
added to each well, the absorbance readings were taken at 450 nm, and
expressed at a percentage of the control. C) Compounds were analyzed alone
and in combination with each other to assess combined effect in cancer cells. αamyrin and β-amyrin showed an additive effect at slightly lower doses than the
effective concentrations.
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Effect of Dandelion Root Extract on the Expression of cFLIP
Although lupeol did not show any significant effect on the viability of HT-29
cells (and BxPC-3 cells [data not shown]), there have been studies that indicate
that lupeol plays a role in TRAIL-mediated apoptosis (Murtaza et al., 2009). This
study showed that lupeol, at 40 M, suppressed the expression of cellular FLICElike inhibitory protein (cFLIP), an inhibitor of the extrinsic pathway of apoptosis,
which prevents the formation of the death inducing signaling complex (DISC) and
the subsequent activation of caspase-8 (Safa, 2012). To further confirm the role
of extrinsic pathway in DRE mediated apoptosis, we compared the effect of DRE
to that of lupeol, in terms of their abilities to suppress the expression of cFLIP.
Western blotting analysis showed that DRE, at 2.5 mg/ml, was sufficient to inhibit
the expression of cFLIP in cancer cells. There was a slight additive effect when
DRE was combined with the lower dose of lupeol, at 10 M, again confirming the
beneficial effect of multiple components within DRE, compared to the use of
individual components. These results further confirm the activity of DRE through
the extrinsic pathway of apoptosis.
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Figure 11: Effect of Dandelion Root Extract on the Expression of cFLIP:
Comparing the effect of DRE and lupeol on the expression of cFLIP. Following
treatment, cell lysates were obtained and proteins were separated on a gel. The
proteins were transferred onto a PVDF membrane and probed for cFLIP levels,
using β-actin as a loading control. A) Imaged blot of cFLIP expression levels. B)
Densitometry analysis of expression levels, compared to β-actin loading control.
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DISCUSSION
Over 38% of Canadians diagnosed with colorectal cancer will succumb to
death from it. This is the third leading cause of cancer related deaths, only
surpassed by lung and prostate cancers (Sigstedt et al., 2008). The lack of safer,
non-toxic modes of therapy reveals a need for better alternatives. The use of
dandelion extracts has been documented, as anecdotal evidence, for centuries. It
has been used in traditional medicine in various cases of diseases, especially as
a detoxifying agent in digestive disorders (Sigstedt et al., 2008), implying that it
does not have significant toxic effects associated with its use. The results
presented in this study, along with our previous published work, back the
conclusion that an aqueous extract of dandelion root, still under the umbrella of a
natural health product (NHP), can provide a safer, more efficacious mode of
treatment, to current chemotherapy. In this study, we show that DRE can
selectively and effectively reduce the viability of aggressive colon cancer cells,
irrespective of p53 status. Furthermore, treatment of these cells with DRE
triggered the process of apoptosis in colon cancer cells, without having a similar
effect on the viability and survival of non-cancerous colon mucosal epithelial cells
(Figure 1), confirming the lack of reports of toxicity. Further confirmation of the
lack of toxicity associated with DRE use was done in animal models of toxicity
and efficacy.
In this study, we show that there is no toxicity associated with the use of
DRE, as animals on oral administration of DRE for over a 3-month period,
showed no decrease/significant change in their body weights, no kidney damage,
as measured by protein urinalysis and no gross morphological changes in tissue
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appearance (Figure 2). This lack of toxicity permitted further investigation into the
anticancer potential of DRE in animal xenograft models of colon tumors.
Following the establishment of tumors, mice were provided with DRE in their
drinking water, at a final concentration of approximately 40 mg/kg/day, and
allowed to drink ad libidum, for the duration of the study. We found that mice in
the treatment group had much slower tumor growth than those in the control,
untreated group (Figure 3). More importantly, we show the efficacy of DRE in exvivo samples of leukemia, from newly diagnosed patients.
We report novel findings that DRE selectively triggers apoptosis in clinical
samples in a dose and time dependent manner, based on nuclear morphology
and reorganization of the cell membrane to expose phosphatidylserine (Figure 4),
with no effect on non-cancerous peripheral blood mononuclear cells, from healthy
volunteers (Ovadje et al., 2012b). Interestingly, the differences in the clinical
diagnosis of each leukemia type did not have a deterrent effect on the activity of
DRE. Further investigations into the different sub-populations of the different
leukemia blood samples is needed. These results therefore provide sufficient
evidence for the anticancer potential of DRE and therefore a need for further
studies in the understanding of this extract, and its benefits as a potential
anticancer agent.
Our previous work aimed at understanding the mechanism of action of
DRE in cancer cells, to better understand how this extract is able to distinguish
between a cancer cell and a non-cancer cell, in order to selectively trigger
programmed cell death programs. This study was designed to delve further into
the mechanism of action of DRE, as well as identify the components responsible
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for its anti-cancer activity. As with our previous works, we observed that DRE is
able to target the vulnerable mitochondria in cancer cells, which may be due to
reduced oxidative phosphorylation and reduced flux through the electron
transport chain (Ralph & Neuzil, 2009). Treatment with DRE led to a decrease in
the mitochondrial membrane potential (Figure 5A) and an increase in ROS levels,
from isolated mitochondria (Figure 5B). These results further confirm our
hypothesis that DRE is able to target the vulnerable aspects of cancer cells, like
the mitochondria, in order to induce the selective cytotoxicity we have observed.
In this study, we further established the rapid activation of the extrinsic
pathway of apoptosis selectively in colon cancer cells, following DRE treatment
(Figure 6A). To further understand the mechanism of extrinsic apoptosis,
following the activation of caspase-8 and look at the effect of DRE on the
mitochondria, HT-29 cells were incubated with MitoTracker dye, as well as
stained with an anti-caspase-8 antibody for immunocytochemical analysis. The
results confirm the activation of caspase-8 by fluorescence microscopy, while
showing the destabilization of the mitochondrial membrane, indicated by the
dispersion of the red cationic dye that will normally aggregate around the
mitochondrial membrane in healthy mitochondria. More importantly, due to the
controversy surrounding the localization of caspases, both the inactive zymogens
and the active forms, this staining was used to determine the localization of
caspase-8 before apoptotic stimuli and following activation. In the control
untreated cells, it was observed that pro-caspase-8 localized in the membrane of
the mitochondria, where the green fluorescence co-localized with the MitoTracker
red in the healthy mitochondria. Following treatment and activation of caspase-8,
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it was observed that the now active caspase-8 was released from mitochondrial
membrane space into the rest of the cells, as was observed with the colocalization of the nuclear stain with the caspase-8 staining under fluorescence.
This result suggests that pro-caspase-8, and possibly other caspases, reside in
the mitochondria and upon activation, translocate to other locations in the cells,
where they lead to the progression of apoptosis. These results correspond to the
results published by Qin and colleagues, where they showed the localization of
caspases to the mitochondria before activation and their release from the
mitochondria, following activation (Qin et al., 2001).
However, unlike our previous study, where we show that the activation of
caspases was essential to DRE’s mechanism in leukemia cells (Ovadje et al.,
2012b), our colon data suggests otherwise. In this study, we find that the
inhibition of caspase activation through a broad caspase inhibitor, Z-VAD-fmk
(data not shown) and a caspase-8 specific inhibitor, IETD-fmk did not discourage
the viability reducing ability of DRE in these cells (Figure 6C). This differential
requirement of caspase-8 activation in the mechanism of DRE’s activity follows in
line with our hypothesis that DRE can target multiple pathways in a cancer cell.
To further assess the effect of DRE in cancer cells, we studied the gene
profiles, using a pathway finder RT2 Profiler assay, it was observed that DRE
treatment in both CMML and HT-29 cells, induced the expression of several cell
death genes, involved in both the apoptotic and autophagic cell death pathways
(Figure 7 and 8). More importantly, there was clear differential gene expression
observed in normal NCM460 cells, as genes that were up-regulated in cancer
cells, were down-regulated or not expressed in normal cells and vice versa. It is
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also observed that the gene expression in the leukemia and the colon cancer cell,
following DRE treatment, overlapped slightly. However, these results reveal that
DRE is able to target multiple cell death inducing pathways in several cancer
cells, while having the opposite effects in non-cancer cell models. There was no
major difference between the control, untreated gene expression and the DRE
treated gene expression in NCM460 cells, further confirming that DRE is able to
selectively target cancer cells, activate multiple pathways and induce cytotoxicity
in cancer cells alone.
To further study our hypothesis of the complexity of DRE and the multiple
components that could target the multiple vulnerable aspects of cancer cells, we
carried out fractionation and phytochemical analysis of an ethanolic extract of
dandelion root, in order to identify the bioactive components within DRE.
Following primary and secondary fractionation, we identified three of the bioactive
compounds, found in two out of the six fractions, with significant bioactivity,
comparable to that of the ethanolic DRE (Figure 9B). These compounds include
α-amyrin, β-amyrin and lupeol (Figure 9C, 10A). At high doses, ≥ 10 μM, αamyrin efficiently reduced the viability of colon cancer cells; however, β-amyrin
and lupeol did not show similar bioactivity at these doses (Figure 10B). Continued
studies using the identified compounds, in combination with each other, showed
an additive effect of α- and β-amyrin, when used in combination, than individually
(Figure 10C). Such an effect was not observed in the combinations with lupeol,
therefore indicating that the multiple components, within this complex extract of
dandelion root, can act together, in synergy or in addition, to trigger the
cytotoxicity that we observe in cancer cells, following treatment.
220

A previous study with lupeol shows that this compound, albeit at high
doses of 40 μM, was able to sensitize pancreatic cancer cells to TRAIL induced
apoptosis, by inhibiting the expression of cFLIP (Murtaza et al., 2009), which is
an inhibitor of the extrinsic pathway of apoptosis. Studying DRE further, we found
that DRE, as a whole complex mixture, has a better effect on reducing the
expression of cFLIP in both HT-29 (Figure 11), and BxPc-3 pancreatic cancer
cells (data not shown). This was a dose and time dependent response, as by 48
hours following treatment, there was a significant reduction in the expression of
cFLIP, in the treated cells, compared to the control, untreated cells. These results
further confirm that DRE does activate the extrinsic pathway of apoptosis and
that, even though its mechanism of action is cell type specific, the complex
mixture of this extract efficiently and selectively imparts its cytotoxicity to various
cancer cell types, in a dose and time dependent response.

CONCLUSIONS
Our results show that a complex mixture of aqueous dandelion root extract (DRE)
is capable of efficiently and selectively triggering multiple programmed cell death
pathways in a variety of cancer cells. These results further confirm our hypothesis
that DRE contains multiple bioactive components, not limited to -amyrin, amyrin and lupeol that could target the multiple vulnerable aspects of cancer
cells, such as the vulnerability of cancer cell mitochondria. Overall, these findings
indicate that a complex mixture of an NHP, such as dandelion root extract, could
provide an alternative to currently available chemotherapy, to improve the quality
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of life of cancer patients and possibly provide a more efficacious mode of
treatment while doing so.
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ABSTRACT
Currently chemotherapy is limited mostly to genotoxic drugs that are
associated with severe side effects due to non-selective targeting of normal
tissue. Natural products play a significant role in the development of most
chemotherapeutic agents, with 74.8% of all available chemotherapy being
derived from natural products. To scientifically assess and validate the anticancer
potential of an ethanolic extract of Long pepper (PLX), a plant of the piperaceae
family that has been used in traditional medicine, especially Ayurveda and
investigate the anticancer mechanism of action of PLX against cancer cells.
Following treatment with ethanolic long pepper extract, cell viability was
assessed using a water-soluble tetrazolium salt; apoptosis induction was
observed following nuclear staining by Hoechst, binding of annexin V to the
externalized phosphatidyl serine and phase contrast microscopy. Image-based
cytometry was used to detect the effect of long pepper extract on the production
of reactive oxygen species and the dissipation of the mitochondrial membrane
potential

following

Tetramethylrhodamine

or

5,5’,6,6'-tetrachloro-1,1',3,3'-

tetraethylbenzimidazolylcarbocyanine chloride staining (JC-1). Assessment of
PLX in-vivo was carried out using Balb/C mice (toxicity) and CD-1 nu/nu
immunocompromised mice (efficacy). HPLC analysis enabled detection of some
primary compounds present within our long pepper extract.
Our results indicated that an ethanolic long pepper extract selectively
induces caspase-independent apoptosis in cancer cells, without affecting noncancerous cells, by targeting the mitochondria, leading to dissipation of the
mitochondrial membrane potential and increase in ROS production. Release of
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the AIF and endonuclease G from isolated mitochondria confirms the
mitochondria as a potential target of long pepper. The efficacy of PLX in in-vivo
studies indicates that oral administration is able to halt the growth of colon cancer
tumors in immunocompromised mice, with no associated toxicity. These results
demonstrate the potentially safe and non-toxic alternative that is long pepper
extract for cancer therapy.
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INTRODUCTION
The continuing increase in the incidence of cancer signifies a need for
further research into more effective and less toxic alternatives to current
treatments. In Canada alone, it was estimated that 267,700 new cases of cancer
will arise, with 76,020 deaths occurring in 2012 alone. The global statistics are
even more dire, with 12.7 million cancer cases and 7.6 million cancer deaths
arising in 2008 (Jemal et al., 2011; Canadian Cancer Statistics, 2012). The
hallmarks of cancer cells uncover the difficulty in targeting cancer cells
selectively. Cancer cells are notorious for sustaining proliferative signaling,
evading growth suppression, activating invasion and metastasis and resisting cell
death among other characteristics (Hanahan & Weinberg, 2011). These
characteristics pose various challenges in the development of successful
anticancer therapies. The ability of cancer cells to evade cell death events has
been the center of attention of much research, with focus centered on targeting
the various vulnerable aspects of cancer cells to induce different forms of
Programmed Cell Death (PCD) in cancer cells, with no associated toxicities to
non-cancerous cells.
Apoptosis (PCD type I) has been studied for decades, the understanding
of which will enhance the possible development of more effective cancer
therapies. This is a form of cell death that is required for regular cell development
and homeostasis, as well as a defense mechanism to get rid of damaged cells;
cells undergoing apoptosis invest energy in their own demise so as not to
become a nuisance (Canadian Cancer Statistics, 2012). Cancer cells evade
apoptosis in order to confer added growth advantage and sustenance, therefore
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current anticancer therapies endeavour to exploit the various vulnerabilities of
cancer cells in order to trigger the activation of apoptosis through either the
extrinsic or intrinsic pathways (Fadeel & Orrenius, 2005; Elmore, 2007). The
challenges facing some of the available cancer therapies are their abilities to
induce apoptosis in cancer cells by inducing genomic DNA damage. Although
this is initially effective, as they target rapidly dividing cells (Fulda & Debatin,
2006), they are usually accompanied by severe side effects caused by the nonselective targeting of normal non-cancerous cells, suggesting a need for other
non-common targets for apoptosis induction without the associated toxicities.
Natural health products (NHPs) have shown great promise in the field of
cancer research. The past 70 years have introduced various natural products as
the source of many drugs in cancer therapy. Approximately 75% of the approved
anticancer therapies have been derived from natural products, an expected
statistic considering that more than 80% of the developing world’s population is
dependent on the natural products for therapy (Davidson et al., 2013). Plant
products especially contain many bioactive chemicals that are able to play
specific roles in the treatment of various diseases. Considering the complex
mixtures and pharmacological properties of many natural products, it becomes
difficult to establish a specific target and mechanism of action of many NHPs.
With NHPs gaining momentum, especially in the field of cancer research, there
are numerous new studies on the mechanistic efficacy and safety of NHPs as
potential anticancer agents (Newman & Cragg, 2012).
Long pepper, from the Piperaceae family, has been used for centuries for
the treatment of various diseases. Several species of long pepper have been
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identified, including Piper longum, Piper betle, Piper retrofactum, extracts of
which have been used for years in the treatment of various diseases. A long list
of uses and benefits are associated with extracts of different Piper spp, with
reports indicating their effectiveness as good digestive agents and pain and
inflammatory suppressants (Bao et al., 2013). However, there is little to no
scientific validation, only anecdotal evidence, for the benefits associated with the
use of long pepper extracts. There are scientific studies have been carried out on
several compounds present in extracts of long pepper, including piperines, which
has been shown to inhibit many enzymatic drug bio-transforming reactions and
play specific roles in metabolic activation of carcinogens and mitochondrial
energy production (Raj et al., 2012; Golovine et al., 2013; Jarvius et al., 2013;
Megwal & Goswami, 2013) and various piperidine alkaloids, with fungicidal
activity (Lee et al., 2001; Bao et al., 2013). Some of these compounds have
shown potent anticancer activity (Bezerra et al., 2007), suggesting that Long
pepper extracts could represent a new NHP, with better selective efficacy against
cancer cells.
In this study, we examine the efficacy of an ethanolic extract of Long
Pepper (PLX) against various cancer cells, as well as attempt to elucidate the
mechanism of action, following treatment. Results from this study demonstrate
that PLX reduced the viability of various cancer cell types in a dose and time
dependent manner, where apoptosis induction was observed following
mitochondrial targeting. Due to the low doses of PLX required to induce
apoptosis in cancer cell, it was easy to find the therapeutic window of this extract.
The induction of apoptosis was found to be caspase-independent, although there
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was activation of both the extrinsic and intrinsic pathways and the production of
ROS was not essential to the mechanism of cell death induction by PLX. The
ability of PLX to target multiple vulnerabilities of cancer cells and still act to
induce apoptosis in the presence of different types of inhibitors suggest the
potential application of PLX in safe and efficacious cancer therapy.
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MATERIALS & METHODS
Cell Culture
A malignant melanoma cell line G-361, human colorectal cancer cell lines
HT-29 and HCT116 (American Type Culture Collection, Manassas, VA, USA Cat.
No.CRL-1687, CCL-218 & CCL-247, respectively) were cultured with McCoy’s
Medium 5a (Gibco BRL, VWR, Mississauga, ON, Canada) supplemented with
10% (v/v) FBS (Thermo Scientific, Waltham, MA, USA) and 40 mg/ml gentamicin
(Gibco, BRL, VWR). The ovarian adenocarcinoma cell line OVCAR-3 (American
Type Culture Collection, Cat. No. HTB-161) was cultured in RPMI-1640 media
(Sigma-Aldrich Canada, Mississauga, ON, Canada) supplemented with 0.01
mg/mL bovine insulin, 20% (v/v) fetal bovine serum (FBS) standard (Thermo
Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin. The pancreatic
adenocarcinoma cell line BxPC-3 (American Type Culture Collection, Cat. No.
CRL-1424) was cultured in RPMI-1640 medium, supplemented with 10% (v/v)
fetal bovine serum (FBS) standard and 40 mg/mL gentamicin. Normal-derived
colon mucosa NCM460 cell line (INCELL Corporation, LLC., San Antonio, TX,
USA) was grown in INCELL’s M3BaseTM medium (INCELL Corporation, LLC.,
Cat. No. M300A500) supplemented with 10 % (v/v) FBS and 10 mg/mL
gentamicin.
All cells were grown in optimal growth conditions of 37°C and 5 % CO2.
Furthermore, all cells were passaged for ≤ 6 months.
Long Pepper Extraction
Indian long pepper seeds were obtained from Quality Natural Foods
limited, Toronto Ontario. The plant material was ground up and extracted in
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anhydrous ethanol (100%) in a ratio of 1:10 (1g plant material to 10 ml ethanol).
The extraction was carried out overnight on a shaker at room temperature. The
extract was passed through a P8 coarse filter, followed by a 0.45 m filter. The
solvent was evaporated using a RotorVap at 40°C and the dried extracted
material was reconstituted in dimethylsulfoxide (Me2SO) at a stock concentration
of 450 mg/ml.
Cell Treatment
Cells were plated and grown to 60-70% confluence, before being treated
with Long Pepper Extracts (PLX), N-Acetyl-L-cysteine (NAC) (Sigma-Aldrich
Canada, Cat. No. A7250), and broad-spectrum caspase inhibitor, Z-VAD-FMK
(EMD Chemicals, Gibbstown, NJ, USA) at the indicated doses and durations.
NAC

was

dissolved

in

sterile

water.

Z-VAD-FMK

was

dissolved

in

dimethylsulfoxide (Me2SO). PLX was extracted as previously described,
reconstituted in Me2SO and cells were treated either crude long pepper extract,
before evaporation or Me2SO reconstituted extract and control cells were treated
with corresponding concentrations of Me2SO.
ASSESSING THE EFFICACY OF LONG PEPPER EXTRACT (PLX) IN
CANCER CELLS:
WST-1 Assay for Cell Viability
To assess the effect of PLX on cancer cells, a water-soluble tetrazolium
salt (WST-1) based colorimetric assay was carried out as per manufacturer’s
protocol (Roche Applied Science, Indianapolis, IN, USA), to quantify cell viability
as a function of cellular metabolism. Equal number of cells were seeded onto 96well clear bottom tissue culture plates then treated with the indicated treatments
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at the indicated concentrations and durations. Following treatment, cells were
incubated with the WST-1 reagent for 4 hours at 37° C with 5 % CO2. The WST1 reagent is cleaved to formazan by cellular enzymes in actively metabolizing
cells. The formazan product was quantified by taking absorbance readings at 450
nm on a Wallac Victor3 TM 1420 Multilabel Counter (PerkinElmer, Woodbridge,
ON, Canada). Cellular viability was expressed as percentages of the solvent
control groups.
Nuclear Staining
Subsequent to treatment, the nuclei of cells were stained with 10 M
Hoechst 33342 dye (Molecular Probes, Eugene, OR, USA) to monitor nuclear
morphology for apoptosis induction at designated time points. Cells were
incubated with 10 μM Hoechst dye for 10 minutes and micrographs were taken
with a Leica DM IRB inverted fluorescence microscope (Wetzlar, Germany) at
400X magnification.
Annexin V Binding Assay
To confirm the induction of apoptosis, the binding of Annexin V to
externalized phosphatidylserine on the outer cellular surface, was assessed.
Following treatment with PLX, cells were washed twice in phosphate buffer saline
(PBS). Subsequently, cells were resuspended and incubated in Annexin V
binding buffer (10 mM HEPES, 10 mM NaOH, 140 mM NaCl, 1 mM CaCl2, pH
7.6) with Annexin V AlexaFluor-488 (1:50) (Invitrogen, Canada, Cat No. A13201)
for 15 minutes. Micrographs were taken at 400X magnification on a Leica DM
IRB inverted microscope (Wetzlar, Germany).
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Whole Cell ROS Generation
Following

treatment

with

PLX,

cells

were

incubated

with

2′,7′-

Dichlorofluorescin diacetate H2DCFDA (Catalog No. D6883, Sigma Aldrich,
Mississauga ON. Canada) for 45 minutes. Cells were collected, washed twice in
PBS and green fluorescence was observed using a TALI image-based cytometer
(Invitrogen, Canada). NAC was used to assess the dependence of PLX on ROS
generation and viability.
ASSESSMENT
TREATMENT:

OF

MITOCHONDRIAL

FUNCTION

FOLLOWING

PLX

Tetramethylrhodamine Methyl Ester (TMRM) Staining
To

monitor

mitochondrial

membrane

potential

(MMP),

tetramethylrhodamine methyl ester (TMRM) (Gibco BRL, VWR, Mississauga, ON,
Canada)

or

5,5,6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine

chloride (JC-1) (Invitrogen, Canada) were used. Cells were grown on coverslips,
treated with the indicated concentrations of treatments at the indicated time
points, and incubated with 200 nM TMRM for 45 minutes at 37° C. Micrographs
were obtained at 400X magnification on a Leica DM IRB inverted fluorescence
microscope (Wetzlar, Germany). To confirm the results obtained by fluorescence
microscopy, image-based cytometry was used to detect red fluorescence. Cells
were seeded in 6-well plates and following treatment, cells were incubated with
TMRM for 45 minutes, washed twice in PBS and placed in TALI slides. Red
fluorescence was obtained using a TALI image-based cytometer (Invitrogen,
Canada).
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Mitochondrial Isolation to Assess Mitochondrial Targeting
Cells were collected by trypsin, washed once in cold PBS, resuspended in
cold hypotonic buffer (1 mM EDTA, 5 mM Tris–HCl, 210 mM mannitol, 70 mM
sucrose, 10 μM Leu-pep and Pep-A, 100 μM PMSF), and manually
homogenized. The homogenized cell solution was centrifuged at 3000 rpm for 5
minutes at 4 °C. The supernatant was centrifuged at 12,000 rpm for 15 minutes
at 4 °C and the mitochondrial pellet was resuspended in cold reaction buffer (2.5
mM malate, 10 mM succinate, 10 μM Leu-pep and Pep-A, 100 μM PMSF in
PBS). The isolated mitochondria were treated with PLX at the indicated
concentrations and incubated for 2 hours in cold reaction buffer. The control
group was treated with solvent (ethanol). Following 2 hour incubation with extract,
mitochondrial samples were vortexed and centrifuged at 12,000 rpm for 15
minutes

at

4°C.

The

resulting

supernatant

and

mitochondrial

pellets

(resuspended in cold reaction buffer) were subjected to Western Blot analysis to
assess for the mitochondrial release/retention of pro-apoptotic factors.
Western Blot Analyses
Protein samples were subjected to SDS-PAGE, transferred onto a
nitrocellulose membrane, and blocked with 5% w/v milk TBST (Tris-Buffered
Saline Tween-20) solution for 1 hour. Membranes were incubated overnight at
4°C with an anti-endonuclease G (EndoG) antibody (1:1000) raised in rabbits
(Abcam,

Cat.

No.

ab9647,

Cambridge,

MA,

USA),

an

anti-succinate

dehydrogenase subunit A (SDHA) antibody (1:1000) raised in mice (Santa Cruz
Biotechnology, Inc., sc-59687, Paso Robles, CA, USA), or an anti-apoptosis
inducing factor (AIF) antibody raised in rabbits (1:1000) (Abcam, Cat. No.
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ab1998, Cambridge, MA, USA). After primary antibody incubation, the membrane
was washed once for 15 minutes and twice for 5 minutes in TBST. Membranes
were incubated for 1 hour at room temperature with an anti-mouse or an antirabbit horseradish peroxidase-conjugated secondary antibody (1:2000) (Abcam,
ab6728, ab6802, Cambridge, MA, USA) followed by three 5-minute washes in
TBST. Chemiluminescence reagent (Sigma-Aldrich, CPS160, Mississauga, ON,
Canada) was used to visualize protein bands and densitometry analysis was
performed using ImageJ software.
IN-VIVO ASSESSMENT OF LONG PEPPER EXTRACT:
Toxicity Assessment
Six week old Balb/C mice were obtained from Charles River Laboratories
and housed in constant laboratory conditions of a 12-hour light/dark cycle, in
accordance with the animal protocols outlined in the University of Windsor
Research Ethics Board- AUPP 10-17). Following acclimatization, mice were
divided into three groups (3 animals/control (untreated), 3 animals/gavage control
(vehicle treatment) and 4 animals/treatment group). The control untreated group
was given plain filtered water, while the second and third group was given 50
mg/kg/day vehicle (DMSO) or PLX, by gavage, respectively for 75 days. During
the period of study, toxicity was measured by weighing mice twice a week and
urine was collected for protein urinalysis by urine dipstick and Bradford assays.
Following the duration of study, mice were sacrificed and their organs (livers,
kidneys and hearts) were obtained for immunohistochemical and toxicological
analysis by Dr. Brooke at the University of Guelph.
242

Efficacy of PLX in Tumor Xenograft Models of Immunocompromised Mice
Six week old male CD-1 nu/nu mice were obtained from Charles River
Laboratories and housed in constant laboratory conditions of a 12-hour light/dark
cycle, in accordance with the animal protocols outlined in the University of
Windsor Research Ethics Board- AUPP 10-17). Following acclimatization, the
mice were injected subcutaneously in the right and left hind flanks with a colon
cancer cell suspension (in Phosphate buffered saline) at a concentration of 2 *
106 cells/mouse (HT-29, p53-/-, in the left flank and HCT116, p53+/+, in the right
flank). Tumors were allowed to develop (approximately a week), following which
the animals were randomized into treatment groups of 4 mice per group, a control
group, a gavage control group given plain filtered sterile water, as well as gavage
regimen of the vehicle (5 µL Me2SO in PBS) twice a week. The final group was
given filtered water supplemented with long pepper extract at a concentration of
100 µg/ mL, as well as gavage regimen of long pepper extract (5 µL extract in
PBS), twice a week, corresponding to 50 mg/kg/day. The tumors were assessed
every other day by measuring the length, width and height, using a standard
caliper and the tumor volume was calculated according to the formula
π/6*length*width. The mice were also assessed for any weight loss every other
day for the duration of the study, which lasted 75 days, following which the
animals were sacrificed and their organs and tissues (liver, kidneys, heart and
tumors) were obtained and stored in 10% formaldehyde for immunohistochemical
and toxicological analysis.
Hematoxylin & Eosin (H & E) Staining
Mice organs were fixed in 10% formaldehyde, following which they were
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slides (Fisherbrand, Fisher Scientific). Sections of organs were stained according
to a standardized H & E protocol25.
Analysis of Long Pepper Extract by HPLC
HPLC analysis of the long pepper crude extract was carried out at
University of Ottawa in the Arnason lab. A total of five well-known piperamides
were analyzed and compared to the crude long pepper extract. The extracts and
piperamide standards were analyzed on a Luna C18-5u-250 x 4.6 mm column at
45ºC at a flow rate of 1.0 mL/min with a mobile phase constituted of H2O and
methanol as outlined below;
Time

H20

MeOH

(mins)

(%)

(%)

0.0

37.5

62.5

15.0

35.0

65.0

35.0

0.0

100.0

45.0

0.0

100.0

46.0

37.5

62.5

Chromatogram profiles were used to detect the any differences between a
sample standard of known piperamides in the crude long pepper extracts.
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RESULTS
Ethanolic Extract of Long Pepper (PLX) Effectively and Selectively Reduces
the Viability of & Induces Apoptosis in Cancer cells in a Dose & Time
Dependent Manner
The first step in understanding the effect of long pepper extract in this
study was to assess the effect of PLX on the viability of cancer cells. Following
treatment with increasing concentration of PLX at increasing time points, cells
were incubated with a water soluble tetrazolium salt, which gets metabolized to a
red formazan product by viable cells with active metabolism. This product can
then be quantified by absorbance spectrometry. We observed the efficacy of
crude PLX in reducing the viability of cancer cells, including colon (HCT116),
pancreatic (BxPC-3), ovarian cancer (OVCAR-3) and melanoma cells. This effect
was dose and time dependent (Figure 1).
To further evaluate the anticancer activity of PLX, we wanted to assess its
role in cell death and its selectivity to cancer cells. Our results demonstrate that
PLX is able to selectively induce cell death in cancer cells (colon, pancreatic and
leukemia) in a dose and time dependent manner, as characterized by the
increase in propidium iodide positive cells in cancer cells treated with PLX (Figure
2). Furthermore, this effect was selective, as normal colon epithelial cells
remained unaffected by this treatment, at the same concentrations and timepoints (Figure 2B). Additionally, apoptosis induction in various cancer cells,
melanoma (G-361), ovarian and colon cancer (HT-29) cells, was confirmed by
Annexin-V binding assay. This induction of apoptosis was confirmed to be
selective to cancer cells, as normal colon cells (NCM460) remained unaffected by
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PLX treatment. This was indicated by nuclear condensation, cell morphology and
externalization of phosphatidyl serine to the outer leaflet of the cell membrane, as
indicated by Hoechst staining, phase contrast images and binding of annexin V
dye respectively (Figure 3A and B).
The selectivity of PLX to cancer cells was further confirmed by the WST-1
cell viability assay that showed that PLX was highly effective at low doses, a
therapeutic window was easily observed (Figure 3C). Treatment of HT-29 with
0.20 mg/ml effectively reduced the viability by approximately 90%, while NCM460
cells remained at 100% viability at the same dose. This indicates that PLX can be
more effective at low doses, further reducing the chances of toxicity associated
with treatment.
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Figure 1: Crude Ethanolic Extract of Long Pepper (PLX) Effectively Reduces
the Percentage of Viable Cancer cells in a Dose & Time Dependent Manner:
Colon (HCT116), Ovarian (OVCAR-3), Pancreatic (BxPC-3) cancer and
Melanoma (G-361) cells were treated with a crude ethanolic extract of long
pepper (PLX), following which they were incubated with WST-1 cell viability dye
for 4 hours. Absorbance was read at 450nm and expressed as a percent of the
control. Values are expressed as mean ± SD from quadruplicates of 3
independent experiments. **P<0.0001
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Figure 2: PLX Selectively Induces Cell Death in Human Cancer Cells in a
Dose & Time Dependent Manner: (A) Following treatment of Human pancreatic
(BxPc-3) cancer and T cell leukemia cells with PLX, at indicated time points, cells
were incubated with propidium iodide and assessed for the induction of cell death
by image-based cytometry. (B) Similar experiments were carried out in human
colon cancer cells (HT-29) and normal colon epithelial cells (NCM460).
Fluorescence microscopy was used to assess the induction of cell death as
characterized by presence of propidium iodide positive cells. Images were taken
at 400x magnification on a fluorescent microscope. Scale bar = 15 μm
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Figure 3: PLX Selectively Targets Cancer Cells for Apoptosis Induction:
Subsequent to treatment with PLX, cells (Ovarian; OVCAR-3, Melanoma; G-361
and Normal Colon Epithelia cells (NCM460) were stained with Hoechst to
characterize nuclear morphology and Annexin-V to detect apoptotic cells (A) and
cellular morphology by phase contrast microscopy (B); Images were taken at
400x magnification on a fluorescent microscope. Scale bar = 15 μm. (C)
Following PLX treatment, HT-29 colorectal cancer cells and non-cancerous
NCM460 cells were incubated with WST-1 cell viability dye for 4 hours and
absorbance was read at 450nm and expressed as a percent of the control.
Values are expressed as mean ± SD from quadruplicates of 3 independent
experiments. **P<0.0001.
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PLX Induces Caspase-Independent Apoptosis in Human Cancer Cells
Caspases are cysteine aspartic proteases that play a predominant role as
death proteases (Earnshaw et al., 1999). Their roles in various cell death
processes remains controversial, as their activation or inhibition could be
essential to the progression of inhibition of cell death pathways (Thorburn, 2008;
Zhivotovsky & Orrenius, 2010).
To assess the role of caspases in our study, BxPc-3 cells treated with PLX
at 0.10 mg/ml at indicated time points. Following treatment, cells were collected,
washed and incubated with lysis buffer to obtain cell lysate. The cell lysate was
incubated with caspase substrates, specific to each caspase (3, 8 and 9) and
incubated for an hour. Fluorescence readings were obtained using a
spectrofluorometer. Our results indicate that PLX is able to activate both
pathways (extrinsic and intrinsic apoptosis) in a time dependent manner. This
was observed as rapid activation of caspases-3, 8 and 9 were observed as early
as an hour, following treatment (Figure 4A).
To determine the importance of these activated caspases to the apoptosisinducing effect of PLX, colon (HCT116) and pancreatic (BxPc-3) cancer cells
were pre-treated with a pan-caspase inhibitor, Z-VAD-fmk (20 M), for an hour
before treatment with PLX. Following treatments, the WST-1 cell viability assay
was used to assess for viability and efficacy of PLX. Our results indicate that the
inhibition of caspases could not prevent the reduction of viability (Figure 4B),
signifying that the effect of PLX in cancer cells is caspase independent.
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Figure 4: Long Pepper Extract (PLX) Activates the Extrinsic & Intrinsic
Pathways of Apoptosis: Following treatment with 0.10 mg/ml PLX, at indicated
time points, BxPc-3 cells were collected, washed and incubated with lysis buffer
to obtain cell lysate. The cell lysate was incubated with caspase substrates,
specific to each caspase (3, 8 and 9) and incubated for an hour. Fluorescence
readings were obtained using a spectrofluorometer. An average of 6 readings per
well and a minimum of three wells were run per experiment. The results here are
reported as activity per µg of protein (in fold) and the average of three
independent experiments is shown. (B) The reduction in viability was caspase
independent, as a pan-caspase inhibitor, Z-VAD-fmk could not prevent the loss of
viability induced by PLX treatment in colon and pancreatic cancer cells.
Absorbance was read at 450 nm and expressed as a percent of the control.
Values are expressed as mean ± SD from quadruplicates of 3 independent
experiments. **P<0.0001
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Long Pepper Extract Induces
Mitochondria of Cancer Cells

Oxidative

Stress

and

Targets

the

Generation of oxidative stress has been well established as a major player
in the induction of several cell death processes, especially apoptosis (Simon et
al., 2000; Madesh & Hajnóczky, 2001). The next part of our study focused on the
role of oxidative stress in PLX induced apoptosis. Following treatment with PLX
for 48 hours, cells were incubated with 2′,7′-Dichlorofluorescin diacetate
H2DCFDA for 45 minutes. The resulting green fluorescence histograms were
obtained using a TALI image-based cytometer. From the results, it was observed
that PLX induced extensive generation of whole cell reactive oxygen species
(ROS) in HT-29 colon cancer cells, while acting to suppress any ROS present in
the non-cancerous cell lines, NCM460 and normal human fibroblasts (NHF)
(Figure 6A & B). This confirms our results of selectivity and indicates that PLX
might act as a pro-oxidant in cancer cells in order to induce apoptosis.
To determine if this oxidative stress was essential to PLX activity, HCT116
colon cancer cells were pre-treated with N-acetyl-L-cysteine (NAC), a wellestablished anti-oxidant, used extensively in vitro studies (Dekhuijzen, 2004;
Dodd et al., 2008), before treatment with PLX. Subsequent to PLX treatment,
cells were analyzed for effect of PLX on viability, using the WST-1 viability assay.
The results suggest that although PLX acts to induce oxidative stress to cause
apoptosis, this oxidative stress is not essential to its activity. Both the cells
treated with PLX alone and NAC followed by PLX showed a reduction in their
viability (Figure 6C).
The mitochondria have also been shown to play a major role in the
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progression

and

execution

of

apoptosis.

The

permeabilization

of

the

mitochondrial membrane usually leads to the release of pro-apoptotic factors,
including cytochrome c, apoptosis inducing factor (AIF) and endonuclease G
(EndoG) (Earnshaw, 1999; Elmore, 2007). These factors cause a caspaseindependent pathway for apoptosis to pass through and could bypass the
antioxidant effects of NAC observed in figure 6C.
To assess the efficacy of PLX on the mitochondria of cancer cells,
OVCAR-3, HT-29 and NCM460 cells were stained with TMRM, a cationic dye
that accumulates in healthy mitochondria. Mitochondrial membrane potential
(MMP) dissipation was only observed in OVCAR-3 and HT-29 cells as seen with
the dissipation of red TMRM fluorescence, by fluorescence microscopy and
image-based cytometry (Figure 5A, B & C). Following mitochondrial membrane
collapse, we wanted to determine if there was release of some pro-apoptotic
factors. Western blot analysis was used to monitor for the release of AIF and
EndoG from isolated OVCAR-3 mitochondria. Results demonstrate that PLX
directly caused the release of both AIF and EndoG from the mitochondria of
OVCAR-3 cells (Fig 5D). These results provide an insight to the mechanism of
PLX action, where the mitochondria appears to be a direct target of PLX for the
reduction of viability and the induction of apoptosis
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Figure 5: PLX Destabilizes the Mitochondrial Membrane of Cancer Cells:
Colon cancer (HT-29), Ovarian cancer (OVCAR-3) and Normal Colon Epithelial
(NCM460) cells were treated for 48 hours with PLX, following which, they were
incubated with JC-1 (A) or TMRM (C) cationic mitochondrial membrane
permeable dyes. Fluorescence readings were obtained using image based
cytometry (A) and fluorescence microscopy; corresponding Hoechst dye images
are also shown (C). Images were taken at 400x magnification on a fluorescent
microscope. Scale bar = 15 μm. (D) Isolated mitochondria of OVCAR-3 cells
were treated directly with PLX or solvent control (ethanol) for 2 hours. Following
treatment, samples were centrifuged, to obtain mitochondrial supernatants, which
were examined for the release of pro-apoptotic factors, AIF and EndoG via
western blot analyses, and mitochondrial pellets which were probed for SDHA to
serve as loading controls. Image is representative of 3 independent experiments
demonstrating similar trends. Values are expressed as mean ± SD of
quadruplicates of 1 independent experiment; *p<0.01 versus solvent control
(ethanol).
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Figure 6: PLX Causes but is Not Dependent on the Production of Reactive
Oxygen Species (ROS): (A) Colon cancer (HT-29), Normal Colon Epithelial
(NCM460) and Normal Human Fibroblast (NHF) cells were treated with PLX for
48 hours, following which, they were incubated with H2DCFDA and fluorescence
results were obtained using an image based cytometer. Results were quantified
using Graphpad prism 6.0 (B). (C) HCT116 colon cancer cells were treated with 3
mM N-acetylcysteine for an hour prior to PLX treatment. Cells were then treated
PLX at indicated concentrations for 72 hours, following which the WST-1 assay
was performed. Absorbance readings were taken at 450 nm and expressed as a
percent of the control. Values are expressed as mean ± SD from quadruplicates
of 3 independent experiments. *p<0.05
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Long Pepper Extract is Well-Tolerated in Animal Models
Long pepper extracts (mainly water extracts) have been used for centuries
and have been associated with various benefits (Bao et al., 2013). With all these
anecdotal reports of benefits, there have been no reports of toxicities associated
with its use. To further scientifically evaluate and validate the safety of PLX,
balb/c mice were orally gavaged with 50 mg/kg/day vehicle (DMSO) or PLX for
75 days and the mice were observed for signs of toxicity. To assess for toxicity,
mice were weighed twice a week, urine was collected for protein urinalysis
studies and following period of treatment, mice were sacrificed and their organs
were obtained for pathological analysis by a certified pathologist at the University
of Guelph (Dr. Brooke). Results from this part of the study demonstrate that there
was no weight loss overall in mice that were given PLX supplemented water
(Figure 7B).
To further assess toxicity, urine was collected from mice once a week and
protein urinalysis was performed using a urine dipstick and a Bradford protein
concentration assay. Protein urinalysis results indicate that there were trace
amounts of protein in the urine of mice both from the control and the PLX group,
with trace readings corresponding to protein concentrations between 5 and 20
mg/dL. Bradford assays confirm the results obtained by dipstick urinalysis (Figure
7A). There was no major difference between the control group and PLX group,
confirming the lack of toxicity associated with oral administration of PLX in
drinking water.
Furthermore, the hearts, livers and kidneys were obtained following the
toxicity study, sliced and stained with hematoxylin and eosin. Results show no
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gross morphologic difference between the control and the treatment group,
confirming the lack of toxicity associated with PLX treatment. Results from the
pathologist indicate that the presence of any lesions in the tissues are minimal or
mild and interpreted as either background or incidental lesions and the lack of
lesion type and frequency was enough to conclude no toxicological effect of PLX
to the balb/c mice (Table 1).
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Table 1: Summary of Histological Lesions in Balb/C Mice on PLX regimen

No
Treatment

Vehicle
(Gavage
Control)

M1

M2

M1

X

X

Liver:
-Infiltration, leukocyte,
predominantly
mononuclear, minimal
-Focal mineralization,
minimal
-Hepatocyte necrosis,
minimal
-Focus
of
cellular
alteration, eosinophilic,
minimal
-Hepatocyte
vacuolation, lipid type,
minimal
Hepatocyte
vacuolation, lipid type, X
mild
Fibrin thrombus
Heart:
-Infiltration, leukocyte,
predominantly
mononuclear, minimal
Myofiber
separation
and vaculation, minimal
(suspect artifact)
Kidney:
- Infiltration, leukocyte,
predominantly
X
mononuclear, minimal
Tubule
vacuolation,
minimal
Fibrin
or
other
extracellular
matrix,
glomerulus

M2

Long Pepper Extract
(Treatment group)
M3

M1

X

X

M2

M3

M4
X

X
X

X

X

X

X
X

X

X

X

X

X
X

X

X

X

X

X

X

X

X

X

X
X
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Figure 7: PLX is Well-Tolerated in Mice Models: Balb/C mice were divided into
three groups (3 animals/control (untreated), 3 animals/gavage control (vehicle
treatment) and 4 animals/treatment group). The control untreated group was
given plain filtered water, while the second and third group was given 50
mg/kg/day vehicle (DMSO) or PLX, respectively. Mice were assessed for toxicity
with protein urinalysis by Bradford Assay and dipstick analysis (A) and weight
changes (B). (C) Hematoxylin and Eosin stained tissue sections of the liver, heart
and kidney of control versus PLX treated group. Images were obtained on a
bright field microscope at 63X objective.
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Oral Administration of Long Pepper Extract Halts the Growth of Human
Colon Cancer Xenografts in Immunocompromised Mice
Following efficacy studies, we wanted to further study the efficacy of PLX.
For this study, CD-1nu/nu immunocompromised mice were subcutaneously
injected with HT-29 cells (left) and HCT116 cells (right). Following the
establishment of tumors, mice were separated into three groups, a control group,
a vehicle (Me2SO) group and a PLX treated group. Mice were observed for 75
days, with weights and tumor volumes measured twice a week. Results
demonstrate that oral administration of PLX could suppress the growth of both
p53 WT (HCT116) and p53 mutant (HT-29) tumors in-vivo. There were no signs
of toxicity, as indicated by increasing weights during the study (Figure 8A & B).
Furthermore, H & E staining revealed less nuclei in the PLX treated group,
compared to the control group, however, as observed in the toxicity studies, there
were no gross morphological differences in the livers, kidneys and hearts of the
control and PLX groups (Figure 8C).
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Figure 8: PLX Halts Growth of Colon Tumors in Xenograft Models: CD-1
nu/nu mice were subcutaneously injected with colon cancer cells; HT-29 (p53-/-)
on the left flank and HCT116 (p53+/+) on the right flank. (A) Representative tumor
size control mice and 50 mg/kg/day vehicle or PLX treated mice, respectively.
PLX halted the growth of both HT-29 and HCT116 tumors in-vivo. (B) Average
body weights of control and PLX treated mice. The body weights did not vary
significantly during the study. Tumor volumes were measured and tumor curve
shows the efficacy of 50 mg/kg/day oral administration of PLX. (C)
Histopathological analysis of tissue samples obtained from control and PLXtreated animals. Hematoxylin and Eosin stained tissue sections of the livers,
hearts, kidneys and tumors. Images were obtained on a bright field microscope at
10X and 63X objective.
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Analysis of Long Pepper Extract
The availability of several species of long pepper and the host of
compounds present within them make it essential to characterize the long pepper
extract that has shown potent anticancer activity, both in in-vitro and in-vivo
studies. HPLC profile studies were carried out on the crude ethanolic extracts,
compared with a piperamide standard mix. The chromatogram profile show that
our PLX extract contained several classes of compounds known to be present in
piper species, including piperines and dihydropiperlongumine, with a peak
corresponding to the presence of piperlongumine(Figure 9A & B). We
hypothesize that the presence of this compound, along with the other compounds
observed in this profile, could lend to the anti-cancer activity of PLX that we
observe in the various cancer cell models. Further studies and characterization
would provide more information about the roles of these compounds in cancer
cell death induction.
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Figure 9: HPLC Analysis of PLX: Chromatograms of Long pepper crude extract
(PLX) used for this study (10mg/mL at 2 L/Sample) (B) compared to
Piperamides Standard mix (1mg/mL at 1 L/standard) (A).
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DISCUSSION
In this report we demonstrate for the first time, the selective anti-cancer
potential of an ethanolic extract of long pepper (PLX) in several cancer cell lines.
PLX effectively reduced the viability of cancer cells and induced apoptosis in a
dose- and time-dependent manner, at low doses, allowing for a greater
therapeutic window in in-vitro studies (Figure 1 – 3). This apoptosis inducing
effect was found to be independent of caspases, cysteine aspartic proteases that
play a role in the progression and execution of apoptosis (Figure 4B). These
results suggest that PLX is not toxic to non-cancerous cells at such low doses, as
was observed in the cancer cells. Selectivity and lack of toxicity was confirmed
with in-vivo toxicological studies. Damage to the kidneys is a common occurrence
during various types to toxic therapies. This damage to the kidney results in large
amounts of protein (>3.5 g/day) leaking into the urine (Bleske et al., 2013; Fang
et al., 2013), and this can be measured by various assays. Lack of toxicity was
confirmed by the lack of increased protein concentration in the urine samples
collected from both the control group and PLX treated group, by two different
assays. The urine dipstick method indicated that all urine samples from the
control and PLX groups had trace amounts of protein, corresponding to
concentrations between 5 mg/dL and 20 mg/dL, well within the acceptable
concentration range. Bradford protein assay showed a concentration of
approximately 30 mg/dL most days urine was collected (Figure 7A). This is still
within the acceptable range of protein concentration in urine. These results
confirm anecdotal studies that suggest no associated toxicity or side effects
observed with take long pepper extracts. The efficacy of PLX in in-vivo models
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also showed that not only was PLX well-tolerated, it was also effective at halting
the growth of human tumor xenografts of colon cancer in nude mice (Figure 7A
and B).
The next step in understanding the effect of PLX on cell death induction in
cancer cells was to identify the mechanism of apoptosis induction observed
following PLX treatment.
The role of oxidative stress in cell death processes has been well
characterized. It is well established the reactive oxygen species (ROS) could be
the cause or effect of apoptosis induction in cells (Simon et al., 2000). Some
studies have suggested cancer cells to be more dependent on cellular response
mechanisms against oxidative stress and have exploited this feature to
selectively target cancer cells (Raj et al., 2012). The role of ROS generation in
PLX-induced apoptosis was assessed following treatment. In this study, we found
that PLX induced whole cell ROS production in a dose dependent manner, as
indicated by the increase in green fluorescence of H2DCFDA dye, cleaved by
intracellular esterases and oxidized by ROS present (Figure 6A & B). However,
we observed that ROS generation was not completely essential to PLX activity,
as the presence of N-acetylcysteine could not entirely hamper the ability of PLX
to reduce the viability of colon cancer cells (Figure 6C).
The caspase-independence observed in figure 4B, suggest that PLX is
acting through pro-apoptotic factors other than caspases. The mitochondria play
a major role in the progression and execution of apoptosis. The permeabilization
of the mitochondrial membrane usually leads to the release of pro-apoptotic
factors,

including

cytochrome

c,

apoptosis

inducing

factor

(AIF)

and
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endonuclease G (EndoG) (Earnshaw, 1999; Elmore, 2007). AIF and EndoG
execute apoptosis in a caspase-independent possibly leading to the caspaseand partial ROS-independence observed. We show here that PLX caused MMP
dissipation in cancer cells, while non-cancerous NCM460 cell mitochondria
remained intact following treatment (Figure 5A – C). The dissipation of the
mitochondrial membrane led to the release of AIF and EndoG (Figure 5D),
allowing for the progression and execution of apoptosis in the absence of
caspases and oxidative stress, providing insight to the mechanism of PLX action
in cancer cells. Cancer cells differ from non-cancerous cells in variety of ways,
which could enhance the selectivity of PLX to cancer cells. The Warburg effect is
characterized by the high dependence of cancer cells on glycolysis and low
dependence on mitochondria for energy production in cancer cells, therefore
creating a more vulnerable target in cancer cell mitochondria (Warburg, 1956).
Moreover, various anti-apoptotic proteins associated to the mitochondria have
been reported to be highly expressed in cancer cells. Such proteins could serve
as targets for selective cancer (Mathupala, 1997; Casellas et al., 2002; Green &
Kroemer, 2004).
Unlike isolated natural compounds, there are usually more benefits to
using a whole plant extract than the isolated compound. Multiple components
within extracts have many different intracellular targets, which may act in a
synergistic way to enhance specific activities (including anticancer activities),
while inhibiting any toxic effects of one compound alone. Additionally, the
presence of multiple components may possibly decrease the chances of
developing chemoresistance (Foster et al., 2005). Moreover, natural extracts can
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be administered orally to patients, as a safe mode of administration. Some known
compounds of the long pepper plants have been isolated and studied for their
various activities (Lee et al., 2001; Raj et al., 2012; Bao et al., 2013; Golovine et
al., 2013; Jarvius et al., 2013; Megwal & Goswami, 2013).
In this study, we show some signature compounds that are present in our
PLX extract, including piperlongumine, dihydropiperlongumine and piperine.
Notably, piperlongumine, a compound from the Piper longum plant, has
previously been shown to have selective anticancer activity (Raj et al., 2011). The
small peak of piperlongumine observed in the HPLC chromatogram in Figure 9,
as piperlongumine may be due to the reduction of piperlongumine to the larger
dihyropiperlongumine peak that we observe. In a previous study that showed the
efficacy of piperlongumine, high concentrations of 10 M was required for
significant cell death induction in cancer cells (Raj et al., 2012). In this study, a
very low amount of the complex mixture of the ethanolic extract of long pepper
(that contains many bioactive compounds) was sufficient in inducing apoptosis in
cancer cells selectively. This indicates that the individual bioactive compounds
(present in nanomolar concentrations within the extract) could act synergistically
to induce apoptosis in cancer cells at very low concentrations. These findings
highlights that the Piper spp. contain novel compounds with potent anticancer
activity, in addition to piperlongumine.
In conclusion, our results demonstrate that long pepper extract (PLX), with
a long historical use in traditional medicine, is selective in inducing cell death in
cancer cells by targeting non-genomic targets. It is well tolerated in mice models
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and effective in reducing the growth of human tumor xenotransplants in animal
models, when delivered orally. This could open a window of opportunity to
develop a novel, safer cancer treatment, using complex natural health products
from the Long Pepper.
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The distinct lack of readily available, efficacious and non-toxic cancer
therapies prompts further investigation and research into other available forms of
treatment, in a bid to promote better quality of life for cancer patients. Natural
health products (NHPs) and natural products (NPs) have been a major focus of
many forms of therapies for centuries, in various traditional medicines and are
often regarded as low risk due to their long history of human use. Anecdotal and
literature reports are inconclusive and sometimes contradictory, therefore, these
reports are not very useful for clinicians and patients (Foster et al., 2005; Jain,
2013). Although NHPs and herbal products are not considered toxic, because of
their long use, there are some reports of adverse drug events (ADEs), as these
are not single-active ingredients (SAIs), but contain multiple pharmacologically
active components that could affect multiple signaling pathways within the
system.
The bioactive components of complex natural products may be associated
with low inherent risks of usage or a higher risk, when there is drug interaction
with pharmacologically active compounds or enzymes that could affect drug
disposition (Foster et al., 2005). Thus, there is a lack of rigorous scientific
investigation into the use of many NHPs, and as such, diligent and rigorous
assessment of potentially efficacious NHPs, NPs and herbal products are
required. This is in a bid to ensure the safe and effective use of these products by
potential users. Over 75% of the anticancer drugs approved since the 1940’s
have been obtained from natural products or are synthetic derivatives of natural
products (both plants and marine/biological sources) (Mann, 2002; Newman &
Cragg, 2012). This signifies that within the vast array of health and herbal
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products, there are pharmacologically active components and whole complex
mixtures that could show better efficacy, while lacking toxicity or reducing
toxicities associated with other treatment options.
The major accomplishment of my work was the identification of natural
health products (NHPs) with significant anti-cancer activity, the determination of
the mode of action, contributing to their anti-cancer activities and the assessment
of the safety of these NHPs in preclinical settings, which led to the clinical
development of one NHP. My work focuses on two NHPs, the water extract of
dandelion root (DRE) and the ethanolic extract of long pepper (PLX), and the
stepwise characterization of their anti-cancer activities and potential toxicities.
Dandelions have been used for centuries, with the first reported evidence
of the therapeutic use of dandelions mentioned by Arabian physicians during the
10th and 11th centuries in the treatment of liver and spleen diseases (Schütz et
al., 2006). Anecdotal evidence shows the efficacy of various parts of this plant for
the treatment of various diseases. For instance, the roots are used as a
gastrointestinal remedy to support digestion and liver function, while the leaves
are used as a diuretic and a bitter digestive stimulant. The roots have been
investigated for demulcent and immune-modulating effects, while the leaves have
been investigated for its role in inflammation (Yarnell & Abascal, 2009). There are
various classes of pharmacologically active compounds within dandelions that
have been predicted to lend to its therapeutic activity (Table 1), but the most
important classes are triterpenoids and sesquiterpene lactones (SLs) (Takasaki
et al., 1999; Schütz et al., 2006; Yarnell & Abascal). Biological studies on 11
triterpenoids found in various Taraxacum species and other plant sources show
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that this class of compounds have significant anti-carcinogenic activity, with
taraxasterol having the best anticancer activity (Takasaki et al., 1999). Studies on
SLs have shown that this class of compounds have both anti-inflammatory and
anti-cancer effects. This class of compounds was originally identified in an initial
screen by the National Cancer Institute (NCI), the same screening that led to the
identification of Taxol, and SLs have proven themselves worthy of continuous
investigations, up to the levels of clinical trials, as anti-inflammatory and anticancer agents (Zhang et al., 2005; Ghantous et al., 2010). Owing to these
characteristics, plant extracts, such as dandelions, with high amounts of SLs are
becoming more important and are being given considerable interest, especially in
cancer and inflammatory diseases. They have been shown to selectively target
cancer stem cells and some have proceeded successfully to Phase I and II
clinical trials (Jeon et al., 2008; Ghantous et al., 2010). All of these findings, along
with the fact that dandelion extracts are complex mixtures, containing both
triterpenoids and SLs, along with other classes of compounds, suggest the
importance of this NHP in the fight against cancer.
The use of long pepper extract is not as well documented as that of
dandelions. Of more interest are some of the components of long pepper, for
instance, piperlongumine (PL), and its role in oxidative stress response,
especially in cancer cells (Raj et al., 2011). PL was also found to induce cell cycle
arrest, induce apoptosis by down-regulating the expression of pro-survival
proteins and up-regulating the expression of pro-apoptotic proteins, as well as
inducing DNA damage in cancer cells (Bezerra et al., 2012). There are other
pharmacologically active compounds, within long pepper extract that have been
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studied for their various activities. Piperidine alkaloids have shown fungicidal
activities, while piperines affect enzymatic drug bio-transforming reactions and
plays specific roles in metabolic activation of carcinogens and mitochondrial
energy production (Jarvius et al., 2013; Megwal & Goswami, 2013). These
studies provide sufficient substantiation that the whole complex mixture of long
pepper extract, as well as dandelion root extract, could provide safer, non-toxic
alternative to conventional modes of treatment, as a potential anti-cancer agent.
In light of this information, my findings of the complex mixture of DRE and
PLX, with very clear anti-cancer activities, are novel and extremely important.
During the period of this work, we found that aqueous dandelion root extract
selectively induced apoptosis (PCD type I) and autophagy (PCD type II) in a
variety of cancer cell models (Table 2). These results were significant, as we
observed the versatility of a simple water extract of dandelion root in different
cancer cell types, each with different and multiple mutations that promote their
ability to proliferate in cell culture. Using various biochemical and morphological
markers, we confirmed the induction of different modes of cell death in cancer
cells. The induction of apoptosis was observed, following the rapid activation the
death receptor mediated extrinsic pathway and the destabilization of the
mitochondrial membrane potential, right before the formation of apoptotic bodies
and the externalization of phosphatidylserine, indicative of apoptosis. The
induction of pro-death autophagy in some of these cell types confirms the
connection between autophagy and apoptosis (Chapter 1, Figure 5), as well as
indicating the versatility of DRE in targeting multiple pathways in a cancer cells
selectively.
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Compound class

Examples

Comments

Sesquiterpene
Lactones

Taraxacosides, taraxinic Generally believed to have antiacid, ainsliosides
inflammatory and anti-cancer
activity. Has antioxidant effects

Triterpenes

Taraxasterol, alpha- and Also believed to have antibeta- amyrin
inflammatory and anti-tumor
activity

Phytosterols

Β-sitosterol

Phenylpropanoids

Monocaffeoyltartaric
acid, caffeic acid

Thought to be useful in cancer
prevention
Has inflammation modulatory
effects

Table 1: Classification of Pharmacologically Active Components in DRE

Cancer cells

Non-cancerous cells

Human T cell leukemia (Jurkat)

Normal human fibroblasts

(Ovadje et al., 2011)
Chronic myelomonocytic leukemia

Peripheral blood mononuclear cells

(Ovadje et al., 2012a)

(from apparently healthy volunteers)

Pancreatic cancer

Human Umbilical Vein Endothelial

(Ovadje et al., 2012b)

Cells

Colon cancer

Normal colon epithelial cells

Melanoma

Normal colon fibroblasts

(Chatterjee et al., 2011)
Patient-derived leukemia samples
Breast cancer (SUM149 & MCF-7)
Table 2: List of Cancer and Non-cancer Cell Lines Analyzed for the Anticancer Efficacy of DRE
279

Following further studies, we observed that DRE efficiently targets multiple
pathways in cancer cells, and is able to distinguish between cancer and noncancerous cells in this ability. We observed this differential targeting in colorectal
cancer cells, compared to non-cancerous colon mucosal epithelial cells, by gene
expression

analysis.

These

analyses,

combined

with

fractionation

and

phytochemical analysis, suggest the ability of DRE to target multiple cell death
pathways, in a dose and time dependent manner, due to the presence of multiple
components within the extract (discussed in Chapter 5). The identification of
three triterpenoids in DRE, -amyrin, -amyrin and lupeol, aid in further
understanding of the mechanism of DRE in cancer cells.
Previous studies have attributed the anticancer activity to some of these
triterpenoids, although the main triterpenoid with the anti-cancer effect,
taraxasterol (Takasaki et al., 1999), has not yet been identified in our extract of
dandelion root. On their own, it was observed that -amyrin, -amyrin and lupeol
had a minimal cytotoxic effect on colon cancer cell proliferation, at the doses
used. However, a study by Murtaza and colleagues provided evidence that
lupeol, at 40 M, induced apoptosis in pancreatic cancer cells, by inhibiting the
expression of cFLIP, thereby activating the extrinsic pathway of apoptosis. This
was a confirmation of another study by Hata and colleagues, showing the efficacy
of lupeol as an anti-cancer agent by activating extrinsic apoptosis (Hata et al.,
2000; Murtaza et al., 2009). Furthermore, sesquiterpene lactones have also been
implicated in the activation of the extrinsic pathway of apoptosis (Zhang et al.,
2005; Ghantous et al., 2010). These reports supports our recent findings that
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dandelion root extract, even at low doses, efficiently and rapidly activates
caspase-8, which is essential for the induction of apoptosis in leukemia cells
(Ovadje et al., 2012a), while in colon cancer cells, this activation was not required
for apoptosis induction, as inhibition of caspase-8 activation did not deter the
induction of PCD by DRE treatment (Chapter 5, Figure 6C). This activation of
extrinsic pathway of apoptosis also corresponded to the inhibition of cFLIP
following DRE treatment in a dose and time dependent manner. The drawback of
the anti-cancer effect of the purified compounds is the requirement of significantly
high concentrations, which may not be achievable physiologically and could be
toxic at such levels. In contrast, DRE as a complex mixture of many of these
compounds, and some yet unidentified components, where the individual
concentrations of these compounds will be very low (potentially sub-micromolar
concentrations), show very high efficacy. This indicates that, in DRE, various
components might act in synergy, to promote the targeting of multiple pathways
of cell death.
All of these findings and previously published data confirm the role of such
complex NHPs in combating a complex disease like cancer, with multiple
vulnerabilities that can be exploited for the development of a more efficacious
form of therapy.
To go one step further to understanding the efficacy, in-vivo studies were
carried out. Although dandelion extracts have been used for centuries, with no
reports of adverse effects, proper scientific validation of the lack of toxicity was
required. In this work, we show, through several biochemical and pathological
markers, that DRE, when administered orally over a long period, was not toxic to
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mice. More importantly, efficacy studies in xenograft models of colon cancer in
immunocompromised mice showed that oral administration of DRE halted the
growth of colon tumors and improved survival of the mice on this regimen. These
results showed that the complex mixture of DRE are absorbed through the
gastrointestinal tract (GIT) and are able to get to the tumor site and halt further
growth. These findings not only provide further evidence of the efficacy of DRE
as an anti-cancer agent, but also proving that this NHP is a safer alternative to
current chemotherapy standards.
Evaluation of the anti-cancer efficacy of therapeutics on cancer tissues
obtained from cancer patients, in ex-vivo model, takes pre-clinical studies one
step close to human testing in clinical trials and could be an indicator of patient
response during clinical studies. Interestingly, we observed the induction of
apoptosis and pro-death autophagy by DRE in several patient derived samples of
leukemia,

following

the caspase-8 activation.

Moreover

cancer-selective

response was further confirmed, as PBMCs from healthy volunteers were not
susceptible to the induction of programmed cell death. These are important
findings as they confirm the efficacy of DRE in ex-vivo models, bringing us one
step close to using this complex mixture as a therapeutic anti-cancer agent in
actual cancer patients, especially those with haematological cancers. These
findings, along with the previous efficacy, safety and mechanistic studies
presented in our application to Health Canada, convinced the review panel and
dandelion root extract was approved for Phase I clinical trials in hematological
cancers.
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The thorough scientific validation of the anti-cancer efficacy of dandelion root
extract in various cancer cell models, provide the necessary background
evidence and guide to further validate and assess other NHPs with potential
efficacies.
The efficacy of piperlongumine as a possible anti-cancer agent, even at
high doses (≥ 5 μM), along with the efficacy studies on other components of long
pepper, suggest that this NHP could possess better effectiveness, and less
associated toxicity. Part of this work was dedicated to laying the groundwork for
studying the anti-cancer efficacy of long pepper extract. In this work, we show
that an ethanolic extract of long pepper extract led to a caspase-independent
mode of apoptosis in several cancer cells. This induction of apoptosis was
associated with the permeabilization of the mitochondrial membrane and the
generation of reactive oxygen species (ROS). The mechanism of action of this
extract was found to be partially dependent on the oxidative stress, as pretreatment with N-acetylcysteine led to a partial rescue of the cells that were later
treated with long pepper extract. These findings are in agreement with previous
reports with piperlongumine, where it was observed that this compound targeted
the oxidative stress response mechanisms, led to the production of ROS and
induced apoptosis selectively in cancer cells (Raj et al., 2011).
Furthermore, the use of this complex mixture of PLX was required at low
doses, compared to the high doses of a single component, providing a significant
therapeutic window for its use. Its efficacy in cell culture and the lack of toxicity in
animal models, further provides the necessary evidence for its safety and
efficacy, as anti-cancer agent. These results are essential for further clinical
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development of this NHP. Furthermore, HPLC analysis of the ethanolic extract of
long pepper showed a small peak corresponding to the presence of
piperlongumine, along with peaks representing other components within long
pepper extract. The miniscule amount of piperlongumine in long pepper extract
suggests that this compound may not be the most essential component that
lends to the anti-cancer activity of this extract.
These findings further provides sufficient evidence that backs up the use
of complex mixtures, with multiple pharmacologically active components, that
work in synergy to promote efficacy and possibly reduce any toxicity associated
with any one component. They further provide the essential scientific validation
behind the use of common natural health products to deliver more efficacious
modes of treatment, that are safer and mostly inexpensive, compared to currently
available forms of treatment.
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FUTURE DIRECTIONS & CONCLUSIONS
The results presented in this thesis afford some scientific evidence for the
use of NHPs in disease treatment, especially in developing better cancer
therapies. However, substantial work is still needed to move these NHPs from
where they are right now to where they could be beneficial to patients.
Future work on this project should involve further determination and
characterization of the pharmacologically active components within dandelion
root and long pepper extracts. 6 of 28 fractions obtained from the secondary
phytochemical fractionation of dandelions were found to have significant
bioactivity, comparable to whole complex DRE and further fractionation of two of
those fractions (with similar profiles) led to the identification of three out of five
compounds. Considering these compounds, on their own, were required at high
doses and only additive effects were observed when -amyrin and -amyrin were
used in combination, it is of utmost importance that the remaining active
components with DRE be identified and their anti-cancer activity be evaluated, as
single agents and in combination. The identification all the bioactive components
within DRE will be beneficial, as it can ensure that better extraction processes
can be employed to extract yield higher amounts of the pharmacologically active
components. HPLC analysis of long pepper, using a standard mix of known
piperines and piperine alkaloids, led to the identification some of the common
components of this extract. Further phytochemical and fractionation analysis of
long pepper will be needed to get all the components.
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Determining the mechanism of action(s) of complex NHPs in cancer cells,
and the ability of these NHPs in particular to identify specific vulnerabilities in
cancer cells, has proven challenging. Due to the presence of multiple
pharmacologically active components that could individually target multiple
pathways, it becomes a puzzle to identify a single mechanism of action of such a
complex mixture. However, as with the expression analysis of genes involved cell
death programs, we identified several key genes that were influenced by DRE
treatment. These findings have helped narrow down the mechanistic efficacy of
this extract. Further investigation into the roles of these genes in promoting the
hallmarks of cancer cells, or in the initiation and progression of PCD is required.
Understanding the roles of these genes in relation to cancer cell growth and
death will be required to better comprehend the differences between cancer cells
and non-cancer cells, in an attempt to better develop more efficacious cancer
therapies.
During the Phase I clinical trials for the use of dandelion root extract in
haematological cancers, blood samples will be collected from patients in the trial,
and assessed for the induction of apoptosis and autophagy. Caspase-8 activation
will also be used as a marker for apoptosis induction. While histopathological
analysis will be carried out by the clinic on patient samples, gene expression
profiling should also be carried out on each sample obtained, before and after
treatment commences. This will enable identification of patients that will benefit
from using DRE, as a treatment option.
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HEALTH AGENCIES & REGULATORY BODIES INVOLVED WITH NHPs
The whole purpose for the scientific validation of NHPs against diseases,
especially cancer, is to provide awareness for these NHPs and NPs that have
been used for centuries in various traditional medicines. Published scientific
studies carried out provide of the necessary evidence regarding the efficacy of
these NHPs, their indications and contra-indications, as well as information on
their safe and effective use. In Canada, Health Canada is the governing agency
for the introduction of drugs and NHPs to the public, with a division completely
dedicated to NHPs, the Natural Health Product Directorate (NHPD). This division
was generated to assist and ensure that Canadians have access to NHPs that
are ―safe, effective and of high quality, while respecting freedom of choice and
philosophical and cultural diversity‖.
Regulations for NHPs came into effect in 2004 and take into account the
unique nature and characteristics of NHPs. At the end of 2012, the NHPD
published information that outline how NHPs are assessed, with a focus on
health claims, the use of risk information and the use of NHPs in combination;
these include the ―Pathway for Licensing NHPs Making Modern Health Claims‖,
Pathway for Licensing NHPs making Traditional Health Claims‖ and ―Quality of
Natural Health Products Guide‖, which summaries the requirement for
standardization of high quality NHPs. Even after clinical trials and progression to
the market, Health Canada continues to collect information on, track and analyze
adverse reaction reports for NHPs through the Canada Vigilance Program and
other regulatory agencies, like the World Health Organization (WHO), thus
allowing constant monitoring of NHPs to ensure continuous safety and efficacy
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associated with their use. More information on Health Canada’s requirements for
NHPs can be found at their website:
http://www.hc-sc.gc.ca/dhp-mps/prodnatur/index-eng.php
Dandelion root extract, as a therapeutic anti-cancer agent, is leading the
movement of natural health products in Canada and is one of the first NHP
approved as a therapeutic complex mixture treatment for Phase I clinical trials in
cancer therapy. In fact, the NHPD is now becoming the Therapeutic Health
Directorate (TPD) in Health Canada, tasked with the duty of assessing the
scientific validation of health claims of NHPs with potential efficacy in the
treatment of diseases, especially cancer, that are still lacking effective forms of
treatment.
In the United States, the Food and Drug Administration (FDA) is the agency
in charge of the regulating the production and provision of NHPs to the public.
NHPs are referred to as complementary and alternative medicine (CAM), which
are divided into 5 main domains –
a) Whole medical systems; Ayurveda, homeopathic medicine and traditional
Chinese medicine (TCM). This is the most common domain of NHPs/CAMs
b) Mind-Body Medicine; meditation, prayer and creative therapies
c) Biologically based practices with herbs, foods, vitamins and dietary
supplements
d) Manipulative and Body-based practices; chiropractic and osteopathic
manipulation and massage
e) Energy medicine; including therapeutic touch.
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These domains undergo the same levels of rigorous review, as described in
the Health Canada review aspect above. More information of application to the
FDA

and

their

requirements

can

be

found

at

their

website:

http://www.fda.gov/regulatoryinformation/guidances/ucm144657.htm
These regulatory agencies ensure that health claims made by traditional
medicine have scientific validations for anecdotal evidence presented for
centuries. They ensure proper standardizations involved in the production and
usage of NHPs/NPs/CAMs to maximize the benefits of these products and
medicines.

CONCLUSIONS
The work presented in this thesis has significantly contributed to the scientific
validation of natural health products and their roles in disease prevention and
treatment. It has laid the groundwork for the validation of other NHPs that could
potentially be used in the development of other cancer treatments, and even
other diseases, with no treatment options available. This work also hinges on the
platform that the complex mixtures of dandelion root and long pepper extracts is
much more beneficial than a single identified component, allowing for the multiple
events that are observed in in-vitro studies. Collectively, this work emphasizes
the importance of natural health products, especially dandelion root and long
pepper extracts in the development of safer, more efficacious anti-cancer agents,
as preferable alternatives to the currently available forms of therapy.
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APPENDIX B
CHEMICAL REAGENTS

COMPANY NAME

CATALOG NO.

2',7'-dichlorodihydrofluorescein

Sigma Aldrich

D6883

5,5’,6,6’-tetrachloro-1,1’,3,3’ –
tetraethylbenzimidazolyl
carbocyanine iodide (JC-1)

Invitrogen

T3168

Amplex Red

Molecular Probes

90101

Annexin-V AlexaFluor 488

Invitrogen

A13201

Anti--actin (Ms mAb)

GeneTex

GTX628802

Anti-cFLIP (Ms mAb)

GeneTex

GTX28421

Anti-LC3 (Rb pAb)

Novus Biologicals

NB100-2220

Anti-caspase-8 (Ms mAb)

Santa Cruz Biotechnology

sc-70501

Anti-EndoG (Rb mAb)

Abcam

ab9647

Anti-SDHA (Ms mAb)

Santa Cruz Biotechnology

sc-59687

Anti-AIF (Rb pAb)

Abcam

ab1998

BioRad Protein reagent

BioRad

500-0006

Bovine Serum Albumin

Sigma Aldrich

A7906

Dandelion Roots

Premier Herbal Inc.

Lot#: 318121

DEVD-AFC

Calbiochem

218829

Eosin

Sigma Aldrich

E4382

Etoposide

Sigma Aldrich

E1383

First Strand cDNA synthesis

Qiagen, Inc

330401

Gentamicin

Life Technologies

157-0-072

Hematoxylin

Sigma Aldrich

HHS16

Hoechst 33342

Molecular Probes

H1399

Horseradish Peroxidase

Sigma Aldrich

P6782

IETD-AFC

Calbiochem

368059

IETD-fmk

calbiochem

218773

diacetate (H2DCFDA)

kit
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Image-iT Live Caspase-8 kit

Invitrogen

I35105

Leupeptin

Sigma Aldrich

L2023

Long pepper Seeds

Quality Natural Foods Ltd

MitoTracker

Invitrogen

M7513

Monodansylcadaverine

Sigma Aldrich

30432

N-acetylcysteine (NAC)

Sigma Aldrich

A9165

Normal Goat Serum

Sigma Aldrich

G9023

PARAQUAT

Sigma Aldrich

856177

Pepstatin A

Sigma Aldrich

77170

Phenylmethanesulfonyl

Sigma Aldrich

P7626

Poly-L-lysine

Sigma Aldrich

P4707

Propidium Iodide

Sigma Aldrich

P4170

Qiagen RT2Profiler Pathway kit

Qiagen, Inc

PAHS-212Z

RNeasy Kit

Qiagen, Inc

74106

SYBR Green MasterMix

Qiagen, Inc

330502

Tamoxifen (TAM)

Sigma Aldrich

T9262

Invitrogen

A23210

TMRM

Life Technologies

T-688

Trypan Blue

Sigma Aldrich

T8154

WST-1

Roche Diagnostics

ZVAD-fmk

EMD4Biosciences

Fluoride

Terminal deoxynucleotidyl
transferase dUTP nick-end
labeling (TUNEL) Assay Kit

11644807001
219007
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